U.S. patent application number 09/893348 was filed with the patent office on 2002-06-13 for activated t cells, nervous system-specific antigens and their uses.
This patent application is currently assigned to YEDA RESEARCH AND DEVELOPMENT CO. LTD.. Invention is credited to Beserman, Pierre, Cohen, Irun R., Eisenbach-Schwartz, Michal, Hauben, Ehud, Moalem, Gila, Mosonego, Alon.
Application Number | 20020072493 09/893348 |
Document ID | / |
Family ID | 25401412 |
Filed Date | 2002-06-13 |
United States Patent
Application |
20020072493 |
Kind Code |
A1 |
Eisenbach-Schwartz, Michal ;
et al. |
June 13, 2002 |
Activated T cells, nervous system-specific antigens and their
uses
Abstract
Compositions and methods to promote nerve regeneration or to
confer neuroprotection and prevent or inhibit neuronal degeneration
within the nervous system, eiteher the central nervous system or
the peripheral nervous system, are provided. Treatment involves
administering NS-specific activated T cells, or an NS-specific
antigen or analog thereof, a peptide derived therefrom or an analog
or derivative of said peptide, or a nucleotide sequence encoding
said antigen or peptide, or any combination thereof.
Inventors: |
Eisenbach-Schwartz, Michal;
(Rehovot, IL) ; Hauben, Ehud; (Rehovot, IL)
; Cohen, Irun R.; (Rehovot, IL) ; Beserman,
Pierre; (Kibbutz Chafeiz Chairn, IL) ; Mosonego,
Alon; (Rehovot, IL) ; Moalem, Gila;
(Pitah-Tiyra, IL) |
Correspondence
Address: |
BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON
DC
20001-5303
US
|
Assignee: |
YEDA RESEARCH AND DEVELOPMENT CO.
LTD.
Weizmann Institute of Science P.O. Box 95
Rehovot
IL
|
Family ID: |
25401412 |
Appl. No.: |
09/893348 |
Filed: |
June 28, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09893348 |
Jun 28, 2001 |
|
|
|
09314161 |
May 19, 1999 |
|
|
|
09314161 |
May 19, 1999 |
|
|
|
09218277 |
Dec 22, 1998 |
|
|
|
09218277 |
Dec 22, 1998 |
|
|
|
PCT/US98/14715 |
Jul 21, 1998 |
|
|
|
Current U.S.
Class: |
424/185.1 ;
424/93.7; 514/17.7; 514/20.9; 514/8.3 |
Current CPC
Class: |
A61K 2039/5158 20130101;
A61K 39/00 20130101; C07K 14/705 20130101; C07K 14/47 20130101;
A61K 48/00 20130101; A61K 38/1709 20130101; A61K 39/0007
20130101 |
Class at
Publication: |
514/12 ;
424/93.7 |
International
Class: |
A61K 038/17 |
Foreign Application Data
Date |
Code |
Application Number |
May 19, 1998 |
IL |
124500 |
Claims
What is claimed is:
1. A method for promoting nerve regeneration or for conferring
neuroprotection and preventing or inhibiting neuronal degeneration
in the central nervous system or peripheral nervous system for
ameliorating the effects of injury or disease, comprising
administering to an individual in need thereof at least one
ingredient selected from the group consisting of: (a) NS-specific
activated T cells; (b) a NS-specific antigen or an analog thereof;
(c) a peptide derived from an NS-specific antigen or from an analog
thereof, or an analog or derivative of said peptide; (d) a
nucleotide sequence encoding an NS-specific antigen or an analog
thereof; (e) a nucleotide sequence encoding a peptide derived from
an NS-specific antigen or from an analog thereof, or an analog of
said peptide; or (f) any combination of (a)-(e).
2. The method according to claim 1 wherein the injury is selected
from the group consisting of spinal cord injury, blunt trauma,
penetrating trauma, hemorrhagic stroke, ischemic stroke or damages
caused by surgery such as tumor excision.
3. The method according to claim 1 wherein the disease is not an
autoimmune disease or a neoplasm.
4. The method according to claim 1 wherein the disease results in a
degenerative process occurring in either gray or white matter or
both.
5. The method according to claim 4 wherein said disease is selected
from the group consisting of diabetic neuropathy, senile dementia,
Alzheimer's disease, Parkinson's disease, facial nerve (Bell's)
palsy, glaucoma, Huntington's chorea, amyotrophic lateral
sclerosis, non-arteritic optic neuropathy, and vitamin
deficiency.
6. The method according to claim 4 wherein said disease is selected
from the group consisting of intervertebral disc herniation, prion
diseases such as Creutzfeldt-Jakob disease, carpal tunnel syndrome,
peripheral neuropathies associated with various diseases, including
but not limited to, uremia, porphyria, hypoglycemia, Sjorgren
Larsson syndrome, acute sensory neuropathy, chronic ataxic
neuropathy, biliary cirrhosis, primary amyloidosis, obstructive
lung diseases, acromegaly, malabsorption syndromes, polycythemia
vera, IgA- and IgG gamma-pathies, complications of various drugs
(e.g., metronidazole) and toxins (e.g., alcohol or
organophosphates), Charcot-Marie-Tooth disease, ataxia
telangectasia, Friedreich's ataxia, amyloid polyneuropathies,
adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease,
Fabry's disease, and lipoproteinemia.
7. The method according to claim 1 which comprises administering to
the individual in need NS-specific activated T cells.
8. The method according to claim 7 wherein said NS-specific
activated T cells are selected from the group consisting of
autologous T cells, semi-allogeneic T cells or allogeneic T cells
from related donors, or from donors who are HLA-matched or
HLA-partially matched, or from unrelated donors.
9. The method according to claim 8 wherein said T cells are
autologous T cells.
10. The method according to claim 8 wherein said T cells are
semi-allogeneic T cells.
11. The method according to claim 9 or 10 wherein said autologous
or semi-allogeneic T cells have been sensitized to an NS-specific
antigen or an analog thereof.
12. The method according to claim 11 wherein the NS-specific
antigen is selected from the group consisting of myelin basic
protein (MBP), myelin oligodendrocyte glycoprotein (MOG),
proteolipid protein (PLP), myelin-associated glycoprotein (MAG),
S-100, .beta.-amyloid, Thy-1, P0, P2, and a neurotransmitter
receptor.
13. The method according to claim 12 wherein the NS-specific
antigen is MBP.
14. The method according to claim 11 wherein the NS-specific
antigen is selected from the group consisting of Nogo-A, Nogo-B,
Nogo-C, and Nogo receptor.
15. The method according to claim 9 or 10 wherein said autologous
or semi-allogeneic T cells have been sensitized to a peptide
derived from an NS-specific antigen or from an analog thereof, or
to an analog or derivative of said peptide.
16. The method according to claim 15 wherein said peptide derived
from an NS-specific antigen is an immunogenic epitope or a cryptic
epitope of said antigen.
17. The method according to claim 16 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from MBP.
18. The method according to claim 17 wherein said peptide
corresponds to a peptide selected from the sequences consisting of
the sequences p11-30, p51-70, p87-99, p91-110, p131-150, and
p151-170 of MBP.
19. The method according to claim 18 wherein said peptide
corresponds to the sequence p51-70 of MBP.
20. The method according to claim 16 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from MOG.
21. The method according to claim 20 wherein said @ peptide
corresponds to the sequence p35-55 of MOG.
22. The method according to claim 16 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from Nogo.
23. The method according to claim 22 wherein said peptide is the
Nogo-A p472 peptide (SEQ ID NO:19).
24. The method according to claim 16 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from Nogo
receptor.
25. The method according to claim 9 or 10 wherein said autologous
or semi-allogeneic T cells have been stored for future use.
26. The method according to claim 1 which comprises administering
to the individual in need a NS-specific antigen or an analog
thereof.
27. The method according to claim 26 wherein the NS-specific
antigen is selected from the group consisting of myelin basic
protein (MBP), myelin oligodendrocyte glycoprotein (MOG),
proteolipid protein (PLP), myelin-associated glycoprotein (MAG),
S-100, .beta.-amyloid, Thy-1, P0, P2, and a neurotransmitter
receptor.
28. The method according to claim 27 wherein the NS-specific
antigen is MBP.
29. The method according to claim 28 wherein the MBP is
administered orally.
30. The method according to claim 23 wherein the NS-specific
antigen is selected from the group consisting of Nogo-A, Nogo-B,
Nogo-C, and Nogo receptor.
31. The method according to claim 1 which comprises administering
to the individual in need a peptide derived from an NS-specific
antigen or from an analog thereof, or an analog or derivative of
said peptide.
32. The method according to claim 31 wherein said peptide derived
from an NS-specific antigen is an immunogenic epitope or a cryptic
epitope of said antigen.
33. The method according to claim 32 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from MBP.
34. The method according to claim 33 wherein said peptide
corresponds to a peptide selected from the sequences consisting of
the sequences p11-30, p51-70, p87-99, p91-110, p131-150, and
p151-170 of MBP.
35. The method according to claim 34 wherein said peptide
corresponds to the sequence p51-70 of NBP.
36. The method according to claim 32 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from MOG.
37. The method according to claim 36 wherein said peptide
corresponds to the sequence p35-55 of MOG.
38. The method according to claim 32 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from Nogo.
39. The method according to claim 38 wherein said peptide is the
Nogo-A p472 peptide (SEQ ID NO:19).
40. The method according to claim 32 wherein said peptide is an
immunogenic epitope or a cryptic epitope derived from Nogo
receptor.
41. The method according to claim 1 wherein said NS-specific
antigen or a peptide derived therefrom is administered
intravenously, intrathecally, intramuscularly, intradermally,
topically, subcutaneously, or mucosally.
42. The method according to claim 41 wherein said mucosal
administration is selected from the group consisting of oral,
intranasal, buccal, vaginal and rectal administration.
43. The method according to claim 42 wherein said NS-specific
antigen or peptide derived therefrom is administered orally and the
individual is actively immunized to build up a critical T cell
response.
44. A method for preventing or inhibiting neuronal degeneration in
the central nervous system or peripheral nervous system comprising
administering to an individual in need thereof an effective amount
of a composition for up-regulating B7.2 co-stimulatory molecule or
genetically manipulating B7.2 co-stimulatory molecule in said
individual.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of
application Ser. No. 09/314,161, filed May 19, 1999, which is a
continuation-in-part of application No. PCT/US98/14715, filed Jul.
21, 1998, and is a continuation-in-part of application Ser. No.
09/218,277, filed Dec. 22, 1998, the entire contents of each of
which are hereby incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to compositions and methods
for the promotion of nerve regeneration or prevention or inhibition
of neuronal degeneration to ameliorate the effects of injury or
disease of the nervous system (NS). In the certain embodiments,
activated T cells, an NS-specific antigen or peptide derived
therefrom or a nucleotide sequence encoding an NS-specific antigen
can be used to promote nerve regeneration or to confer
neuroprotection and prevent or inhibit neuronal degeneration caused
by injury or disease of nerves within the central nervous system or
peripheral nervous system of a human subject. The compositions of
the present invention may be administered alone or may be
optionally administered in any desired combination.
[0003] Abbreviations: APC: antigen-presenting cell; BSA: bovine
serum albumin; CAP: compound action potential; CFA: complete
Freund's adjuvant; CNS: central nervous system; 4-Di-10-Asp:
4-(4-didecylamino)styryl)-N-met- hylpyridinium iodide; EAE:
experimental autoimmune encephalomyelitis; FCS: fetal calf serum;
IFA: incomplete Freund's adjuvant MAG: myelin-associated
glycoprotein; MBP: myelin basic protein; MOG: myelin
oligodendrocyte glycoprotein; NS: nervous system; OVA: ovalbumin;
PBS: phosphate-buffered saline; PLP: proteolipid it protein; PNS:
peripheral nervous system; RGC: retinal ganglion cells; TCR: T-cell
receptor.
BACKGROUND OF THE INVENTION
[0004] The nervous system comprises the central (CNS) and the
peripheral (PNS) nervous system. The CNS is composed of the brain,
the spinal cord and the visual system; the PNS consists of all of
the other neural elements, namely the nerves and ganglia outside of
the brain and spinal cord.
[0005] Damage to the nervous system may result from a traumatic
injury, such as penetrating trauma or blunt trauma, or a disease or
disorder including, but not limited to Alzheimer's disease,
Parkinson's disease, multiple sclerosis, Huntington's disease,
amyotrophic lateral sclerosis (ALS), diabetic neuropathy, senile
dementia, stroke and ischemia.
[0006] Maintenance of CNS integrity is a complex balancing act in
which compromises are struck with the immune system. In most
tissues, the immune system plays an essential part in protection,
repair, and healing. In the CNS, because of its unique immune
privilege, immunological reactions are relatively limited
(Streilein, 1993). A growing body of evidence indicates that the
failure of the mammalian CNS to achieve functional recovery after
injury is a reflection of an ineffective dialog between the damaged
tissue and the immune system. For example, the restricted
communication between the CNS and blood-borne macrophages affects
the capacity of axotomized axons to regrow; transplants of
activated macrophages can promote CNS regrowth (Lazarov-Spiegler et
al, 1996; Rapalino et al, 1998).
[0007] Activated T cells have been shown to enter the CNS
parenchyma, irrespective of their antigen specificity, but only T
cells capable of reacting with a CNS antigen seem to persist there
(Hickey et al, 1991; Werkele, 1993; Kramer et al, 1995). T cells
reactive to antigens of CNS white matter, such as myelin basic
protein (MBP), can induce the paralytic disease experimental
autoimmune encephalomyelitis (EAE) within several days of their
inoculation into naive recipient rats (Ben-Nun et al, 1981a).
Anti-MPB T cells may also be involved in the human disease multiple
sclerosis (Ota et al, 1990; Martin, 1997). However, despite their
pathogenic potential, anti-MBP T cell clones are present in the
immune systems of healthy subjects (Burns et al, 1983; Pette et al,
1990; Martin et al, 1990; Schluesener et al, 1985). Activated T
cells, which normally patrol the intact CNS, transiently accumulate
at sites of CNS white matter lesions (Hirschberg et al, 1998).
[0008] A catastrophic consequence of CNS injury is that the primary
damage is often compounded by the gradual secondary loss of
adjacent neurons that apparently were undamaged, or only marginally
damaged, by the initial injury (Faden et al, 1992; Faden, 1993;
McIntosh, 1993). The primary lesion causes changes in extracellular
ion concentrations, elevation of amounts of free radicals, release
of neurotransmitters, depletion of growth factors, and local
inflammation These changes trigger a cascade of destructive events
in the adjacent neurons that initially escaped the primary injury
(Lynch et al, 1994; Bazan et al, 1995; Wu et al, 1994). This
secondary damage is mediated by activation of voltage-dependent or
agonist-gated channels, ion leaks, activation of calcium-dependent
enzymes such as proteases, lipases and nucleases, mitochondrial
dysfunction and energy depletion, culminating in neuronal cell
death (Yoshina et al, 1991; Hovda et al, 1991; Zivin et al, 1991;
Yoles et al, 1992). The widespread loss of neurons beyond the loss
caused directly by the primary injury has been called "secondary
degeneration."
[0009] Another tragic consequence of CNS injury is that neurons in
the mammalian CNS do not undergo spontaneous regeneration following
an injury. Thus, a CNS injury causes permanent impairment of motor
and sensory functions.
[0010] Spinal cord lesions, regardless of the severity of the
injury, initially result in a complete functional paralysis known
as spinal shock. Some spontaneous recovery from spinal shock may be
observed, starting a few days after the injury and tapering off
within three to four weeks. The less severe the insult, the better
the functional outcome. The extent of recovery is a function of the
amount of undamaged tissue minus the loss due to secondary
degeneration. Recovery from injury would be improved by
neuroprotective treatment that could reduce secondary
degeneration.
[0011] The parent applications, application Ser. Nos. 09/218,277
and 09/314,161 and PCT Publication WO 99/60021, describe the
discovery made in the laboratory of the present inventors that
activated T cells that recognize an antigen of the NS of the
patient confer neuroprotection. More specifically, T cells reactive
to MBP were shown to be neuroprotective in rat models of partially
crushed optic nerve (see also Moalem et al, 1999a, the entire
contents of which being hereby incorporated herein by reference)
and of spinal cord injury (see also Hauben et al, 2000, the entire
contents of which being hereby incorporated herein by reference).
Until recently, it had been thought that immune cells do not
participate in NS repair. Furthermore, any immune activity in the
context of CNS damage was traditionally considered detrimental for
recovery. It was quite surprising to discover that NS-specific
activated T cells could be used to protect nervous system tissue
from secondary degeneration which may follow damage caused by
injury or disease of the CNS or PNS. The mechanism of action of
such NS-specific T cells has yet to be discovered, but the massive
accumulation of exogenously administered T cells at the site of CNS
injury suggests that the presence of T cells at the site of injury
plays a prominent role in neuroprotection. It appears, however,
that the accumulation, though a necessary condition, is not
sufficient for the purpose, as T cells specific to the non-self
antigen ovalbumin also accumulate at the site, but have no
neuroprotective effect (Hirschberg et al, 1998).
[0012] In addition to the NS-specific activated T cells, the
above-referenced U.S. applications and PCT publication WO 99/60021
disclose that therapy for amelioration of effects of injury or
disease of NS can be carried out also with a natural or synthetic
NS-specific antigen such as MAG, S-100, .beta.-amyloid, Thy-1, P0,
P2, a neurotransmitter receptor, and preferably human MBP, human
proteolipid protein (PLP), and human oligodendrocyte glycoprotein
(MOG), or with a peptide derived from an NS-specific antigen such
as a peptide comprising amino acids 51-70 of MBP or amino acids
35-55 of MOG.
[0013] Citation or identification of any reference in this section
or any other part of this application shall not be construed as an
admission that such reference is available as if prior art to the
invention.
SUMMARY OF THE INVENTION
[0014] The present invention is directed to methods and
compositions for promotion of nerve regeneration or for
neuroprotection and prevention or inhibition of neuronal
degeneration to ameliorate the effects of injury to, or disease of,
the nervous system (NS).
[0015] The present invention is based in part on the inventors'
unexpected discovery that activated T cells that recognize an
antigen of the NS of the patient promote nerve regeneration or
confer neuroprotection. As used herein, "neuroprotection" refers to
the prevention or inhibition of degenerative effects of injury or
disease in the NS. Since it was thought until recently that immune
cells do not participate in nervous system repair, it was quite
surprising to discover that NS-specific activated T cells and also
the NS-specific antigens themselves and peptides derived therefrom
can be used to promote nerve regeneration or to protect nervous
system tissue from secondary degeneration which may follow damage
caused by injury or disease of the CNS or PNS.
[0016] Thus, in one aspect, the invention relates to a method for
promoting nerve regeneration or for conferring neuroprotection and
preventing or inhibiting neuronal degeneration in the central
nervous system or peripheral nervous system for ameliorating the
effects of injury or disease, comprising administering to an
individual in need thereof at least one ingredient selected from
the group consisting of:
[0017] (a) NS-specific activated T cells;
[0018] (b) a NS-specific antigen or an analog thereof;
[0019] (c) a peptide derived from an NS-specific antigen or from an
analog thereof, or an analog or derivative of said peptide;
[0020] (d) a nucleotide sequence encoding an NS-specific antigen or
an analog thereof;
[0021] (e) a nucleotide sequence encoding a peptide derived from an
NS-specific antigen or from an analog thereof, or an analog of said
peptide; or
[0022] (f) any combination of (a)-(e).
[0023] In another aspect, the invention relates to a pharmaceutical
composition for promoting nerve regeneration or for neuroprotection
and prevention or inhibition of neuronal degeneration in the CNS or
PNS for ameliorating the effects of injury or disease in the NS,
comprising a therapeutically effective amount of at least one
ingredient selected from the group consisting of (a) to (e) above
or any combination of (a)-(e).
[0024] The term "NS-specific antigen" as used herein refers to an
antigen of the NS that specifically activates T cells such that
following activation the activated T cells accumulate at a site of
injury or disease in the NS of the patient. Examples of NS-specific
antigens according to the invention include, but are not limited
to, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein
(MOG), proteolipid protein (PLP), myelin-associated glycoprotein
(MAG), S-100, .beta.-amyloid, Thy-1, P0, P2, neurotransmitter
receptors, the protein Nogo (Nogo-A, Nogo-B and Nogo-C) and the
Nogo receptor (NgR). This definition also includes analogs of said
NS-specific antigens as described in the section on NS-specific
antigens, analogs thereof, peptides derived therefrom and analogs
and derivatives thereof of said peptides hereinafter.
BRIEF DESCRIPTION OF THE FIGURES
[0025] FIG. 1 is a bar graph showing the presence of T cells in
uninjured optic nerve or in injured optic nerve one week after
injury. Adult Lewis rats were injected with activated T cells of
the anti-MBP (T.sub.MBP), anti-OVA (T.sub.OVA), anti-p277 (a
peptide of the human hsp60) (Tp.sub.277) lines, or with PBS,
immediately after unilateral crush injury of the optic nerve. Seven
days later, both the injured and uninjured optic nerves were
removed, cryosectioned and analyzed immunohistochemically for the
presence of immunolabeled T cells. T cells were counted at the site
of injury and at randomly selected areas in the uninjured optic
nerves. The histogram shows the mean number of T cells per
mm.sup.2.+-.s.e.m., counted in two to three sections of each nerve.
Each group contained three to four rats. The number of T cells was
considerably higher in injured nerves of rats injected with
anti-MBP, anti-OVA or anti-p277 T cells; statistical analysis
(one-way ANOVA) showed significant differences between T cell
numbers in injured optic nerves of rats injected with anti-MBP,
anti-OVA, or anti-p277 T cells and the T cell numbers in injured
optic nerves of rats injected with PBS (P<0.001); and between
injured optic nerves and uninjured optic nerves of rats injected
with anti-MBP, anti-OVA, or anti-p277 T cells (P<0.001).
[0026] FIG. 2 is a bar graph illustrating that T cells specific to
MBP, but not to OVA or p277, protect neurons from secondary
degeneration. Immediately after optic nerve injury, rats were
injected with anti-MBP, anti-OVA or anti-p277 T cells, or with PBS.
The neurotracer dye 4-Di-10-Asp was applied to optic nerves distal
to the site of the injury, immediately after injury (for assessment
of primary damage) or two weeks later (for assessment of secondary
degeneration). Five days after dye application, the retinas were
excised and flat-mounted. Labeled retinal ganglion cells (RGCs)
from three to five randomly selected fields in each retina (all
located at approximately the same distance from the optic disk)
were counted by fluorescence microscopy. RGC survival in each group
of injured nerves was expressed as the percentage of the total
number of neurons spared after the primary injury (42% of neurons
remained undamaged after the primary injury). The neuroprotective
effect of anti-MBP T cells compared with that of PBS was
significant (P<0.001, one-way ANOVA). Anti-OVA T cells or
anti-p277 T cells did not differ significantly from PBS in their
effects on the protection of neurons that had escaped primary
injury (P>0.05, one-way ANOVA). The results are a summary of
five experiments. Each group contained five to ten rats.
[0027] FIGS. 3(A-C) present photomicrographs of retrogradely
labeled retinas of injured optic nerves of rats. Immediately after
unilateral crush injury of their optic nerves, rats were injected
with PBS (FIG. 3A) or with activated anti-p277 T cells (FIG. 3B) or
activated anti-MBP T cells (FIG. 3C). Two weeks later, the
neurotracer dye 4-Di-10-Asp was applied to the optic nerves, distal
to the site of injury. After 5 days, the retinas were excised and
flat-mounted. Labeled (surviving) RGCs, located at approximately
the same distance from the optic disk in each retina, were
photographed.
[0028] FIGS. 4(A-B) are graphs showing that clinical severity of
EAE is not influenced by an optic nerve crush injury. For the
results presented in FIG. 4A, Lewis rats, either uninjured (dash
line) or immediately after optic nerve crush injury (solid line),
were injected with activated anti-MBP T cells. EAE was evaluated
according to a neurological paralysis scale. [Data points
represent.+-.s.e.m.] These results represent a summary of three
experiments. Each group contained five to nine rats. FIG. 4B shows
that the number of RGCs in the uninjured optic nerve is not
influenced by injection of anti-MBP T cells. Two weeks after the
injection of anti-MBP T cells or PBS, 4-Di-10-Asp was applied to
the optic nerves. After 5 days the retinas were excised
and-flat-mounted. Labeled RGCs from five fields (located at
approximately the same distance from the optic disk) in each retina
were counted and the average number per mm.sup.2 was calculated.
There was no difference between the numbers of labeled RGCs in rats
injected with anti-MBP T cells (TMBP) and in PBS-injected control
rats.
[0029] FIG. 5 is a bar graph showing that T cells specific to
p51-70 of MBP protect neurons from secondary degeneration.
Immediately after optic nerve injury, rats were injected with
anti-MBP T cells, anti-p51-70 T cells, or PBS. 4-Di-10-Asp was
applied to optic nerves distal to the site of the injury,
immediately after injury (for assessment of primary damage) or two
weeks later (for assessment of secondary degeneration). Five days
after dye application, the retinas were excised and flat-mounted.
Labeled RGCs from three to five randomly selected fields in each
retina (all located at approximately the same distance from the
optic disk) were counted by fluorescence microscopy. RGC survival
in each group of injured nerves was expressed as the percentage of
the total number of neurons spared after primary injury. Compared
with that of PBS treatment, the neuroprotective effects of anti-MBP
and of anti-p51-70 T cells were significant (P<0.001, one-way
ANOVA).
[0030] FIGS. 6(A-B) are graphs showing that anti-MBP T cells
increase the compound action potential (CAP) amplitudes of injured
optic nerves. Immediately after optic nerve injury, rats were
injected with either PBS or activated anti-MBP T cells (T.sub.MBP)
. Two weeks later, the CAPs of injured (FIG. 6A) and uninjured
(FIG. 6B) nerves were recorded. There were no significant
differences in mean CAP amplitudes between uninjured nerves
obtained from PBS-injected and anti-MBP T cell-injected rats (n-8;
p=0.8, Student's t-test). The neuroprotective effect of anti-MBP T
cells (relative to PBS) on the injured nerve on day 14 after injury
was significant (n=8, p=0.009, Student's t-test).
[0031] FIGS. 7(A-B) are graphs showing recovery of voluntary motor
activity as a function of time after contusion, with and without
injection of autoimmune anti-MBP T cells. (FIG. 7A) Twelve rats
were deeply anesthetized and laminectomized, and then subjected to
a contusion insult produced by a 10 gram weight dropped from a
height of 50 mm. Six of the rats, selected at random, were then
inoculated i.p. with 10.sup.7 anti-MBP T cells and the other six
were inoculated with PBS. At the indicated time points, locomotor
behavior in an open field was scored by observers blinded to the
treatment received by the rats. Results are expressed as the mean
values for each group. The vertical bars indicate SEM. Differences
tested by repeated ANOVA, including all time points, were
significant (p<0.05). (FIG. 7B) A similar experiment using five
PBS-treated animals and six animals treated with anti-MBP T cells
were all subjected to a more severe contusion. At the indicated
time points, locomotor behavior in an open field was scored. The
results are expressed as the mean values for each group. The
vertical bars indicate SEM. Rats in the treated group are
represented by open circles and rats in the control group are
represented by black circles. Horizontal bars show the median
values. The inset shows the median plateau values of the two
groups.
[0032] FIGS. 8(A-C) show retrograde labeling of cell bodies at the
red nucleus in rats treated with autoimmune anti-MBP T cells (8A)
and in control injured (8B) rats. Three months after contusion and
treatment with anti-MBP T cells, some rats from both the treated
and the control groups were re-anesthetized and a dye was applied
below the site of the contusion. After five to seven days, the rats
were again deeply anesthetized and their brains were excised,
processed, and cryosectioned. Sections taken through the red
nucleus were inspected and analyzed qualitatively and
quantitatively under fluorescent and confocal microscopes.
Significantly, more labeled nuclei were seen in the red nuclei of
rats treated with anti-MBP T cells (8A) than in the red nuclei of
PBS-treated rats (8B). The quantitative differences are shown in
the bar graph (8C) and were obtained from animals with scores of 10
and 11 in the T-cell-treated group and scores of 6 in the control
group. The bar graph shows mean.+-.SD.
[0033] FIG. 9 is a series of photographs showing diffusion-weighted
imaging of contused spinal cord treated with anti-MBP T cells.
Spinal cords of MBP-T cell-treated and PBS-treated animals (with
locomotion scores of 10 and 8, respectively) were excised under
deep anesthesia, immediately fixed in 4% paraformaldehyde solution,
and placed into 5 mm NMR tubes. Diffusion anisotropy was measured
in a Bruker DMX 400 widebore spectrometer using a microscopy probe
with a 5-mm Helmholtz coil and actively shielded magnetic field
gradients. A multislice pulsed gradient spin echo experiment was
performed with 9 axial slices, with the central slice positioned at
the center of the spinal injury. Images were acquired with TE of 31
ms, TR of 2000 ms, a diffusion time of 15 ms, a diffusion gradient
duration of 3 ms, field of view 0.6 mm, matrix size 128.times.128,
slice thickness 0.5 mm, and slice separation of 1.18 mm. Four
diffusion gradient values of 0, 28, 49, and 71 g/cm were applied
along the read direction (transverse diffusion) or along the slice
direction (longitudinal diffusion). Diffusion anisotropy is
manifested by increased signal intensity in the images with the
highest transverse diffusion gradient relative to the longitudinal
diffusion gradient. The excised spinal cords of a PBS-treated rat
and in the rat treated with MBP-T cells were subjected to
diffusion-weighted MRI analysis. In the PBS-treated injured
control, diffusion anisotropy was seen mainly in sections near the
proximal and distal stumps of the cord, with low anisotropy in
sections taken through the site of injury. In contrast, in the
treated rat, higher levels of diffusion anisotropy can be seen in
sections taken through the site of injury.
[0034] FIG. 10 is a graph illustrating inhibition of secondary
degeneration after optic nerve crush injury in adult rats. See
text, Example 3, for experimental details. Rats were injected
intradermally through the footpads with a 21-mer peptide based on
MOG amino acid residues 35-55 (MOG p35-55) ((50 .mu./animal,
chemically synthesized at the Weizmann Institute of Science,
Rehovot, Israel) or PBS ten days prior to optic nerve crush injury
or MOG p35-55 in the absence of crush injury. MOG p35-55 was
administered with IFA. Surviving optic nerve fibers were monitored
by retrograde labeling of RGCs. The number of RGCs in rats injected
with PBS or MOG p35-55 was expressed as a percentage of the total
number of neurons in rats injected with MOG p35-55 in the absence
of crush injury.
[0035] FIG. 11 is a graph illustrating inhibition in adult rats of
secondary degeneration after optic nerve crush injury by MBP. See
text, Example 4, for experimental details. MBP (Sigma, Israel) (1
mg in 0.5 ml saline) was administered orally to adult rats by
gavage using a blunt needle. MBP was administered 5 times, i.e.,
every third day beginning two weeks prior to optic nerve crush
injury. Surviving optic nerve fibers were monitored by retrograde
labeling of RGCs. The number of RGCs in treated rats was expressed
as a percentage of the total number of neurons in untreated rats
following the injury.
[0036] FIGS. 12 (A-F) show expression of B7 co-stimulatory
molecules in intact and injured rat optic nerve. Optic nerves were
excised from adult Lewis rats before (12A, 12B) and three days
after injury (12C, 12D, 12E) and analyzed immunohistochemically for
expression of the B7 co-stimulatory molecule. The site of injury
was delineated by GFAP staining. Using calibrated cross-action
forceps, the right optic nerve was subjected to a mild crush injury
1-2 mm from the eye. The uninjured cointralateral nerve was left
undisturbed. Immunohistochemical analysis of optic nerve antigens
was performed as follows. Briefly, longitudinal cryosections of the
excised nerves (20 .mu.m thick) were picked up onto gelatin-coated
glass and fixed with ethanol for ten minutes at room temperature.
The sections were washed and incubated for one hour at room
temperature with mouse monoclonal antibody to rat GFAP (BioMakor,
Israel), diluted 1:100, and with antibodies to B7.2 co-stimulatory
molecule and the B7.1 co-stimulatory molecule (Pharmingen, San
Diego, Calif.), diluted 1:25. The sections were washed again and
incubated with rhodamine isothiocyanate-conjugated goat anti-mouse
IgG (with minimal cross-reaction to rat, human, bovine and horse
serum protein) go (Jackson ImmunoResearch, West Grove, Pa.), for
one hour at room is temperature. All washing solutions contained
PBS and 0.05% Tween-20. All diluting solutions contained PBS
containing 3% fetal calf serum and 2% bovine serum albumin. The
sections were treated with glycerol containing
1,4-diazobicyclo-(2,2,2)-octane and were then viewed with a Zeiss
microscope. Note the morphological changes of the B7.2 positive
cells after injury, from a rounded (12A, 12B) to a star-like shape
(12C, 12D). The B7.2 positive cells were present at a higher
density closer to the injury site (12E). Expression of B7.1 was
detectable only from day seven and only at the injured site
(12F).
[0037] FIGS. 13A-C show immunohistochemical analysis of T cells,
macrophages or microglia, and B7.2 co-stimulatory molecules in the
injured optic nerves of rats fed MBP. Lewis rats aged 6-8 weeks
were fed 1 mg of bovine MBP (Sigma, Israel) (2 mg MBP/ml PBS) or
0.5 ml PBS only every other day by gastric intubation using a
stainless steel feeding needle (Thomas Scientific, Swedesboro,
N.J.) (Chen et al, 1994). Ten days after starting MBP, the right
optic nerves were subjected to calibrated crush injury, as
described for FIG. 12. Three days later, the nerves were excised
and prepared for immunohistochemical analysis of T cells using
mouse monoclonal antibodies to T cell receptor 11, diluted 1:25,
macrophages or microglia using anti-ED1 antibodies (Serotek,
Oxford, U.K) diluted 1:250, astrocytes using anti-GFAP antibodies
and B7.2 co-stimulatory molecules as described for FIG. 12. There
were no significant quantitative differences in T cells or in ED-1
positive cells between injured optic nerves of PBS-fed (13A) and
MBP-fed (13B) rats. The number of B7.2 positive cells at the site
of injury of MBP-fed rats (13C) should be noted, as compared with
injured controls (see FIG. 12E above).
[0038] FIG. 14 is a graph showing the slowing of neuronal
degeneration in rats with orally induced tolerance to MBP. Lewis
rats were fed 1 mg MBP daily, or every other day, or 4 times a day
at two-hour intervals for five consecutive days. Control animals
were given PBS or the non-self antigen OVA Sigma, Israel). Ten days
after the start of MBP ingestion, the right optic nerves were
subjected to a calibrated mild crush injury. Two weeks later the
RGCs were retrogradely labelled by application of the fluorescent
lipophilic dye 4-Di-10-Asp(Molecular Probes Europe BV,
Netherlands), distally to the site of injury, as described.
Briefly, complete axotomy was performed 1-2 mm from the distal
border to the injury site, and solid crystals (0.2-0.4 mm in
diameter) of 4-Di-10-Asp were immediately deposited at the site of
the lesion. Retrograde labeling of RGCs by the dye gives a reliable
indication of the number of still-functioning neurons, as only
intact axons can transport the dye to their cell bodies in the
retina. Six days after dye application, the retina was detached
from the eye, prepared as a flattened whole mount in 4%
paraformaldehyde solution, and examined for labeled RGCs by
fluorescence microscopy. RGCs were counted from three different
regions in the retina. The results are expressed as normalized
percentage of each retina to untreated injured animal mean of the
same experiment. The median of each group is shown as a bar
(Control vs. MBP OTx4 ** P<0.01; Control vs. MBP OT ** P, 0.01;
Control vs. OVA OT ns P>0.05.
[0039] FIG. 15 shows the nucleotide sequence of rat MBP gene, SEQ
ID NO:1, Genbank accession number M25889 (Schaich et al, 1986).
[0040] FIG. 16 shows the nucleotide sequence of human MBP gene, SEQ
ID NO:2, Genbank accession number M13577 (Kamholz et al, 1986).
[0041] FIGS. 17(A-F) show the nucleotide sequences of human PLP
gene exons 1-7, SEQ ID NOs:3-8, respectively, Genbank accession
numbers M15026-M15032, respectively (Diehl et al, 1986).
[0042] FIG. 18 shows the nucleotide sequence of human MOG gene, SEQ
ID NO:9, Genbank accession number Z48051 (Roth et al, submitted
(Jan. 17, 1995) Roth, CNRS UPR 8291, CIGH, CHU Purpan, Toulouse,
France, 31300; Gonzalez et al, 1996).
[0043] FIG. 19 shows the nucleotide sequence of rat PLP gene and
variant, SEQ ID NO:10, Genbank accession number M16471 (Nave et al,
1987).
[0044] FIG. 20 shows the nucleotide sequence of rat MAG gene, SEQ
ID NO:11, Genbank accession number M14871 (Arquint et al,
1987).
[0045] FIG. 21 shows the amino acid sequence of human MBP, SEQ ID
NO:12, Genbank accession number 307160 (Kamholz et al, 1986).
[0046] FIG. 22 shows the amino acid sequence of human PLP, SEQ ID
NO:13, Genbank accession number 387028.
[0047] FIG. 23 shows the amino acid sequence of human MOG, SEQ ID
NO:14, Genbank accession number 793839 (Roth et al, 1995; Roth
Submitted (JAN. 17, 1995) Roth CNRS UPR 8291, CIGH, CHU Purpan,
Toulouse, France, 31300; Gonzalez et al, 1996).
[0048] FIGS. 24(A-B) show that post-traumatic immunization with
Nogo peptide p472 emulsified in CFA promotes functional recovery
from spinal cord contusion in comparison to PBS+CFA-treated rats.
Spinal cords of male SPD rats were laminectomized at the level of
T9 and a 10-g rod was dropped onto the laminectomized cord from a
height of 50 mm (FIG. 24A) or of 25 mm (FIG. 24B). See text,
Example 5, for experimental details.
[0049] FIG. 25 show that post-traumatic immunization with Nogo
peptide p472 emulsified in CFA promotes functional recovery from
spinal cord contusion in comparison to PBS-treated or
PBS+CFA-treated rats. Spinal cords of female SPD rats were
laminectomized at the level of T9 and a 10-g rod was dropped onto
the laminectomized cord from a height of 50 mm. See text, Example
5, for experimental details.
DETAILED DESCRIPTION OF THE INVENTION
[0050] As exposed above, the present invention relates to
compositions and methods for promoting nerve regeneration or for
conferring neuroprotection and preventing or inhibiting neuronal
degeneration in the CNS or PNS for ameliorating the effects of
injury or disease, comprising administering to an individual in
need thereof at least one ingredient selected from the group
consisting of:
[0051] (a) NS-specific activated T cells;
[0052] (b) a NS-specific antigen or an analog thereof;
[0053] (c) a peptide derived from an NS-specific antigen or from an
analog thereof, or an analog or derivative of said peptide;
[0054] (d) a nucleotide sequence encoding an NS-specific antigen or
an analog thereof;
[0055] (e) a nucleotide sequence encoding a peptide derived from an
NS-specific antigen or from an analog thereof, or an analog of said
peptide; or
[0056] (f) any combination of (a)-(e).
[0057] Merely for ease of explanation, the detailed description of
the present invention is divided into the following sections:
NS-specific activated T cells and T-cell banks; NS-specific
antigens, analogs thereof, peptides derived therefrom and analogs
and derivatives thereof of said peptides; nucleotide sequences
encoding NS-specific antigens, analogs thereof, peptides derived
therefrom and analogs thereof; therapeutic uses; and formulations
and modes of administration.
[0058] NS-Specific Activated T Cells and T-Cell Banks
[0059] In one embodiment of the invention, NS-specific activated T
cells can be used in an amount which is effective to confer
neuroprotection for ameliorating or inhibiting the effects of
injury or disease of the CNS or PNS that result in NS degeneration
or for promoting regeneration in the NS, in particular the CNS, as
described in the section on therapeutic uses hereinafter.
[0060] In the practice of the invention, administration of
NS-specific activated T cells may optionally be in combination with
an NS-specific antigen or an analog thereof or a peptide derived
therefrom or an analog or derivative of said peptide. Additionally,
oral administration of NS-specific antigen or an analog thereof or
a peptide derived therefrom or an analog or derivative thereof, can
be combined with active immunization to build up a critical T-cell
response immediately after injury.
[0061] Activation of T cells is initiated by interaction of a TCR
complex with a processed antigenic peptide bound to a MHC molecule
on the surface of an antigen-presenting cell (APC). As used herein,
the term "activated T cells" includes both (i) T cells that have
been activated by exposure to a cognate antigen or peptide derived
therefrom or derivative thereof; and (ii) progeny of such activated
T cells. As used herein, a "cognate antigen" is an antigen that is
specifically recognized by the TCR of a T cell that has been
previously exposed to the antigen. Alternatively, the T cell which
has been previously exposed to the antigen may be activated by a
mitogen, such as phytohemagglutinin (PHA) or concanavalin A (Con
A).
[0062] The term "NS-specific activated T cell" as used herein
refers to an activated T cell having specificity for an antigen of
the NS, said NS-specific antigen being an antigen of the NS that
specifically activates T cells such that these activated T cells
will accumulate at a site of injury or disease in the NS of the
patient. The NS-specific antigen used to confer the specificity to
the T cells may be a self NS-antigen of the patient or a non-self
NS-antigen of another individual or even of another species, or an
analog of said NS-antigen, or a peptide derived from said
NS-antigen or from said analog thereof, or an analog or derivative
of said peptide, all as described in the section on NS-specific
antigens, analogs thereof, peptides derived therefrom and analogs
and derivatives thereof of said peptides hereinafter, as long as
the activated T cell recognizes an antigen in the NS of the
patient.
[0063] If the disease being treated by the NS-specific activated T
cells of the invention is an autoimmune disease, in which the
autoimmune antigen is an NS antigen, the T cells which are used in
accordance with the present invention for the treatment of neural
damage or degeneration caused by such disease are preferably not
activated against the same autoimmune antigen involved in the
disease. While the prior art has described methods of treating
autoimmune diseases by administering activated T cells to create a
tolerance to the autoimmune antigen, the T cells of the present
invention are not administered in such a way as to create
tolerance, but are administered in such a way as to create
accumulation of the T cells at the site of injury or disease so as
to facilitate neural regeneration or to inhibit neural
degeneration.
[0064] The prior art also discloses uses of immunotherapy against
tumors, including brain tumors, by administering T cells specific
to an NS antigen in the tumor so that such T cells may induce an
immune system attack against the tumors. The present invention is
not intended to comprehend such prior art techniques. However, the
present invention is intended to comprehend the inhibition of
neural degeneration or the enhancement of neural regeneration in
patients with brain tumors by means other than the prior art
immunotherapy of brain tumors. Thus, for example, NS-specific
activated T cells, which are activated to an NS-antigen of the
patient other than an antigen which is involved in the tumor, would
be expected to be useful for the purpose of the present invention
and would not have been suggested by known immunotherapy
techniques.
[0065] The NS-specific activated T cells are preferably autologous,
most preferably of the CD4 and/or CD8 phenotypes, but they may also
be semi-allogeneic T cells or allogeneic T cells from related
donors, e.g., siblings, parents, children, or from donors with the
same HLA type (HLA-matched) or a very similar HLA type
(HLA-partially matched), or even from unrelated donors.
[0066] Thus, in addition to the use of autologous T cells isolated
from the subject, the present invention also comprehends the use of
semi-allogeneic T cells for neuroprotection. The T cells may be
prepared as short- or long-term lines and stored by conventional
cryopreservation methods for thawing and administration, either
immediately or after culturing for 1-3 days, to a subject suffering
from injury to the CNS and in need of T-cell neuroprotection.
[0067] The use of semi-allogeneic T cells is based on the fact that
T cells can recognize a specific antigen epitope presented by
foreign APC, provided that the APC expresses the MHC molecule,
class I or class II, to which the specific responding T-cell
population is restricted, along with the antigen epitope recognized
by the T cells. Thus, a semi-allogeneic population of T cells that
can recognize at least one allelic product of the subject's MHC
molecules, preferably a class II HLA-DR or HLA-DQ or other HLA
molecule, and that is specific for a NS-associated antigen epitope,
will be able to recognize the NS antigen in the subject's area of
NS damage and produce the needed neuro-protective effect. There is
little or no polymorphism in the adhesion molecules, leukocyte
migration molecules, and accessory molecules needed for the T cells
to migrate to the area of damage, accumulate there, and undergo
activation. Thus, the semi-allogeneic T cells will be able to
migrate and accumulate at the CNS site in need of neuroprotection
and will be activated to produce the desired effect.
[0068] It is known that semi-allogeneic T cells will be rejected by
the subject's immune system, but that rejection requires about two
weeks to develop. Hence, the semi-allogeneic T cells will have the
two-week window of opportunity needed to exert neuroprotection.
After two weeks, the semi-allogeneic T cells will be rejected from
the body of the subject, but that rejection is advantageous to the
subject because it will rid the subject of the foreign T cells and
prevent any untoward consequences of the activated T cells. The
semi-allogeneic T cells thus provide an important safety factor and
are a preferred embodiment.
[0069] It is known that a relatively small number of HLA class II
molecules are shared by most individuals in a population. For
example, about 50% of the Jewish population express the HLA-DR5
gene. Thus, a bank of specific T cells reactive to NS-antigen
epitopes that are restricted to HLA-DR5 would be useful in 50% of
that population. The entire population can be covered essentially
by a small number of additional T cell lines restricted to a few
other prevalent HLA molecules, such as DR1, DR4, DR2, etc. Thus, a
functional bank of uniform T cell lines can be prepared and stored
for immediate use in almost any individual in a given population.
Such a bank of T cells would overcome any technical problems in
obtaining a sufficient number of specific T cells from the subject
in need of neuroprotection during the open window of treatment
opportunity. The semi-allogeneic T cells will be safely rejected
after accomplishing their role of neuroprotection. This aspect of
the invention does not contradict, and is in addition to the use of
autologous T cells as described herein.
[0070] The NS-specific activated T cells are preferably
non-attenuated, although attenuated NS-specific activated T cells
may be used. T cells may be attenuated using methods well-known in
the art including, but not limited to, by gamma-irradiation, e.g.,,
1.5-10.0 Rads (Ben-Nun et al, 1981; Ben-Nun and Cohen, 1982);
and/or by pressure treatment, for example as described in U.S. Pat.
No. 4,996,194 (Cohen et al); and/or by chemical cross-linking with
an agent such as formaldehyde, glutaraldehyde and the like, for
example as described in U.S. Pat. No. 4,996,194 (Cohen et al);
and/or by cross-linking and photoactivation with light with a
photoactivatable psoralen compound, for example as described in
U.S. Pat. No. 5,114,721 (Cohen et al); and/or by a cytoskeletal
disrupting agent such as cytochalsin and colchicine, for example as
described in U.S. Pat. No. 4,996,194 (Cohen et al). In a preferred
embodiment the NS-specific activated T cells are isolated as
described below. T cells can be isolated and purified according to
methods known in the art (Mor and Cohen, 1995). For an illustrative
example, see Example 1, Materials and Methods.
[0071] Circulating T cells of a subject which recognize an
NS-antigen are isolated and expanded using known procedures (Burns
et al, 1983; Pette et al, 1990; Martin et al, 1990; Schluesener et
al, 1985; Suruhan-Dires Keneli et al, 1993, which are incorporated
herein by reference in their entirety). In order to obtain
NS-specific activated T cells, T cells are isolated and the
NS-specific activated T cells are then expanded.
[0072] The isolated T cells may be activated by exposure of the
cells to one or more of a variety of natural or synthetic
NS-specific antigens or epitopes as described in section on
NS-specific antigens, analogs thereof, peptides derived therefrom
and analogs and derivatives thereof of said peptides hereinafter.
During ex vivo activation of the T cells, the T cells may be
activated by culturing in medium to which at least one suitable
growth promoting factor has been added, such as cytokines, e.g.,
TNF-.alpha., IL-2 and/or IL-4.
[0073] In one embodiment, the NS-specific activated T cells
endogenously produce a substance that ameliorates the effects of
injury or disease in the NS.
[0074] In another embodiment, the NS-specific activated T cells
endogenously produce a substance that stimulates other cells,
including, but not limited to, transforming growth factor-.beta.
(TGF-.beta.), nerve growth factor (NGF), neurotrophic factor 3(NT
3), neurotrophic factor 4/5 (NT-4/5), brain derived neurotrophic
factor (BDNF); IFN-.gamma. and IL-6, wherein the other cells,
directly or indirectly, ameliorate the effects of injury or
disease.
[0075] Following their proliferation in vitro, the T cells are
administered to a mammalian, preferably a human, subject. T cell
expansion is preferably performed using peptides corresponding to
sequences in a non-pathogenic, NS-specific, self-protein.
[0076] A subject can initially be immunized with an NS-specific
antigen using a non-pathogenic peptide of the self-protein. A
T-cell preparation can be prepared from the blood of such immunized
subjects, preferably from T cells selected for their specificity
towards the NS-specific antigen. The selected T cells can then be
stimulated to produce a T cell line specific to the self-antigen
(Ben-Nun and Cohen, 1982).
[0077] NS-specific antigen activated T cells, obtained as described
above, can be used immediately or may be preserved for later use,
e.g., by cryopreservation as described below. NS-specific activated
T cells may also be obtained using previously cryopreserved T
cells, i.e., after thawing the cells, the T cells may be incubated
with NS-specific antigen, optimally together with thymocytes, to
obtain a preparation of NS-specific activated T cells.
[0078] As will be evident to those skilled in the art, the T cells
can be preserved, e.g., by cryopreservation, either before or after
culture.
[0079] Cryopreservation agents which can be used include, but are
not limited to, dimethyl sulfoxide (DMSO) (Lovelock and Bishop,
1959; Ashwood-Smith, 1961), polyvinylpyrrolidone (Rinfret, 1960),
glycerol, polyethylene glycol (Sloviter and Ravdin, 1962), albumin,
dextran, sucrose, ethylene glycol, i-erythritol, D-ribitol,
D-mannitol (Rowe et al, 1962), D-sorbitol, i-inositol, D-lactose,
choline chloride (Bender et al, 1960), amino acids (Phan The Tran
and Bender, 1960), methanol, acetamide, glycerol monoacetate
(Lovelock, 1954), inorganic salts (Phan The Tran and Bender, 1960
and 1961) and DMSO combined with hydroxyethyl starch and human
serum albumin (Zaroulis and Leiderman, 1980).
[0080] A controlled cooling rate is critical. Different
cryoprotective agents (Rapatz et al, 1968) and different cell types
have different optimal cooling rates. See, e.g., Rowe and Rinfret,
1962; Rowe, 1966; Lewis et al, 1967; Mazur, 1970) for effects of
cooling velocity on survival of cells and on their transplantation
potential. The heat of fusion phase where water turns to ice should
be minimal. The cooling procedure can be carried out by use of,
e.g., a programmable freezing device or a methanol bath
procedure.
[0081] Programmable freezing apparatuses allow determination of
optimal cooling rates and facilitate standard reproducible cooling.
Programmable controlled-rate freezers such as Cryomed or Planar
permit tuning of the freezing regimen to the desired cooling rate
curve.
[0082] After thorough freezing, cells can be rapidly transferred to
a long-term cryogenic storage vessel. In one embodiment, samples
can be cryogenically stored in mechanical freezers, such as
freezers that maintain a temperature of about -80.degree. C. or
about -20.degree. C. In a preferred embodiment, samples can be
cryogenically stored in liquid nitrogen (-196.degree. C.) or its
vapor. Such storage is greatly facilitated by the availability of
highly efficient liquid nitrogen refrigerators, which resemble
large Thermos containers with an extremely low vacuum and internal
super insulation, such that heat leakage and nitrogen losses are
kept to an absolute minimum.
[0083] Considerations and procedures for the manipulation,
cryopreservation, and long term storage of T cells can be found,
for example, in the following references, incorporated by reference
herein: Gorin, 1986; Bone-Marrow Conservation, it Culture and
Transplantation, 1968.
[0084] Other methods of cryopreservation of viable cells, or
modifications thereof, are available and envisioned for use, e.g.,
cold metal-mirror techniques. See Livesey and Linner, 1987; Linner
et al, 1986; see also U.S. Pat. No. 4,199,022 by Senken et al, U.S.
Pat. No. 3,753,357 by Schwartz, U.S. Pat. No. 4,559,298 by
Fahy.
[0085] Frozen cells are preferably thawed quickly (e.g., in a water
bath maintained at 37-47.degree. C.) and chilled immediately upon
thawing. It may be desirable to treat the cells in order to prevent
cellular clumping upon thawing. To prevent clumping, various
procedures can be used, including but not limited to the addition
before or after freezing of DNAse (Spitzer et al, 1980), low
molecular weight dextran and citrate, citrate, hydroxyethyl starch
(Stiff et al, 1983), or acid citrate dextrose (Zaroulis and
Leiderman, 1980), etc.
[0086] The cryoprotective agent, if toxic in humans, should be
removed prior to therapeutic use of the thawed T cells. One way in
which to remove the cryoprotective agent is by dilution to an
insignificant concentration.
[0087] Once frozen T cells have been thawed and recovered, they are
used to promote neuroprotection as described herein with respect to
non-frozen T cells. Once thawed, the T cells may be used
immediately, assuming that they were activated prior to freezing.
Preferably, however, the thawed cells are cultured before injection
to the patient in order to eliminate non-viable cells. Furthermore,
in the course of this culturing over a period of about one to three
days, an appropriate activating agent can be added so as to
activate the cells, if the frozen cells were resting T cells, or to
help the cells achieve a higher rate of activation if they were
activated prior to freezing. Usually, time is available to allow
such a culturing step prior to administration as the T cells may be
administered as long as a week after injury, and possibly longer,
and still maintain their neuro-regenerative and neuroprotective
effect.
[0088] To minimize secondary damage after nerve injury, patients
can be treated by administering autologous or semi-allogeneic T
lymphocytes sensitized to at least one appropriate NS-antigen. As
the window of opportunity has not yet been precisely defined,
therapy should be administered as soon as possible after the
primary injury to maximize the chances of success, preferably
within about one week.
[0089] To bridge the gap between the time required for activation
and the time needed for treatment, a bank with autologous,
semi-allogeneic or allogeneic T cells can be established for future
use.
[0090] Thus, in another embodiment, the invention provides cell
banks that can be established to store NS-sensitized T cells for
neuroprotective treatment of individuals at a later time, as
needed.
[0091] In one embodiment, autologous T cells may be obtained from
an individual and the cell bank will contain personal vaults of
autologous T lymphocytes prepared for future use for
neuroprotective therapy against secondary degeneration in case of
NS injury. T lymphocytes are isolated from the blood, sensitized to
a NS-antigen, and the cells are then frozen and suitably stored
under the person's name, identity number, and blood group, in a
cell bank until needed.
[0092] Additionally, autologous stem cells of the CNS can be
processed and stored for potential use by an individual patient in
the event of traumatic disorders of the NS such as ischemia or
mechanical injury, as well as for treating neurodegenerative
conditions such as Alzheimer's disease or Parkinson's disease.
[0093] Alternatively, allogeneic or semi-allogeneic T cells may be
stored such that a bank of T cells of each of the most common
MHC-class II types are present. The semi-allogeneic or allogeneic T
cells are stored frozen for use by any individual who shares one
MHC type II molecule with the source of the T cells.
[0094] In case an individual is to be treated for an injury,
preferably autologous stored T cells are used, but, if autologous T
cells are not available, then cells should be used which share an
MHC type II molecule with the patient, and these would be expected
to be operable in that individual.
[0095] The cells are preferably stored in an activated state after
exposure to an NS-antigen or peptide derived therefrom. However,
the cells may also be stored in a resting state and activated once
they are thawed and prepared for use. The cell lines of the bank
are preferably cryopreserved. The cell lines are prepared in any
way which is well known in the art. Once the cells are thawed, they
are preferably cultured prior to injection in order to eliminate
non-viable cells. During this culturing, the cells can be activated
or reactivated using the same NS-antigen or peptide as used in the
original activation. Alternatively, activation may be achieved by
culturing in the presence of a mitogen, such as phytohemagglutinin
(PHA) or concanavalin A (preferably the former). This will place
the cells into an even higher state of activation. The few days
that it takes to culture the cells should not be detrimental to the
patient as the treatment in accordance with the present invention
may occuo still be effective. Alternatively, if time is of the
essencer any time up to a week or more after the injury in order t,
the stored cells may be administered immediately after thawing.
[0096] NS-Specific Antigens, Analogs thereof, Peptides Derived
Therefrom, and Analogs and Derivatives Thereof
[0097] The term "NS-specific antigen" as used herein refers to an
antigen of the NS that specifically activates T cells such that
following activation the activated T cells accumulate at a site of
injury or disease in the NS of the patient.
[0098] The NS-specific antigen used according to the present
invention may be an antigen obtained from NS tissue, preferably
from tissue at a site of CNS injury or disease. It may be a crude
NS-tissue preparation, e.g., derived from NS tissue obtained from
mammalian NS that may include cells, both living or dead cells,
membrane fractions of such cells or tissue, etc., and may be
obtained by an NS biopsy or necropsy from a mammal, preferably
human, tissue including, but not limited to, from a site of CNS
injury; from cadavers; and from cell lines grown in culture.
[0099] In one embodiment, the NS-specific antigen is an isolated or
purified antigen. The NS-specific antigen may be isolated and
purified by standard methods including chromatography (e.g., ion
exchange, affinity, and sizing column chromatography),
centrifugation, differential solubility, or by any other standard
technique for the purification of antigens. The functional
properties may be evaluated using any suitable assay. Additionally,
an NS-specific antigen may be a protein obtained by genetic
engineering, chemically synthesized, etc.
[0100] In the practice of the invention, natural or synthetic
NS-specific antigens are preferred and include, without being
limited to, myelin basic protein (MBP), proteolipid protein (PLP),
myelin oligodendrocyte glycoprotein (MOG), myelin-associated
glycoprotein (MAG), S-100, .beta.-amyloid, Thy-1, P0, P2,
neurotransmitter receptors, Nogo and Nogo receptor (NgR).
[0101] Specific illustrative examples of useful NS-specific
antigens include but are not limited to, human MBP, depicted in
FIG. 21 (SEQ ID NO:12); human PLP, depicted in FIG. 22 (SEQ ID
NO:13); human MOG, depicted in FIG. 23 (SEQ ID NO:14), rat Nogo A,
B and C (Chen et al, 2000; WO 00/31235) (SEQ ID NOs:18, 20 and 21),
peptide p472 (SEQ ID NO:19), human Nogo A, B and C (Prinjha et al,
2000) (SEQ ID NOs:23-25), and human or mouse Nogo receptor (NgR)
(Fournier et al, 2001) (SEQ ID NOs:26 and 27, respectively).
[0102] Also encompassed by the present invention are analogs of
NS-specific antigens including, but not being limited to, those
molecules comprising regions that are substantially homologous to
the full-length NS-specific antigen, or fragments thereof. In
various embodiments, these analogs will have at least 60% or 70% or
80% or 90% or 95% identity over an amino acid sequence of identical
size or when compared to an aligned sequence in which the alignment
is done by a computer homology program known in the art or whose
encoding nucleic acid is capable of hybridizing to a coding
nucleotide sequence of the full-length NS-specific antigen, under
high stringency, moderate stringency, or low stringency conditions.
Computer programs for determining homology may include, but are not
limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson
and Lipman, 1988; Altschul et al, 1990; Thompson, et al, 1994;
Higgins, et al, 1996).
[0103] The NS-specific antigen analogs of the invention can be
produced by various methods known in the art. The manipulations
which result in their production can occur at the gene or protein
level. For example, a cloned gene sequence can be modified by any
of numerous strategies known in the art (Maniatis, 1990). The
sequence can be cleaved at appropriate sites with restriction
endonuclease(s), followed by further enzymatic modification if
desired, isolated, and ligated in vitro.
[0104] Additionally, the coding nucleic acid sequence can be
mutated in vitro or in vivo, to create and/or destroy translation,
initiation, and/or termination sequences, or to create variations
in coding regions and/or form new restriction endonuclease sites or
destroy preexisting ones, to facilitate further in vitro
modification. Any technique for mutagenesis known in the art can be
used, including but not limited to, chemical mutagenesis, in vitro
site-directed mutagenesis (Hutchinson, et al, 1978), etc.
[0105] Manipulations may also be made at the protein level.
Included within the scope of the invention are NS-specific antigen
derivatives which are differentially modified during or after
translation, e.g., by glycosylation, acetylation, phosphorylation,
amidation, derivatization by known protecting/blocking groups,
proteolytic cleavage, linkage to an antibody molecule or other
cellular ligand, etc. Any of numerous chemical modifications may be
carried out by known techniques, including but not limited to
specific chemical cleavage by cyanogen bromide, trypsin,
chymotrypsin, papain, V8 protease, NaBH.sub.4; acetylation,
formylation, oxidation, reduction; metabolic synthesis in the
presence of tunicamycin; etc.
[0106] In a preferred embodiment, the invention relates to peptides
derived from NS-specific antigens or from analogs thereof and to
analogs or derivatives of said peptides, which are functionally
active, i.e., they are capable of displaying one or more known
functional activities associated with a full-length NS-specific
antigen. Such functional activities include, but are not limited
to, antigenicity (ability to bind, or compete with an NS-antigen
for binding, to an anti-NS-specific antibody), immunogenicity
(ability to generate antibody which binds to an NS-specific
protein), and ability to interact with T cells, resulting in
activation comparable to that obtained using the corresponding
full-length NS-specific antigen. The crucial test is that the
antigen which is used for activating the T cells causes the T cells
to be capable of recognizing an antigen in the NS of the mammal
(patient) being treated.
[0107] The NS-antigen derived peptide may be either: (1) an
immunogenic peptide, i.e., a peptide that can elicit a human T-cell
response detected by a T-cell proliferation assay or by cytokine,
e.g., IFN-.gamma., IL-2, IL-4 or IL-10, production, or (2) a
"cryptic epitope" (also designated herein as "immunosilent" or
"non-immunodominant" epitope), i.e., a peptide that by itself can
induce a T-cell immune response that is not induced by the whole
antigen protein (see Moalem et al, 1999).
[0108] A peptide derived from a NS-specific antigen preferably has
a sequence comprised within the NS-specific antigen sequence and
has at least 10, 13, 15, 18, 20 or 50 contiguous amino acids of the
NS-specific antigen sequence. In one embodiment, the peptide
derived from an NS-specific antigen is a "cryptic epitope" of the
antigen. A cryptic epitope activates specific T cells after an
animal is immunized with the particular peptide, but not with the
whole antigen. Cryptic epitopes for use in the present invention
include, but are not limited to, peptides of the MBP sequence:
peptides p11-30, p51-70, p87-99, p91-110, p131-150, and p151-170.
Such cryptic epitopes are particularly preferred as T cells
activated thereby will accumulate at the injury site, but are
particularly weak in autoimmunity. Thus, they would be expected to
have fewer side effects.
[0109] In another embodiment, the peptide derived from an
NS-specific antigen is an immunogenic epitope of the antigen.
[0110] Examples of further peptides according to the invention are
immunogenic peptides derived from the Nogo protein sequence such
as, but not being limited to, the 18-mer p472 Nogo peptide (SEQ ID
NO:18) and peptides derived from the Nogo receptor (Fournier et al,
2001) such as the 15-mer peptides of the sequences:
[0111] S G V P S N L P Q R L A G R D (SEQ ID NO:28)
[0112] T R S H C R L G Q A G S G S S (SEQ ID NO:29)
[0113] In still another embodiment of the invention, the peptide is
an analog of a peptide derived from an NS-specific antigen that is
immunogenic but not encephalitogenic. The most suitable peptides
for this purpose are those in which an encephalitogenic
self-peptide is modified at the T-cell receptor (TCR) binding site
and not at the MHC binding site(s), so that the immune response is
activated but not anergized (Karin et al, 1998; Vergelli et al,
1996).
[0114] These analogs, also referred herein as modified peptides or
altered peptides, may be produced by replacement of one or more
amino acid residues of the peptide by other amino acid residues,
preferably in their TCR binding site. Suitable replacements are
those in which charged amino residues like lysine, proline or
arginine are replaced by glycine or alanine residues. For example,
altered peptides can be produced from peptides p11-30, p51-70,
p87-99, p91-110, p131-150, and p151-170 of human MBP, for example
from the p87-99 peptide in which the lysine 91 is replaced by
glycine and/or the proline 96 is replaced by an alanine residue,
thus converting an encephalitogenic peptide in immunogenic but
non-encephalitogenic peptide that still recognizes the TCR. In the
same way, altered peptides can be produced from the
encephalitogenic p472 Nogo peptide (Nogo p623-640) by replacement
of the lys 628 residue and from the Nogo receptor peptides above by
replacement of the arg (R) residue by Val or Ala or another similar
residue.
[0115] In addition, the analogs also comprise replacement of one or
more amino acid residues of the peptide or addition to the peptide
of non-natural amino acids including, but not limited to, the
D-isomers of the common amino acids, .alpha.-aminoisobutyric acid;
4-aminobutyric acid (Abu); 2-Abu (.gamma.-Abu); 6-amino hexanoic
acid (.epsilon.-Ahx); 2-aminoisobutyric acid (Aib);
3-aminopropionic acid; ornithine; norleucine (Nle); norvaline
(Nva); hydroxyproline; sarcosine; citrulline; cysteic acid;
t-butylglycine; t-butylalanine; phenylgylcine; cyclohexylalanine;
.beta.-alanine; fluoro-amino acids; designer amino acids such as
.beta.-methyl amino acids, C.alpha.-methyl amino acids,
N.alpha.-methyl amino acids, and amino acid analogs in general.
Furthermore, the amino acid can be D (dextrorotary) or L
(levorotary).
[0116] Furthermore, the invention also comprises chemical
derivatives of the peptides of the invention including, but not
being limited to, esters of both carboxylic and hydroxy groups,
amides, and the like.
[0117] The NS-specific antigen peptides of the invention can be
chemically synthesized- For example, a peptide corresponding to a
portion of an antigen which comprises the desired domain or which
mediates the desired activity can be synthesized by use of a
peptide synthesizer.
[0118] The functional activity of NS-specific antigens and peptides
derived therefrom and analogs and derivatives thereof can be
assayed by various methods known in the art, including, but not
limited to, T-cell proliferation assays (Mor and Cohen, 1995) and
cytokine production assays.
[0119] An NS-specific antigen or peptide derived therefrom or
derivative thereof may be kept in solution or may be provided in a
dry form, e.g., as a powder or lyophilizate, to be mixed with
appropriate solution prior to use. They may be used both as
ingredients of pharmaceutical compositions for neuroprotection and
preventing or inhibiting the effects of injury or disease that
result in NS degeneration or for promoting nerve regeneration in
the NS, particularly in the CNS as well as for in vivo or in vitro
activation of T cells.
[0120] Nucleotide Sequences Encoding NS-Antigens and Peptides
Derived Therefrom
[0121] The present invention further provides pharmaceutical
compositions comprising a therapeutically effective amount of a
nucleotide sequence encoding an NS-specific antigen or a peptide
derived therefrom or an analog thereof and methods of use of such
compositions to promote nerve regeneration or for neuroprotection
and prevention or inhibition of neuronal degeneration in the CNS or
PNS in which the amount is effective to ameliorate the effects of
an injury or disease of the NS.
[0122] Specific illustrative examples of useful nucleotide
sequences encoding NS-specific antigens or peptides derived from an
NS-specific antigen include, but are not limited to, nucleotide
sequences encoding rat MBP, depicted in FIG. 15 (SEQ ID NO:1);
human MBP, depicted in FIG. 16 (SEQ ID NO:2); human PLP, depicted
in FIGS. 17(A-F) (SEQ ID NOs:3-8); human MOG, depicted in FIG. 18
(SEQ ID NO:9); rat PLP and variant, depicted in FIG. 19 (SEQ ID
NO:10); rat MAG, depicted in FIG. 20 (SEQ ID NO:11); rat Nogo (SEQ
ID NO:17); and human Nogo (SEQ ID NO:22). Other illustrative
examples are the nucleotide sequences disclosed in Chen et al
(2000), Prinjha et al (2000) and Fournier et al (2001) (the
contents of each of which being hereby incorporated herein by
reference) encoding rat and human Noga A, B and C and mouse and
human NgR.
[0123] Therapeutic Uses
[0124] The T cells, NS-specific antigens, analogs thereof, peptides
derived therefrom and analogs and derivatives thereof, and
nucleotide sequences described in the previous sections and
compositions comprising them may be used to promote nerve
regeneration or to confer neuroprotection and prevent or inhibit
secondary degeneration which may otherwise follow primary NS
injury, e.g., spinal cord injury, blunt trauma, penetrating trauma,
hemorrhagic stroke, ischemic stroke or damages caused by surgery
such as tumor excision.
[0125] In addition, such compositions may be used to ameliorate the
effects of disease that result in a degenerative process, e.g.,
degeneration occurring in either gray or white matter (or both) as
a result of various diseases or disorders, including, without
limitation: diabetic neuropathy, senile dementias, Alzheimer's
disease, Parkinson's disease, facial nerve (Bell's) palsy,
glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS),
non-arteritic optic neuropathy, intervertebral disc herniation,
vitamin deficiency, prion diseases such as Creutzfeldt-Jakob
disease, carpal tunnel syndrome, peripheral neuropathies associated
with various diseases, including but not limited to, uremia,
porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute sensory
neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary
amyloidosis, obstructive lung diseases, acromegaly, malabsorption
syndromes, polycythemia vera, IgA- and IgG gamma-pathies,
complications of various drugs (e.g., metronidazole) and toxins
(e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease,
ataxia telangectasia, Friedreich's ataxia, amyloid
polyneuropathies, adrenomyeloneuropathy, Giant axonal neuropathy,
Refsum's disease, Fabry's disease, lipoproteinemia, etc.
[0126] In a preferred embodiment, the NS-specific activated T
cells, the NS-specific antigens, peptides derived therefrom,
analogs and derivatives thereof or the nucleotides encoding said
antigens, or peptides or any combination thereof of the present
invention are used to treat diseases or disorders where promotion
of nerve regeneration or prevention or inhibition of secondary
neural degeneration is indicated, which are not autoimmune diseases
or neoplasias. In a preferred embodiment, the compositions of the
present invention are administered to a human subject.
[0127] While activated NS-specific T cells may have been used in
the prior art in the course of treatment to develop tolerance to
autoimmune antigens in the treatment of autoimmune diseases, or in
the course of immunotherapy in the treatment of NS neoplasms, the
present invention can also be used to ameliorate the degenerative
process caused by autoimmune diseases or neoplasms as long as it is
used in a manner not suggested by such prior art methods. Thus, for
example, T cells activated by an autoimmune antigen have been
suggested for use to create tolerance to the autoimmune antigen
and, thus, ameliorate the autoimmune disease. Such treatment,
however, would not have suggested the use of T cells directed to
other NS antigens or NS antigens which will not induce tolerance to
the autoimmune antigen or T cells which are administered in such a
way as to avoid creation of tolerance. Similarly, for neoplasms,
the effects of the present invention can be obtained without using
immunotherapy processes suggested in the prior art by, for example,
using an NS antigen which does not appear in the neoplasm. T cells
activated with such an antigen will still accumulate at the site of
neural degeneration and facilitate inhibition of this degeneration,
even though it will not serve as immunotherapy for the tumor per
se.
[0128] Nogo protein or a fragment thereof which are active in
inhibiting cell proliferation have been disclosed as useful for
treatment of a neoplastic disease of the CNS such as glioma,
glioblastoma, medulloblastoma, craniopharyngioma, ependyoma,
neuroblastoma and retinoblastoma. The present invention does not
encompass the use of Nogo or a peptide derived therefrom for
treatment of neoplasias in general, and for treatment of a
neoplastic disease of the CNS, in particular.
[0129] Formulations and Administration
[0130] The present invention also provides pharmaceutical
compositions useful in methods to promote nerve regeneration or to
confer neuroprotection and prevent or inhibit neuronal degeneration
in the CNS or PNS, comprising a therapeutically effective amount of
at least one ingredient selected from the group consisting of:
[0131] (a) NS-specific activated T cells;
[0132] (b) a NS-specific antigen or an analog thereof;
[0133] (c) a peptide derived from an NS-specific antigen or from an
analog thereof, or an analog or derivative of said peptide;
[0134] (d) a nucleotide sequence encoding an NS-specific antigen or
an analog thereof;
[0135] (e) a nucleotide sequence encoding a peptide derived from an
NS-specific antigen or from an analog thereof, or an analog of said
peptide; or
[0136] (f) any combination of (a)-(e).
[0137] The compositions comprising ingredients (b) and/or (c) above
are also effective to activate T cells in vitro, wherein the
activated T cells inhibit or ameliorate the effects of an injury or
disease of the NS.
[0138] Pharmaceutical compositions for use in accordance with the
present invention may be formulated in conventional manner using
one or more physiologically acceptable carriers or excipients. The
carrier(s) must be "acceptable" in the sense of being compatible
with the other ingredients of the composition and not deleterious
to the recipient thereof.
[0139] The term "carrier" refers to a diluent, adjuvant, excipient,
or vehicle with which the therapeutic is administered. The carriers
in the pharmaceutical composition may comprise a binder, such as
microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or
povidone), gum tragacanth, gelatin, starch, lactose or lactose
monochydrate; a disintegrating agent, such as alginic acid, maize
starch and the like; a lubricant or surfactant, such as magnesium
stearate or sodium lauryl sulphate; a glidant, such as colloidal
silicon dioxide; a sweetening agent, such as sucrose or saccharin;
and/or a flavoring agent, such as peppermint, methyl salicylate, or
orange flavoring.
[0140] Methods of administration include, but are not limited to,
parenteral, e.g., intravenous, intraperitoneal, intramuscular,
subcutaneous, mucosal (e.g., oral, intranasal, buccal, vaginal,
rectal, intraocular), intrathecal, topical and intradermal routes.
Administration can be systemic or local.
[0141] For oral administration, the pharmaceutical preparation may
be in liquid form, for example, solutions, syrups or suspensions,
or may be presented as a drug product for reconstitution with water
or other suitable vehicle before use. Such liquid preparations may
be prepared by conventional means with pharmaceutically acceptable
additives such as suspending agents (e.g., sorbitol syrup,
cellulose derivatives or hydrogenated edible fats); emulsifying
agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g.,
almond oil, oily esters, or fractionated vegetable oils); and
preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic
acid). The pharmaceutical compositions may take the form of, for
example, tablets, lozenges or capsules prepared by conventional
means with pharmaceutically acceptable excipients such as binding
agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or
hydroxypropyl methylcellulose); fillers (e.g., lactose,
microcrystalline cellulose or calcium hydrogen phosphate);
lubricants (e.g., magnesium stearate, talc or silica);
disintegrants (e.g., potato starch or sodium starch glycolate); or
wetting agents (e.g., sodium lauryl sulphate). The tablets may be
coated by methods well-known in the art.
[0142] Preparations for oral administration may be also suitably
formulated to give controlled release of the active compound.
[0143] The compositions may be formulated for parenteral
administration by injection, e.g., by bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g., in ampoules or in multidose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient may
be in powder form for constitution with a suitable vehicle, e.g.,
sterile pyrogen-free water, before use.
[0144] The compositions may also be formulated as rectal
compositions such as suppositories or retention enemas, e.g.,
containing conventional suppository bases such as cocoa butter or
other glycerides.
[0145] For administration by inhalation, the compositions for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebulizer, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of, e.g., gelatin, for use in an inhaler or insufflator
may be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0146] In one embodiment, compositions comprising NS-specific
activated T cells, an NS-specific antigen or peptide derived
therefrom, or derivative thereof, or a nucleotide sequence encoding
such antigen or peptide, are formulated in accordance with routine
procedures as pharmaceutical compositions adapted for intravenous
or intraperitoneal administration to human beings. Typically,
compositions for intravenous administration are solutions in
sterile isotonic aqueous buffer. Where necessary, the composition
may also include a solubilizing agent and a local anesthetic such
as lignocaine to ease pain at the site of the injection. Generally,
the ingredients are supplied either separately or mixed together.
Where the composition is to be administered by infusion, it can be
dispensed with an infusion bottle containing sterile pharmaceutical
grade water or saline. Where the composition is administered by
injection, an ampoule of sterile water or saline for injection can
be provided so that the ingredients may be mixed prior to
administration.
[0147] Pharmaceutical compositions comprising NS-specific antigen
or peptide derived therefrom or derivative thereof may optionally
be administered with an adjuvant.
[0148] The invention also provides a pharmaceutical pack or kit
comprising one or more containers filled with one or more of the
ingredients of the pharmaceutical compositions of the
invention.
[0149] In a preferred embodiment, the pharmaceutical compositions
of the invention are administered to a mammal, preferably a human,
shortly after injury or detection of a degenerative lesion in the
NS. The therapeutic methods of the invention may comprise
administration of an NS-specific activated T cell or an NS-specific
antigen or peptide derived therefrom or derivative thereof, or a
nucleotide sequence encoding such antigen or peptide, or any
combination thereof. When using combination therapy, the
NS-specific antigen may be administered before, concurrently or
after administration of NS-specific activated T cells, a peptide
derived from an NS-specific antigen or derivative thereof or a
nucleotide sequence encoding such antigen or peptide.
[0150] In one embodiment, the compositions of the invention are
administered in combination with one or more of the following: (a)
mononuclear phagocytes, preferably cultured monocytes (as described
in PCT publication No. WO 97/09985, which is incorporated herein by
reference in its entirety), that have been stimulated to enhance
their capacity to promote neuronal regeneration; (b) a neurotrophic
factor such as acidic fibroblast growth factor; and (c) an
anti-inflammatory therapeutic substance, e.g., an anti-inflammatory
steroid, such as dexamethasone or methyl-prednisolone, or a
non-steroidal anti-inflammatory peptide, such as Thr-Lys-Pro
(TKP)).
[0151] In another embodiment, mononuclear phagocyte cells according
to PCT Publication No. WO 97/09985 and U.S. patent application Ser.
No. 09/041,280, filed Mar. 11, 1998, are injected into the site of
injury or lesion within the CNS, either concurrently, prior to, or
following parenteral administration of NS-specific activated T
cells, an NS-specific antigen or peptide derived therefrom or
derivative thereof, or a nucleotide sequence encoding such antigen
or peptide
[0152] In another embodiment, administration of NS-specific
activated T cells, NS-specific antigen or peptide sequence encoding
such antigen or peptide, may be administered as a single dose or
may be repeated, preferably at 2-week intervals and then at
successively longer intervals once a month, once a quarter, once
every six months, etc. The course of treatment may last several
months, several years or occasionally also through the life-time of
the individual, depending on the condition or disease which is
being treated. In the case of a CNS injury, the treatment may range
between several days to months or even years, until the condition
has stabilized and there is no or only a limited risk of
development of secondary degeneration. In chronic human disease or
Parkinson's disease, the therapeutic treatment in accordance with
the invention may be for life.
[0153] As will be evident to those skilled in the art, the
therapeutic effect depends at times on the condition or disease to
be treated, on the individual's age and health condition, on other
physical parameters (e.g., gender, weight, etc.) of the individual,
as well as on various other factors, e.g., whether the individual
is taking other drugs, etc.
[0154] The optimal dose of the therapeutic compositions comprising
NS-specific activated T cells of the invention is proportional to
the number of nerve fibers affected by NS injury or disease at the
site being treated. In a preferred embodiment, the dose ranges from
about 5.times.10.sup.6 to about 10.sup.7 for treating a lesion
affecting about 10 nerve fibers, such as a complete transection of
a rat optic nerve, and ranges from about 10.sup.7 to about 10.sup.8
for treating a lesion affecting about 10.sup.6-10.sup.7 nerve
fibers, such as a complete transection of a human optic nerve. As
will be evident to those skilled in the art, the dose of T cells
can be scaled up or down in proportion to the number of nerve
fibers thought to be affected at the lesion or site of injury being
treated.
[0155] The following examples illustrate certain features of the
present invention but are not intended to limit the scope of the
present invention.
EXAMPLE 1
[0156] Accumulation of Activated T Cells in Injured Optic Nerve
Materials and Methods
[0157] Animals
[0158] Female Lewis rats were supplied by the Animal Breeding
Center of the Weizmann Institute of Science (Rehovot, Israel),
matched for age (8-12 weeks) and housed four to a cage in a light
and temperature-controlled room.
[0159] Media
[0160] The T-cell proliferation medium contained the following:
Dulbecco's modified Eagle's medium (DMEM, Biological Industries,
Israel) supplemented with 2 mM L-glutamine (L-Glu, Sigma, USA),
5.times.10.sup.-5 M 2-mercaptoethanol (2-ME, Sigma), penicillin
(100 IU/ml; Biological Industries), streptomycin (100 .mu./ml;
Biological Industries), sodium pyruvate (1 mM; Biological
Industries), non-essential amino acids (1 ml/100 ml; Biological
Industries) and autologous rat serum 1% (vol/vol) (Mor et al,
1990). Propagation medium contained: DMEM, 2-ME, L-Glu, sodium
pyruvate, non-essential amino acids and antibiotics in the same
concentration as above with the addition of 10% fetal calf serum
(FCS), and 10% T cell growth factor (TCGF) obtained from the
supernatant of concanavalin A-stimulated spleen cells (Mor et al,
1990).
[0161] Antigens
[0162] MBP from the spinal cords of guinea pigs was prepared as
described (Hirshfeld, et al, 1970). OVA was purchased from Sigma
(St. Louis, Mo.). The p51-70 of the rat 18.5 kDa isoform of MBP
(sequence: APKRGSGKDSHTRTTHYG) (SEQ ID NO:15) and the p277 peptide
of the human hsp60 (sequence: VLGGGCALLRCPALDSLTPANED) (SEQ ID
NO:16) (Elias et al, 1991) were synthesized using the
9-fluorenylmethoxycarbonyl (Fmoc) technique with an automatic
multiple peptide synthesizer (AMS 422, ABIMED, Langenfeld,
Germany). The purity of the peptides was analyzed by HPLC and amino
acid composition.
[0163] T Cell Lines
[0164] T-cell lines were generated from draining lymph node cells
obtained from Lewis rats immunized with an antigen (described above
in Antigens). The antigen was dissolved in PBS (1 mg/ml) and
emulsified with an equal volume of IFA (Difco Laboratories,
Detroit, Mich.) supplemented with 4 mg/ml Mycobacterium
tuberculosis (Difco 15 Laboratories, Detroit, Mich.). The emulsion
(0.1 ml) was injected into hind foot pads of the rats. Ten days
after the antigen was injected, the rats were killed and draining
lymph nodes were surgically removed and dissociated. The cells were
washed and activated with the antigen (10 .mu.g/ml) in
proliferation medium (described above in Media). After incubation
for 72 h at 37.degree. C., 90% relative humidity and 7% CO.sub.2,
the cells were transferred to propagation medium (described above
in Media). Cells were grown in propagation medium for 4-10 days
before being re-exposed to antigen (10 .mu.g/ml) in the presence of
irradiated (2000 rad) thymus cells (10.sup.7 cells/ml) in
proliferation medium. The T cell lines were expanded by repeated
re-exposure and propagation.
[0165] Crush Injury of Rat Optic Nerve
[0166] Crush injury of the optic nerve was performed as previously
described (Duvdevani et al, 1990). Briefly, rats were deeply
anesthetized by i.p. injection of Rompum (xylazine, 10 mg/kg;
Vitamed, Israel) and Vetaler (ketamine, 50 mg/kg; Fort Dodge
Laboratories, Fort Dodge, Iowa). Using a binocular operating
microscope, a lateral canthotomy was performed in the right eye and
the conjunctiva was incised lateral to the cornea. After separation
of the retractor bulbi muscles, the optic nerve was exposed
intraorbitally by blunt dissection. Using calibrated cross-action
forceps, a moderate crush injury was inflicted on the optic nerve,
2 mm form the eye (Duvdevani et al, 1990). The contralateral nerve
was left undisturbed and was used as a control.
[0167] Immunocytochemistry of T Cells
[0168] Longitudinal cryostat nerve sections (20 .mu.m thick) were
picked up onto gelatin glass slides and frozen until preparation
for fluorescent staining. Sections were thawed and fixed in ethanol
for 10 minutes at room temperature, washed twice with
double-distilled water (ddH.sub.2O), and incubated for 3 minutes in
PBS containing 0.05% polyoxyethylene-sorbitan monolaurate
(Tween-20; Sigma, USA). Sections were then incubated for 1 hr at
room temperature with a mouse monoclonal antibody directed against
rat T cell receptor (TCR) (1:100, Hunig et al, 1989), in PBS
containing 3% FCS and 2% BSA. After three washes with PBS
containing 0.05% Tween-20, the sections were incubated with
fluorescein isothiocyanate-conjugated goat anti-mouse IgG (with
minimal cross-section to rat, human, bovine and horse serum
proteins) (Jackson ImmunoResearcch, West Grove, Pa.) for one hour
at room temperature. The sections were then washed with PBS
containing Tween-20 and treated with glycerol containing
1,4-diazobicyclo-(2,2,2) octane (Sigma), to inhibit quenching of
fluorescence. The sections were viewed with a Zeis microscope and
cells were counted. Staining in the absence of first antibody was
negative.
Results
[0169] FIG. 1 shows accumulation of T cells measured
immunohistochemically. The number of T cells was considerably
higher in injured nerves rats injected with anti-MBP, anti-OVA or
anti-p277 cells; statistical analysis (one-way ANOVA) showed
significant differences between T cell numbers in injured optic
nerves of rats injected with anti-MBP, anti-OVA, or anti-p277 T
cells and in injured optic nerves of rats injected with PBS
(P<0.001); and between injured optic nerves and uninjured optic
nerves of rats injected with anti-MBP, anti-OVA, or anti-p277 T
cells (P<0.001).
EXAMPLE 2
[0170] Neuroprotection by Autoimmune Anti-MBP T Cells Material and
Methods
[0171] Animals, media, antigens, crush injury of rat optic nerve,
sectioning of nerves, T cell lines, and immunolabeling of nerve
sections are described in Example 1, supra.
[0172] Retrograde Labeling and Measurement of Primary Damage and
Secondary Degeneration
[0173] Primary damage of the optic nerve axons and their attached
RGCs were measured after the immediate post-injury application of
the fluorescent lipophilic dye 4-Di-10-Asp) (Molecular Probes
Europe BV, Netherlands) distal to the site of injury. Only axons
that are intact are capable of transporting the dye back to their
cell bodies; therefore, the number of labeled cell bodies is a
measure of the number of axons that survived the primary damage.
Secondary degeneration was also measured by application of the dye
distal to the injury site, but two weeks after the primary lesion
was inflicted. Application of the neurotracer dye distal to the
site of the primary crush after two weeks ensures that only axons
that survived both the primary damage and the secondary
degeneration will be counted. This approach makes it possible to
differentiate between neurons that are still functionally intact
and neurons in which the axons are injured but the cell bodies are
still viable, as only those neurons whose fibers are
morphologically intact can take up dye applied distally to the site
of injury and transport it to their cell bodies. Using this method,
the number of labeled RGCs reliably reflects the number of still
functioning neurons. Labeling and measurement were done by exposing
the right optic nerve for a second time, again without damaging the
retinal blood supply. Complete axotomy was done 1-2 mm from the
distal border of the injury site and solid crystals (0.2-0.4 mm in
diameter) of 4-Di-10-Asp were deposited at the site of the newly
formed axotomy. Uninjured optic nerves were similarly labeled at
approximately the same distance from the globe. Five days after dye
application, the rats were killed. The retina was detached from the
eye, prepared as a flattened whole mount in 4% paraformaldehyde
solution and examined for labeled RGCs by fluorescence microscopy.
The percentage of RGCs surviving secondary degeneration was
calculated using the following formula:
(Number of spared neurons after secondary degeneration)/(Number of
spared neurons after primary damage).times.100.
[0174] Electrophysiological Recordings
[0175] Nerves were excised and their compound action potentials
(CAPs) were recorded in vitro using a suction electrode
experimental set-up (Yoles et al, 1996). At different times after
injury and injection of T cells or PBS, rats were killed by
intraperitoneal injection of pentobarbitone (170 mg/kg) (CTS
Chemical Industries, Israel). Both optic nerves were removed while
still attached to the optic chiasma, and were immediately
transferred to a vial containing a fresh salt solution consisting
of 126 mM NaCl, 3 mM KCl, 1.25 mM NaH.sub.2PO.sub.2 26 mM
NaHCO.sub.3 2 mM MgSO.sub.4, 2 mM CaCl.sub.2 and 10 mM D-glucose,
aerated with 95% O.sub.2 and 5% CO.sub.2 at room temperature. After
1 hour, electrophysiological recordings were made. In the injured
nerve, recordings were made in a segment distal to the injury site.
This segment contains axons of viable RGCs that have escaped both
primary and secondary damage, as well as the distal stumps of
non-viable RGCs that have not yet undergone Wallerian degeneration.
The nerve ends were connected to two suction Ag--AgCl electrodes
immersed in the bathing solution at 37.degree. C. A stimulating
pulse was applied through the electrode, and the CAP was recorded
by the distal electrode. A stimulator (SD9; Grass Medical
Instruments, Quincy, Mass.) was used for supramaximal electrical
stimulation at a rate of 1 pps to ensure stimulation of all
propagating axons in the nerve. The measured signal was transmitted
to a microelectrode AC amplifier (model 1800; A-M Systems, Everett,
Wash.). The data were processed using the LabView 2.1.1 data
acquisition and management system (National Instruments, Austin,
Tex.). For each nerve, the difference between the peak amplitude
and the mean plateau of eight CAPs was computed and was considered
as proportional to the number of propagating axons in the optic
nerve. The experiments were done by experimenters "blinded", to
sample identity. In each experiment the data were normalized
relative to the mean CAP of the uninjured nerves from PBS-injected
rats.
[0176] Clinical Evaluation of Experimental Autoimmune
Encephalomyelitis (EAE)
[0177] Clinical disease was scored every 1 to 2 days according to
the following neurological scale: 0, no abnormality; 1, tail atony;
2, hind limb paralysis; 3, paralysis extending to thoracic spine;
4, front limb paralysis; 5, moribund state.
Results
[0178] Neuroprotection by Autoimmune Anti-MBP T Cells
[0179] Morphological analyses were done to assess the effect of the
T cells on the response of the nerve to injury, and specifically on
secondary degeneration. Rats were injected intraperitoneally
immediately after optic nerve injury with PBS or with
1.times.10.sup.7 activated T cells of the various cell lines. The
degree of primary damage to the optic nerve axons and their
attached RGCs was measured by injecting the dye 4-Di-10-Asp distal
to the site of the lesion immediately after the injury. A time
lapse of 2 weeks between a moderate crush injury and dye
application is optimal for demonstrating the number of still viable
labeled neurons as a measure of secondary degeneration, and as the
response of secondary degeneration to treatment. Therefore,
secondary degeneration was quantified by injecting the dye
immediately or 2 weeks after the primary injury, and calculating
the additional loss of RGCs between the first and the second
injections of the dye. The percentage of RGCs that had survived
secondary degeneration was then calculated. The percentage of
labeled RGCs (reflecting still-viable neurons) was significantly
greater in the retinas of the rats injected with anti-MBP T cells
than in the retinas of the PBS-injected control rats (FIG. 2). In
contrast, the percentage of labeled 30 RGCs in the retinas of the
rats injected with anti-OVA or anti-p277 T cells was not
significantly greater than that in the control retinas. Thus,
although the three T cell lines accumulated at the site of injury,
only the MBP-specific autoimmune T cells had a substantial effect
in limiting the extend of secondary degeneration. Labeled RGCs of
injured optic nerves of rats injected with PBS (FIG. 3A), with
anti-p277 T cells (FIG. 3B) or with anti-MBP T cells (FIG. 3C) were
compared morphologically using micrographs.
[0180] Clinical Severity of EAE
[0181] Animals were injected i.p. with 10.sup.7 T.sub.MBP cells
with or without concurrent optic nerve crush injury. The clinical
course of the rats injected with the T.sub.MBP cells was evaluated
according to the neurological paralysis scale. Each group contained
5-9 rats. The functional autoimmunity of the injected anti-MBP T
cells was demonstrated by the development of transient EAE in the
recipients of these cells. As can be seen in FIG. 4A, the course
and severity of the EAE was not affected by the presence of the
optic nerve crush injury.
[0182] Survival of RGCS in Non-Injured Nerves
[0183] Animals were injected i.p. with 10.sup.7 T.sub.MBP cells or
PBS. Two weeks later, 4-Di-10-Asp was applied to the optic nerves.
After five days the retinas were excised and flat mounted. Labeled
RGCs from five fields (located at approximately the same distance
from the optic disk), in each retina were counted and their average
number per are (mm.sup.2) was calculated.
[0184] As can be seen in FIG. 4B, there is no difference in the
number of surviving RGCs per area (mm.sup.2) in non-injured optic
nerves of rats injected with anti-MBP T cells compared to in rats
injected with PBS.
[0185] Neuroprotection by T Cells Reactive to a Cryptic
Epitope--(p51-70)MBP
[0186] To determine whether the neuroprotective effect of the
anti-MBP T cells is correlated with their virulence, the effect of
T cells reactive to a "cryptic" epitope of MBP, the peptide 51-70
(p51-70) was examined. "Cryptic" epitopes activate specific T cells
after an animal is immunized with the particular peptide, but not
with the whole antigen (Mor et al, 1995). The T cell line reactive
to the whole MBP and the T cell line reactive to the cryptic
epitope p51-70 were compared for the severity of the EAE they
induced, and for their effects on secondary degeneration. In rats
injected with the T cell line reactive to the cryptic epitope,
disease severity (as manifested by the maximal EAE score) was
significantly lower than that in rats injected with the T cell line
reactive to the whole protein (Table 1). Whereas anti-MBP T cells
caused clinical paralysis of the limbs, rats injected with the
anti-p51-70 T cells developed only tail atony, not hind limb
paralysis, and almost none showed weakness of the hind limbs.
Despite this difference in EAE severity, the neuroprotective effect
of the less virulent (anti-p51-70) T cells was similar to that of
the more virulent (anti-MBP) T cells (FIG. 5). The percentage of
RGCs surviving secondary degeneration in the retinas of rats
injected with either of the lines was significantly higher than in
the retinas of the PBS-injected rats. Thus, there was no
correlation between the neuroprotective effect of the autoimmune T
cells and their virulence. It is possible that the anti-p51-70 T
cells encounter little antigen in the intact CNS, and therefore
cause only mild EAE. Their target antigen may however become more
available after injury, enabling these T cells to exert a
neuroprotective effect.
1TABLE 1 Anti-MBP and Anti-p501-70 T Cells Vary in Pathogenicity T
Cell Line Clinical EAE Mean Max. Score Whole MBP Moderate to Severe
2.00 + 0.2 p51-70 of MBP Mild 0.70 + 0.2 Immediately after optic
nerve crush injury, Lewis rats were injected with activated
anti-MBP T cells or anti-p51-70 T cells. The clinical course of EAE
was evaluated according to the neurological paralysis scale. The
mean maximal (max.) score .+-. s.e.m. was calculated as the average
maximal score of all the diseased rats in each group. The table is
a summary of nine experiments. Each group contains five to ten
rats. Statistical analysis showed a significant difference between
# the mean maximal score of rats injected with anti-MBP T cells and
that of rats injected with anti-p51-70 T cells (P = 0.039,
Student's t-test).
[0187] Electrophysiological Activity
[0188] To confirm the neuroprotective effect of the anti-MBP T
cells, electrophysiological studies were done. Immediately after
optic nerve injury, the rats were injected intraperitoneally with
PBS or with 1.times.10.sup.7 activated anti-MBP or anti-OVA T
cells. The optic nerves were excised 7, 11 or 14 days later and the
CAPs, a measure of nerve conduction, were recorded from the injured
nerves. On day 14, the mean CAP amplitudes of the distal segments
recorded from the injured nerves obtained from the PBS-injected
control rats were 33% to 50% of those recorded from the rats
injected with the anti-MBP T cells (FIG. 6A, Table 2). As the
distal segment of the injured nerve contains both neurons that
escaped the primary insult and injured neurons that have not yet
degenerated, the observed neuroprotective effect could reflect the
rescue of spared neurons, or a delay of Wallerian degeneration of
the injured neurons (which normally occurs in the distal stump), or
both. No effect of the injection of anti-MBP T cells on the mean
CAP amplitudes of uninjured nerves was observed (FIG. 6B, Table 2).
It is unlikely that the neuroprotective effect observed on day 14
could have been due to the regrowth of nerve fibers, as the time
period was too short for this.
[0189] The strong neuroprotective effect of the anti-MBP T cells
seen on day 14 was associated with a significantly decreased CAP
amplitude recorded on day 7 (Table 2). The anti-MBP T cells
manifested no substantial effect on the uninjured nerve on day 7,
indicating that the reduction in electrophysiological activity
observed in the injured nerve on day 7 might reflect the larger
number of T cells present at the injury site relative to the
uninjured nerve (FIG. 1). The observed reduction in CAP amplitude
in the injured nerve on day 7 reflected a transient resting state
in the injured nerve. This transient effect has not only
disappeared, but was even reversed by day 14 (Table 2). Early signs
of the neuroprotective effect could already be detected on day 11
in the rats injected with anti-OVA T cells, no reduction in CAP
amplitude on day 7 could be detected in either the injured or the
uninjured nerves, and no neuroprotective effect was observed on day
14 (Table 2). Thus, it seems that the early reduction in CAP and
the late neuroprotection shown specifically by the anti-MBP T cells
are related.
2TABLE 2 Transient Reduction in Electrophysiological Activity of
the Injured Optic Nerve Induced by Anti-MBP T Cells, Followed by a
Neuroprotective Effect Uninjured Optic Nerve Injured Optic Nerve
Day 7 Day 14 Day 7 Day 14 Ratio (%) 89.9 .+-. 9.4 101.2 .+-. 22.7
63.8* .+-. 14.9 243.1** .+-. 70.8 T.sub.MPB/PBS (n = 22) (n = 10)
(n = 17) (n = 8) Ratio (%) 109.7 .+-. 13. 92.5 .+-. 12.6 125.5 .+-.
24.4 107.3 .+-. 38.9 T.sub.OVA/PBS (n = 11) (n = 3) (n = 11) (n =
4) Immediately after optic nerve injury, rats were injected with
PBS or with activated anti-MBP or anti-OVA T cells. After 7 or 14
days, the CAPs of injured and uninjured nerves were recorded.
Ratios were calculated for uninjured nerves as (mean CAP of
uninjured nerves from T cell-injected rats/mean CAP of uninjured
nerves from PBS-injected rats) .times. 100, or for injured nerves
as (mean CAP of injured nerves from T cell- # injected rats/mean
CAP of injured nerves from PBS-injected rats) .times. 100. The P
value was calculated by comparing the logarithms of the normalized
CAP amplitudes of nerves from PBS-injected rats and rats injected
with T cells, using the unpaired Student's test, *P <0.05; **P
<0.001 n = sample size.
[0190] Neuroprotection in Spinal Cord Injury by Anti-MBP T
Cells
[0191] Materials and Methods
[0192] Animals, antigens (MBP, OVA) and T cell lines were as
described hereinbefore in Example 6 animals, antigens and T cell
lines, respectively.
[0193] Contusion. Adult rats (300 to 350 g) were anesthetized and
the spinal cord was exposed by laminectomy at the level of T7-T8.
One hour after induction of anesthesia, a 10-gram rod was dropped
onto the laminectomized cord from a height of 50 mm. The impactor
device (designed by Prof. Wise Young) allowed, for each animal,
measurement of the trajectory of the rod and its contact with the
spinal cord to allow uniform lesion. Within an hour of the
contusion, rats were injected i.p., on a random basis, with either
10.sup.7 cells (specific to either MBP or OVA, depending on the
experimental design) or with PBS. Bladder expression was done at
least twice a day (particularly during the first 48 h after injury,
when it was done 3 times a day) until the end of the second week,
by which time the rats had developed autonomous bladder voidance.
Approximately twice a week, locomotor activity (of the trunk, tail
and hind limbs) in an open field was evaluated by placing the rat
for 4 min in the middle of a circular enclosure made of molded
plastic with a smooth, non-slip floor (90 cm diameter, 7 cm wall
height).
[0194] Results
[0195] The present study of spinal cord neuroprotection was
prompted by the previous example that partial injury to an optic
nerve can be ameliorated administering T cells directed to a CNS
self-antigen. The question was whether autoimmune T cells could
have a beneficial effect on recovery from traumatic spinal cord
injury with its greater mass of injured CNS tissue and the
attendant spinal shock.
[0196] Adult Lewis rats were subjected to a calibrated spinal cord
contusion produced by dropping a 10-gram weight from a height of 50
mm onto the laminectomized cord at the level of T7-T8 (see Basso et
al, 1996). The rats were then injected intraperitoneally with
autoimmune T cells specific to MBP. Control rats were similarly
injured but received either no T cells or T cells specific to the
non-self antigen ovalbumin (OVA). Recovery of the rats was assessed
every 3 to 4 days in terms of their behavior in an open-field
locomotion test, in which scores range from 0 (complete paraplegia)
to 21 (normal mobility). The locomotor performance of the rats was
judged by observers blinded to the identity of the treatment
received by the rats. Included in the study was a group of
uninjured, sham-operated (laminectomized but not contused) rats
that were injected with anti-MBP T cells to verify the activity of
the T cells. In all the sham-operated rats, the anti-MBP T cells
induced clinical EAE, which developed by day 4, reached a peak at
day 7 and resolved spontaneously by day 11. Note, therefore, that
at the early post-traumatic stage, any effect of the autoimmune T
cells on the injured spinal cord, whether positive or negative,
would be transiently masked both by spinal shock and by the
paralysis of EAE.
[0197] Indeed, none of the rats with contused spinal cords showed
any locomotor activity in the first few days after the contusion
(FIG.7A). Interestingly, however, the rats treated with anti-MBP T
cells recovered earlier from spinal shock; on day 11, for example,
when no recovery could be detected in any of the untreated control
rats, significant improvement was noted in the T cell-treated rats
(FIG. 7A). At all time points thereafter, the rats that had
received the autoimmune T cells showed better locomotor recovery
than did the untreated injured rats (FIG. 7A). Thus the autoimmune
T cells, in spite of being encephalitogenic, did confer significant
neuroprotection. Moreover, the phase of neuroprotective activity
coincided with the phase of immune paralysis, supporting our
suggestion that neuroprotection might be related to transient
paralysis.
[0198] By one month after trauma the rats in both groups had
reached a maximal behavioral score, which then remained at plateau
for at least 3 months of follow-up. In the untreated rats, maximal
recovery of locomotor behavior, as noted in previous reports of
similarly severe contusion (Basso et al, 1996), was marked by some
ineffectual movement of hind-limb joints, but the rats showed no
ability to support their body weight and walk, and obtained a score
of 7.3.+-.0.8 (mean.+-.SEM). In contrast, the average score of the
rats that had been treated with the anti-MBP T cells was
10.2.+-.0.8, and in some rats the value was as high as 13. All the
rats in the treated group could support their body weight and some
could frequently walk in a coordinated fashion. The difference
between the two groups, based on 2-factor repeated ANOVA, was
statistically significant (p<0.05). The recovery curve based on
locomotor activity is nonlinear. The above-described increase in
motor activity seen after treatment with the anti-MBP T cells could
result from much higher percentage of spared tissue based on a
linear regression curve on which the behavioral score is correlated
with the amount of neural spinal cord tissue (for example, a
difference between 11 and 7 on the locomotion score would be read
as a difference between 30% and less than 10% of spared
tissue).
[0199] In another set of experiments the rats were subjected to a
more severe insult, resulting in a functional score of 1.9.+-.0.8
(mean.+-.SEM) in the untreated group and 7.7.+-.1.4 in the treated
group (FIG. 7B). This difference of more than 3 fold in behavioral
scores was manifested by the almost total lack of motor activity in
the control rats as compared with the ability of the autoimmune T
cell-treated rats to move all their joints. The beneficial effect
was specific to treatment with anti-MBP T cells; no effect was
observed after treatment with T cells specific to the non-self
antigen OVA (data not shown). The positive effect of the autoimmune
T cells seems to be expressed in the preservation of CNS tissue
that escaped the initial lesion, i.e., in neuroprotection.
Therefore, the magnitude of the effect would be inherently limited
by the severity of the insult; the more severe the lesion, the less
the amount of spared tissue amenable to neuroprotection.
[0200] To determine whether clinical recovery could be explained in
terms of preservation of spinal axons, we performed retrograde
labeling of the descending spinal tracts by applying the dye
rhodamine dextran amine (Brandt et al, 1992) at T12, below the site
of damage. The number of dye-stained cells that could be counted in
the red nucleus of the brain constituted a quantitative measure of
the number of intact axons traversing the area of contusion.
Sections of red nuclei from injured rats treated with anti-MBP T
cells (FIG. 8) contained 5-fold more labeled cells than sections
taken from the untreated injured rats. Photomicrographs of red
nuclei taken from rats treated with anti-MBP T cells (with an open
field score of 10) and from PBS-treated rats (with a score of 6)
are shown in FIG. 8. These findings indicate that the reduction in
injury-induced functional deficit observed in the T cell-treated
rats can be attributed to the sparing of spinal tracts, resulting
in a higher degree of neuron viability.
[0201] After a follow-up of more than 3 months, when the locomotor
activity scores had reached a plateau, the site of injury of three
of PBS-treated animals and three animals treated with anti-MBP T
cells were analyzed by diffusion-weighted MRI. The cords were
excised in one piece from top to bottom and were immediately placed
in fixative (4% paraformaldehyde). Axial sections along the excised
contused cord were analyzed. FIG. 9 shows the diffusion anisotropy
in axial sections along the contused cord of a rat treated with
autoimmune T cells, as compared with that of PBS-treated control
rat. The images show anisotropy in the white matter surrounding the
gray matter in the center of the cord. Sections taken from the
lesion sites of PBS-treated control rats show limited areas of
anisotropy, which were significantly smaller than those seen at
comparable sites in the cords of the rats treated with the anti-MBP
T cells. Quantitative analysis of the anisotropy, reflecting the
number of spared fibers, is shown in FIG. 9. The imaging results
show unequivocally that, as a result of the treatment with the
autoimmune anti-MBP T cells, some spinal cord tracts had escaped
the degeneration that would otherwise have occurred.
[0202] Discussion of Results
[0203] No cure has yet been found for spinal cord lesions, one of
the most common yet devastating traumatic injuries in industrial
societies. It has been known for more that 40 years that CNS
neurons, unlike neurons of the PNS, possess only a limited ability
to regenerate after injury. During the last two decades, attempts
to promote regeneration have yielded approaches that lead to
partial recovery. In the last few years it has become apparent
that, although most of the traumatic injuries sustained by the
human spinal cord are partial, the resulting functional loss is
nevertheless far worse than could be accounted for by the severity
of the initial insult; the self-propagating process of secondary
degeneration appears to be decisive.
[0204] A substantial research effort has recently been directed to
arresting injury-induced secondary degeneration. All attempts up to
now have been pharmacologically based, and some have resulted in
improved recovery from spinal shock. The present study, in
contrast, describes a cell therapy that augments what seems to be a
natural mechanism of self-maintenance and leads, after a single
treatment, to long-lasting recovery. The extent of this recovery
appears to exceed that reported using pharmacological methods.
[0205] In most tissues, injury-induced damage triggers a cellular
immune response that acts to protect the tissue and preserve its
homeostasis. This response has been attributed to macrophages and
other cells comprising the innate arm of the immune system.
Lymphocytes, which are responsible for adaptive immunity, have not
been thought to participate in tissue maintenance. Adaptive
immunity, according to traditional teaching, is directed against
foreign dangers. Our studies now show, however, that the adaptive T
cell immune response can be protective even when there is no
invasion by foreign pathogens. In the case of tissue maintenance,
the specificity of the T cells is to tissue self-antigens.
[0206] Our observation of post-traumatic CNS maintenance by
autoimmune T cells suggests that we might do well to reevaluate
some basic concepts of autoimmunity. T cells that are specific to
CNS self antigens in general, and to MBP in particular, have long
been considered to be only detrimental to health. In the present
study, however, the same T cell preparation that can produce EAE in
the undamaged CNS was found to be neuroprotective in the damaged
spinal cord, suggesting that the context of the tissue plays an
important part in determining the outcome of its interaction with T
cells. It would seem that the tissue deploys specific signals to
elicit particular T cell behaviors. Among such signals are
co-stimulatory molecules, particularly members of the B7 family
(Lenchow et al, 1996). As shown hereinafter, the injured rat optic
nerve transiently expresses elevated levels of the co-stimulatory
molecule B7.2, which is constitutively expressed at low levels in
the rat CNS white matter and which is thought to be associated with
regulation of the cytokine profile of the responding T cells
(Weiner, 1997). The early post-injury availability of the exogenous
anti-MBP T cells, coinciding with the observed early post-injury
increase in B7.2, would support the idea that signals expressed by
the tissue might modulate the T cell response. It is thus
conceivable that anti-MBP T cells which cause a monophasic
autoimmune disease upon interacting with a healthy CNS nerve, might
implement a maintenance program when they interact with damaged CNS
tissue expressing increased amounts of B7.2 and probably other
co-stimulatory molecules. The neuroprotective effects of the T
cells may be mediated, at least in part, by antigen-dependent
regulation of specific cytokines or neurotrophic factors
(Kerschensteiner et al, 1999) produced locally at the site of
injury.
[0207] Thus, the present invention is also directed to manipulating
B7.2 co-stimulatory molecule to prevent or inhibit neuronal
degeneration and ameliorate the effects of injury to or disease of
the nervous system. B7.2 molecule can be up-regulated for this
purpose, using drugs or by genetic manipulation, without undue
experimentation.
[0208] In a recent study, it was reported that injury to the spinal
cord triggers a transient autoimmune response to MBP (Popovich et
al, 1996). However, whether that response is detrimental or
beneficial remained an open question (Popovich et al, 1997). From
our present data, it would appear that the activation of anti-MBP T
cells could indeed be beneficial. However, a supplement of
exogenous autoimmune T cells may be required to overcome the
restrictions on immune reactivity imposed by the immune-privilege
of the CNS (Streilein, 1995). The finding that autoimmune response
can be advantageous suggests that natural autoimmune T cells may
have undergone positive selection during ontogeny, as proposed by
the theory of the immunological homunculus (Cohen, 1992), and are
not merely a default resulting from the escape from negative
selection of T cells that recognize self antigens (Janeway, 1992).
Such a response could then be considered as a mechanism of
potential physiological CNS self-maintenance, which is, however,
not sufficient for the purpose because of the immune-privileged
character of the CNS.
[0209] A single injection of autoimmune T cells lasted for at least
100 days. Thus, this procedure offers a form of self-maintenance.
This specific autoimmune response, when properly controlled, is
useful as part of a self-derived remedy for spinal cord injury.
EXAMPLE 3
[0210] Neuroprotective Effects of a NS-Specific Antigen
Peptide--MOG p35-55
Materials and Methods
[0211] Animals, crush injury of rat optic nerve, and retrograde
labeling are described above in Examples 3 and 4. A peptide based
on amino acids 35-55 of MOG (MOG p35-55) was chemically synthesized
at the Weizmann Institute, Israel.
[0212] Inhibition of Secondary Degeneration
[0213] Rats were injected intradermally in the footpads with MOG
p35-55 (50 .mu.g/animal) and IFA, or PBS, ten days prior to optic
nerve crush injury. RGCs were assessed two weeks after injury using
retrograde labeling as described above. The number of RGCs in rats
injected with PBS or MOG p35-55 was expressed as a percentage of
the total number of neurons in rats injected with MOG p35-55 in the
absence of crush injury.
[0214] Results
[0215] As shown in FIG. 10, the number of labeled RGCs (indicating
viable axons) was about 12.5 fold greater in animals injected with
MOG p35-55 compared to animals receiving PBS.
EXAMPLE 4
[0216] Neuroprotective Effects of MBP Administered Orally
Materials and Methods
[0217] Animals, crush injury of rat optic nerve, and retrograde
labeling of RGCs are described above in Examples 3 and 4.
[0218] Inhibition of Secondary Degeneration
[0219] Bovine MBP (Sigma, Israel) (1 mg/dose) was administered to
rats by gavage using a blunt needle. MBP was administered 5 times,
every third day, beginning 2 weeks prior to optic nerve crush
injury. The number of RGCs in treated animals was expressed as a
percentage of the total number of neurons in animals subjected to
optic nerve crush injury but which did not receive MBP.
Results
[0220] As shown in FIG. 11, the number of labeled RGCs was about
1.3 fold greater in animals treated with MBP compared to untreated
animals.
[0221] The B7.2 Co-Stimulatory Molecule is Associated with
Post-Traumatic Maintenance of the Optic Nerve by Oral
Administration of MBP
[0222] Introduction
[0223] Autoimmune T cells can under certain conditions be
beneficial to traumatized CNS axons. The effect of such T cells on
the damaged tissue might be influenced by the nature and amount of
the co-stimulatory molecules it expresses. We show that the B7.2
co-stimulatory molecule is constitutively expressed in the intact
rat optic nerve, and after injury is up-regulated at the margins of
the injury site. Pre-injury induction of oral tolerance to MBP
resulted in a further post-injury increase in B7.2 at the margins
and at the injury site itself, as well as a better preservation of
the traumatized nerve. Thus, B7.2 expression in the brain and its
up-regulated after trauma seem to be directly related to
post-traumatic maintenance displayed by autoimmune T cells.
[0224] Neuronal injury in the CNS causes degeneration of directly
damaged fibers as well as of fibers that escaped the primary
insult. It also triggers a systemic response of autoimmune T cells
to MBP that might affect the course of degeneration of the injured
nerve. Whether the effect of these T cells on the nerve is
detrimental or beneficial may depend, in part, on the nature and
level of the co-stimulatory molecules expressed by the damaged
tissue.
[0225] Several co-stimulatory molecules have recently been
identified, including the B7 and CD40 molecules (Caux et al, 1994;
Lenschow et al, 1996). CD40 appears to be dominant during cell
differentiation in the lymph nodes and B7 during activation of T
cells in the target organ (Grewal et al, 1996).
[0226] The B7 co-stimulatory molecule is a member of the
immunoglobulin superfamily that interacts with CD28 and CTLA-4 on
T.sub.H cells. There are two related forms of B7 (B7.1 and B7.2).
Both molecules have a similar organization of extracellular domains
but markedly different cytosolic domains. Both B7 molecules are
expressed on antigen-presenting cells (APCs) such as dendritic
cells, activated macrophages and activated B cells as B7.1 or
B7.2., which might preferentially support activation of the Th1 or
the Th2 type of immune response, respectively (Kuchroo et al, 1995;
Karandikar et al, 1998). We were therefore interested in
determining the identity of B7 molecule subtype expressed in intact
and injured CNS white matter, and its possible influence on the
course of the response to the injury.
Results
[0227] The co-stimulatory molecule expressed constitutively in the
intact optic nerves of adult Lewis rats was identified as B7.2.
(FIGS. 12A, 12B). To examine the effects of neurotrauma on the
expression of B7 co-stimulatory molecules, we inflicted a mild
crush injury on the optic nerves of Lewis rats and assessed the
neural expression of B7 by immunohistochemical analysis. The most
striking effect of the injury was seen on B7.2 expression
manifested on post-injury day 3 by its elevation at the margins of
the injury site (FIGS. 12C, D, E). In contrast, expression of B7.1
was not detected in the optic nerve either before or 3 days after
injury. On day 7, however, B7.1 was detectable at the site of
injury, having pattern reminiscent of that seen for macrophages or
microglia (FIG. 12F).
[0228] Next, we attempted to determine whether the degenerative
response to optic nerve injury could be modified by peripheral
manipulation of the immune system. The manipulation chosen was
induction of oral tolerance, known to cause a "bystander" T cell
immunosuppressive effect (Weiner et al, 1997b). Ingestion of low
doses of MBP results in the activation of T cells which, based on
antigen recognition, secrete TGF as the dominant cytokine and thus
favor an immune response of Th2/3 type (Chen et al, 1994).
[0229] Lewis rats were fed with food to which 1 mg of bovine MBP
had been added five times daily every other day. Ten days after
first receiving the supplement, the rats were subjected to mild
unilateral optic nerve crush injury. This time, interval between
initiation of oral tolerance and injury was chosen to allow
adequate build-up of the systemic T cell response. As shown in
FIGS. 13A and 13B, the numbers of macrophages or active microglia
(indicated by ED-1 labeling) and T cells (indicated by
immunolabeling for T cell receptor), assessed 3 days after injury,
did not differ from those observed in control injured rats which
did receive any treatment or were fed with PBS. In the rats with
induced oral tolerance to MBP, however, the amounts of B7.2 were
further increased at the margins of the site of injury (FIG. 13C)
as compared with controls (FIG. 12E). In addition, in the rats with
induced oral tolerance to MBP, B7.2 was also elevated at the site
of injury relative to the control nerves (FIG. 13C). It seems
reasonable to assume that the T cells exposed to MBP via intestinal
absorption, upon invading the injured CNS, contributed to the
increase in expression of B7.2 by the injured nerve.
[0230] We then attempted to determine whether the observed changes
in B7.2 expression in the injured rats was correlated with the
extent of neuronal degeneration. Acute injury of the rat optic
nerve is followed by a process of nerve degeneration, which can be
quantified by retrograde labeling of the surviving neurons and
counting of the corresponding cell bodies. Two weeks after optic
nerve injury, the number of surviving RGCs, representing
still-viable neurons, in the group of MBP-fed rats, was
significantly higher than that in the control group, or that in the
group of rats with injured nerves that were fed with ovalbumin
(OVA). Interestingly, the benefit of the induced oral tolerance to
MBP was increased by feeding the rats with more intensive schedule
(FIG. 14).
EXAMPLE 5
[0231] Posttraumatic Immunization with Nogo P472 Peptide Promoted
Functional Recovery from Spinal Cord Contusion
Material and Methods
[0232] Animals. Female and male SPD rats were supplied by the
Animal Breeding Center of the Weizmann Institute of Science,
Rehovot, Israel, matched for age (8-12 weeks) and housed in light-
and temperature-controlled rooms.
[0233] Antigen. The Nogo p472 peptide (SEQ ID NO:19) was
synthesized at the Weizmann Institute of Science, Rehovot,
Israel.
[0234] Immunization. Rats were immunized with 100-150 .mu.g of Nogo
p472 peptide emulsified in CFA containing 1 mg/ml Mycobacterium
tuberculosis. The emulsion was injected subcutaneously at one site
in the upper back in the rats. The p472-immunized rats were boosted
one week after injury with p472 (100 .mu.g/rat) in IFA. Control
rats were injected either with PBS or with PBS emulsified in CFA
(Difco, Detroit, Mich., USA).
[0235] Contusion. Adult rats were anesthetized and their spinal
cords were exposed by laminectomy at the level of T9. One hour
after induction of anesthesia, a 10-g rod was dropped onto the
laminectomized cord from a height of 25 mm or 50 mm, using the NYU
impactor (Basso et al, 1995 and 1996).
[0236] Introduction
[0237] Regeneration of axons after injury in the CNS of higher
vertebrates is extremely limited and almost absent. Growth
inhibitors associated with CNS myelin play an important role in
this aspect. A potent neurite growth inhibitory activity associated
with adult CNS oligodendrocytes and myelin was reported by Caroni
and Schwab, 1988, and found to be neutralized by a monoclonal
antibody, IN-1, which was shown to promote axonal regeneration and
to enhance compensatory plasticity following spinal cord or brain
lesions in adult rats.
[0238] This activity was later related to a high molecular weight
membrane protein, designated NI-250, with a smaller component,
NI-35, in rat. The bovine homologue of rat NI-250, bNI-220, was
recently purified (Chen et al, 2000; PCT Publication WO 00/31235).
The cloning of nogo A, the rat cDNA encoding NI-220/250, was
recently reported (see FIG. 1a of Chen et al, 2000; and PCT
Publication WO 00/31235, the entire contents of both of which being
hereby incorporated herein by reference). The rat nogo gene (SEQ ID
NO: 17) encodes at least three major protein products: Nogo-A (SEQ
ID NO:18) (1,163 amino acids; database accession number AJ242961),
Nogo-B (SEQ ID NO:20) (360 amino acids; AJ242962) and Nogo-C (SEQ
ID NO:21) (199 amino acids; AJ242963). The sequence of the amino
acid p472 (SEQ ID NO:19) containing the residues 623-640 of rat
Nogo-A, is shown in the box in FIG. 1a of Chen et al, 2000. The
cloning of the corresponding human cDNA and protein is reported in
Prinjha et al, 2000. See also WO 00/60083 and WO 01/36631.
[0239] PCT Publication WO 00/31235 describes methods for the
production of recombinant Nogo proteins, fragments, derivatives and
analogs thereof, and DNA molecules coding therefor. This
publication further describes the use of a Nogo protein or fragment
thereof for the treatment of neoplastic diseases of the CNS such as
glioma, glioblastoma, retinoblastoma, and the like; and further
describes the use of a ribozyme or an antisense Nogo nucleic acid
for treatment of a subject with damage to the CNS and/or for
inducing regeneration of neurons, wherein said ribozyme or
antisense Nogo nucleic acid acts by inhibiting the production of
Nogo in the subject. It is thus unexpected that immunization with
Nogo or fragments thereof and/or administration of T cells
activated therewith can promote nerve regeneration or prevent or
inhibit neuronal degeneration in the NS, as shown according to the
present invention.
[0240] PCT publication WO 00/31235, WO 00/60083 and WO 01/36631 are
all hereby incorporated herein by reference. All CNS protein
polypeptides and nucleotides disclosed herein can be used in the
process of the present invention.
Results
[0241] SPD male rats (n=5 per group) were subjected to severe
spinal cord contusion as described in the Materials and Methods
section of this example and a 10-g rod was dropped onto the
laminectomized cord from a height of 50 mm (FIG. 24A) or 25 mm
(FIG. 24B) using the NYU impactor. Soon thereafter the rats were
immunized subcutaneoulsy with Nogo p472 peptide (100 .mu.g/rat)
emulsified in CFA containing 1 mg/ml Mycobacterium tuberculosis.
Control male rats (n=5 per group) were injected with PBS emulsified
in CFA.
[0242] In another experiment, 5 female rats were subjected to
severe spinal cord contusion as described in the Materials and
Methods section of this example and a 10-g rod was dropped onto the
laminectomized cord from a height of 50 mm (FIG. 25) using the NYU
impactor. Soon thereafter the rats were immunized subcutaneoulsy
with Nogo p472 peptide (100 .mu.g/rat) emulsified in CFA containing
1 mg/ml Mycobacterium tuberculosis. Control female rats (n=5 per
group) were injected with PBS emulsified in CFA or with PBS alone.
P472-immunized rats were boosted one week after injury and
immunization with p472 (100 .mu.g/rat) in IFA.
[0243] Acute incomplete spinal cord injury at the low thoracic
levels causes an immediate loss of hindlimb motor activity that
spontaneously recovers within the first 12 days post-injury and
stabilizes on deficient movement abilities. The amount of motor
function restoration is the sum up effect of the positive recovery
from spinal shock and the negative effect of longitudinal and
ventral spread of damage. A therapeutic approach aiming at reducing
the spread of damage through neuroprotection will result in a
better recovery in terms of hindlimb motor activity. The hind limb
motor skills of the animals were scored using the BBB scoring
method developed by Basso et al, 1996, following the kinetics and
amount of hindlimb motor activity in the two experimental
groups.
[0244] The results of the experiments above, depicted in FIGS.
24(A-B) and 25, show that both female (squares, FIG. 25) and male
(triangles, FIGS. 24A-B) p472-immunized rats showed significantly
improved overall functional recovery compared to the control rats
injected with PBS in CFA (squares, FIGS. 24A-B and circles, FIG.
25) or PBS only (triangles, FIG. 25) (P<0.01, one way repeated
measurements ANOVA). Males (FIGS. 24A-B) showed significantly
better locomotor performance than PBS+CFA-treated controls from day
11 after the injury and at all times points measured thereafter.
Females (FIG. 25) showed significantly better hind limb locomotion
than PBS-treated controls from day 25 and on ((P.ltoreq.0.05,
**P.ltoreq.0.01, ***P.ltoreq.0.001, two-tail Student T-test).
[0245] Discussion of Experimental Results
[0246] The results of the experiments described in Examples 1 and 2
show that activated T cells accumulate at a site of injury in the
CNS. Furthermore, the results also demonstrate that the
accumulation of T cells at the site of injury is a non-specific
process, i.e., T cells which accumulated at the site of injury
included both T cells which are activated by exposure to an antigen
present at the site of injury as well as T cells which are
activated by an antigen not normally present in the individual.
[0247] The results of experiments described in Example 3
demonstrate that the beneficial effects of T cells in ameliorating
damage due to injury in the CNS are associated with an NS-specific
self-antigen as illustrated by MBP. More specifically, the
administration of non-recombinant T cells which were activated by
exposure to an antigen which can cause autoimmune disease
(T.sub.MBP), rather than aggravating the injury, led to a
significant degree of protection from secondary degeneration. Thus,
activating T cells by exposure to a fragment of an NS-specific
antigen was beneficial in limiting the spread of injury in the CNS.
The present findings show that secondary degeneration can be
inhibited by the transfer into the individual on non-recombinant T
cells which recognize an NS-specific self antigen which is present
at a site of injury. The T cells may recognize cryptic or
non-pathogenic epitopes of NS-self antigens.
[0248] In addition, the experiments described in Examples 3, 4 and
5 show that activation of T cells by administering an immunogenic
antigen (e.g., MBP) or immunogenic epitope of an antigen (e.g., MOG
p35-55 or Nogo p472), may be used for preventing or inhibiting
secondary CNS degeneration following injury.
[0249] The foregoing description of the specific embodiments will
so fully reveal the general nature of the invention that others
can, by applying current knowledge, readily modify and/or adapt for
various applications such specific embodiments without undue
experimentation and without departing from the generic concept,
and, therefore, such adaptations and modifications should and are
intended to be comprehended within the meaning and range of
equivalents of the disclosed embodiments. It is to be understood
that the phraseology or terminology employed herein is for the
purpose of description and not of limitation, and that other means
or steps for carrying out the same function can be used; and it is
intended that such expressions be given their broadest
interpretation.
[0250] All publications cited herein are incorporated by reference
in their entirety.
REFERENCES
[0251] Altschul, et al, 1990, J. Mol. Biol. 215(3):403-410.
[0252] Arquint et al, Proc. Natl. Acad. Sci. USA 84:600-604,
1987.
[0253] Ashwood-Smith, 1961, Nature 190:1204-1205.
[0254] Basso, D M, Beattie, M S and Bresnahan, J C, 1995, "A
sensitive and reliable locomotor rating scale for open field
testing in rats, J. Neurotrauma 12(1):1-21.
[0255] Basso D M, Beattie, M S and Bresnahan, J C, 1996, "Graded
histological and locomotor outcomes after spinal cord contusion
using the NYU weight-drop device versus transection, Exp. Neurol.
139(2): 244-256.
[0256] Bazan, N. G., Rodriguez de Turco, E. B., Allan, G., 1995,
"Mediators of injury in neurotrauma: intracellular signal
transduction and gene expression", J. Neurotrauma 12:791-814.
[0257] Bender et al, 1960, J. Appl. Physiol. 15:520.
[0258] Ben-Nun, A., et al, 1981a, "The rapid isolation of clonable
antigen-specific T-lymphocyte lines capable of mediating autoimmune
encephalomyelitis Eur. J. Immunol. 11:195-199.
[0259] Ben-Nun, A., Wekerle, H. and Cohen, I. R., 1981,
"Vaccination against autoimmune encephalomyelitis with T-lymphocyte
line cells reactive against myelin basic protein", Nature
292:60-61.
[0260] Ben-Nun, A. and Cohen, I. R., 1982, "Experimental autoimmune
encephalomyelitis (EAE) mediated by T-cell lines: process of
selection of lines and characterization of the cells", J. Immunol.
129:303-308.
[0261] Bone-Marrow Conservation, Culture and Transplantation,
Proceedings of a Panel, Moscow, Jul. 22-26, 1968, International
Atomic Energy Agency, Vienna, pp. 107-186.
[0262] Brandt et al, 1992, J. Neurosci. Methods 45:35-40.
[0263] Burns, J., Rosenzweig, A., Zweiman, B., Lisak, R. P., 1983,
Isolation of myelin basic protein-reactive T-cell lines from normal
human blood", Cell Immunol. 81:435-440.
[0264] Caroni, P. and Schwab, M. E., 1988, "Two membrane protein
fractions from rat central myelin with inhibitory properties for
neurite growth and fibroblast spreading" J. Cell Biol. 106:
1281-1288.
[0265] Caux et al, 1994, "Activation of Human Dendritic Cells
through CD40 Cross-Linking", J. Exp. Med. 180:1263-1272.
[0266] Chen, Y., Kuchroo, V. K.,. Inobe, J. Hafler, D. A. &
Weiner, H. L., 1994, "Regulatory T cell clones induced by oral
tolerance: suppression of autoimmune encephalomyelitis" Science
265:1237-1240.
[0267] Chen, M. S., Huber, A. B., van der Haar, M. E., Schwab, M.
E., 2000, "Nogo-A is a myelin-associated neurite outgrowth
inhibitor and an antigen for monoclonal antibody IN-1", Nature
403:434-439.
[0268] Cohen, I. R., 1992, Immunol. Today 13, 490-494.
[0269] Diehl et al, Proc. Natl. Acad Sci. U.S.A. 83(24):9807-9811,
1986 (published erratum appears in Proc Natl Acad Sci U.S.A.
86(6):617-8, 1991).
[0270] Duvdevani et al, 1990, Neurol. Neurosci. 2:31-38.
[0271] Elias et al, 1991, Proc. Natl. Acad. Sci. USA
88:3088-3091.
[0272] Faden, A. I., et al, 1992, Trends Pharmacol. Sci.
13:29-35.
[0273] Faden, A. I., 1993, "Experimental neurobiology of central
nervous system trauma", Crit. Rev. Neurobiol. 7:175-186.
[0274] Fournier, A. E., GrandPre, T., Strittmatter, S. M., 2001,
"Identification of a receptor mediating Nogo-66 inhibition of
axonal regeneration", Nature 409:341.
[0275] Gonzalez et al, Mol. Phylogent. Evol. 6:63-71, 1996.
[0276] Gorin, Clinics in Haematology, 1986, 15(1):19-48.
[0277] Grewal et al, 1996, "Requirement for CD40 Ligand in
Co-stimulation Induction, T Cell Activation, and Experimental
Allergic Encephalomyelitis", Science 273:1864-1867.
[0278] Hauben, E. et al, 2000, "Passive or active immunization with
myelin basic protein promotes recovery from spinal cord contusion",
J. Neurosci. 20:6421-6430.
[0279] Hickey, W. F. et al, 1991, "T-lymphocyte entry into the
central nervous system", J. Neurosci. Res. 28:254-260.
[0280] Higgins, et al, 1996, Methods Enzymol 266:383-402.
[0281] Hirschberg, D. L., et al, 1998, "Accumulation of passively
transferred primed T cells independently of their antigen
specificity following central nervous system trauma", J.
Neuroimmunol. 89:88-96.
[0282] Hirshfeld, et al, 1970, FEBS Lett. 7:317.
[0283] Hovda, D. A. et al, 1991, Brain Res. 567:1-10.
[0284] Hunig et al, 1989, "A monoclonal antibody to a constant
determinant of the rat T cell antigen receptor that induces T cell
activation. Differential reactivity with subsets of immature and
mature T lymphocytes", J. Exp. Med., 169:73-86.
[0285] Hutchinson, C., et al, 1978, J. Biol. Chem 253:6551.
[0286] Janeway, C. A. Jr., 1992, "The immune system evolved to
discriminate infectious nonself from noninfectious self", Immunol.
Today 13:11-16.
[0287] Karnholz et al, 1986, Proc. Natl. Acad. Sci. U.S.A.
83(13):4962-4966.
[0288] Karandikar et al, 1998, "Targeting the B7/CD28:CTLA-4
co-stimulatory system in CNS autoimmune disease", J. Neuroimmunol.
89:10-18.
[0289] Kerschensteiner, M. et al, 1999, J. Exp. Med.
189:865-870.
[0290] Kramer, R. et al, 1995, Nature Med. 1(11):1162-1166.
[0291] Kuchroo et al, 1995, "B7-1 and B7-2 co-stimulatory molecules
activate differentially the Th1/Th2 developmental pathways:
application to autoimmune disease therapy", Cell 80:707-718.
[0292] Lazarov Spiegler, O., et al, 1996, FASEB J.
19:1296-1302.
[0293] Lenschow et al, 1996, "CD28/B7 System of T Cell
co-stimulation", Annu. Rev. Immunol. 14:233-258.
[0294] Lewis et al, 1967, Transfusion 7(1):17-32.
[0295] Linner et al, J. Histochem. Cytochem., 1986,
34(9):1123-1135.
[0296] Livesey and Linner, Nature, 1987, 327:255.
[0297] Lovelock, Biochem. J. 56:265, 1954.
[0298] Lovelock and Bishop, Nature 183:1394-1395, 1959.
[0299] Lynch, D. R. et al, 1994, "Secondary mechanisms in neuronal
trauma", Curr. Opin. Neurol. 7:510-516.
[0300] Maniatis, T., 1990, Molecular Cloning, A Laboratory Manual,
2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
[0301] Martin, R. et al, 1990, J. Immunol. 145:540-548.
[0302] Martin, R. 1997, J. Neural Transm. Suppl. 49:53-67.
[0303] Mazur, Science, 1970, 168:939-949.
[0304] McIntosh, T. K., 1993, :Novel pharmacologic therapies in the
treatment of experimental traumatic brain injury: a review", J.
Neurotrauma 10:215-261.
[0305] Moalem, G. et al, 1999, "Autoimmune T cells protect neurons
from secondary degeneration after central nervous system axotomy",
Nature Med. 5: 49-55.
[0306] Mor et al, 1990, "Clinical modeling of T cell vaccination
against autoimmune diseases in rats. Selection of antigen-specific
T cells using a mitogen", Clin. Invest. 85:1594-1598.
[0307] Mor et al, 1995, "Pathogenicity of T cells responsive to
diverse cryptic epitopes of myelin basic protein in the Lewis rat",
J. Immunol. 155:3693-3699.
[0308] Nave et al, Proc. Natl. Acad. Sci. U.S.A 84:600-604,
1987.
[0309] Ota, K. et al, 1990, "T-cell recognition of an
immunodominant myelin basic protein epitope in multiple sclerosis",
Nature 346:183-187.
[0310] Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA
85:2444-8.
[0311] Pette, M. et al, 1990, "Myelin basic protein-specific T
lymphocytes lines from MS patients and healthy individuals", Proc.
Natl. Acad. Sci. USA 87:7968-7972.
[0312] Phan The Tran and Bender, 1960, Proc. Soc. Exp. Biol. Med.
104:388.
[0313] Phan The Tran and Bender, Exp. Cell Res. 20:651, 1960.
[0314] Phan The Tran and Bender, 1961, in Radiobiology, Proceedings
of the Third Australian Conference on Radiobiology, Ilbery, P. L.
T., ed., Butterworth, London, p. 59.
[0315] Popovich, P. G., Stokes, B. T., Whitacre, D. C., 1996,
"Concept of autoimmunity following spinal cord injury: possible
roles for T lymphocytes in the traumatized central nervous system",
J. Neurosci. Res. 45:349-63.
[0316] Popovich et al, 1997, J. Comp. Neurol. 377:443-464.
[0317] Prinja et al, "Inhibitor of neurite outgrowth in humans",
Nature 403(6768):383-384 (2000)
[0318] Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Schwartz,
M., 1998, "Implantation of stimulated homologous macrophages
results in partial recovery of paraplegic rats", Nature Med.
4:814-821.
[0319] Rapatz et al, Cryobiology, 1968, 5(1):18-25.
[0320] Rinfret, Ann. N.Y. Acad. Sci. 85:576, 1960.
[0321] Roth et al, Genomics 28(2):241-250, 1995.
[0322] Rowe, Cryobiology, 1966, 3(1):12-18.
[0323] Rowe and Rinfret, 1962, Blood, 20:636.
[0324] Rowe et al, Fed. Proc., 1962, 21:157.
[0325] Schaich et al, 1986, Biol. Chem. 367:825-834.
[0326] Schluesener, H. J. and Wekerle, H., 1985, "Autoaggressive T
lymphocyte lines recognizing the encephatoligenic region of myelin
basic protein: in vitro selection from unprimed rat T lymphocyte
populations", J. Immunol. 135:3128-3133.
[0327] Sloviter and Ravdin, Nature 196:548, 1962.
[0328] Spitzer et al, Cancer, 1980, 45:3075-3085.
[0329] Stiff et al, Cryobiology, 1983, 20:17-24.
[0330] Streilein, J. W., 1993, Curr. Opin. Immunol. 5:428-423.
[0331] Streilein, J. W., 1995, Science 270:1158-1159.
[0332] Suruhan-Dires Keneli et al, 1993 Euro. J. Immunol.
23:530.
[0333] Thompson, et al, 1994, Nucleic Acids Res.
22(22):4673-80.
[0334] Vergelli, M. et al, 1996, "Differential activation of human
autoreactive T cell clones by altered peptide ligands derived from
myelin basic protein peptide (87-99)", Eur. J. Immunol. 26:
2624-2634.
[0335] Weiner et al, 1997a, Annu. Rev. Med. 48:341-51.
[0336] Weiner et al, 1997b, "Tolerance Immune Mechanisms and
Treatment of Autoimmune Diseases", Immunol. Today 18:335-343.
Werkele, H., 1993, In The Blood-Brain Barrier, Pardridge, Ed.,
Raven Press, Ltd. New York, 67-85.
[0337] Wu, D. et al, 1994, J.Neurochem. 62:37-44.
[0338] Yoles, E. et al, 1992, Invest. Ophthalmol. Vis. Sci.
33:3586-3591).
[0339] Yoles et al, 1996, J. Neurotrauma 13:49-57.
[0340] Yoshina, A. et al, 1991 Brain Res. 561:106-119.
[0341] Zaroulis and Leiderman, Cryobiology 17:311-317, 1980.
[0342] Zivin, J. A., et al, 1991 Sci. Am. 265:56-63.
Sequence CWU 1
1
29 1 612 DNA Homo sapiens 1 ccaagaagat cccacagcag cttccgaagg
cctggatgtg atggcatcac agaagagacc 60 ctcacagcga cacggatcca
agtacttggc cacagcaagt accatggacc atgcccggca 120 tggcttcctc
ccaaggcaca gagacacggg catccttgac tccatcgggc gcttctttag 180
cggtgacagg ggtgcgccca agcggggctc tggcaaggac tcacacacaa gaactaccca
240 ctacggctcc ctgccccaga agtcgcagag gacccaagat gaaaacccag
tagtccactt 300 cttcaagaac attgtgacac ctcgtacacc ccctccatcc
caaggaaagg ggagaggcct 360 gtccctcagc agatttagct ggggaggaag
agacagccgc tctggatctc ccatggcaag 420 acgctgagag cctccctgct
cagccttccc gaatcctgcc ctcggcttct taatataact 480 gccttaaacg
tttaattcta cttgcaccaa atagctagtt agagcagacc ctctcttaat 540
cccgtggggc tgtgaacgcg gcgggccagc ccacggcacc ctgactggct aaaactgttt
600 gtcccttttt at 612 2 2139 DNA Homo sapiens 2 gaaaacagtg
cagccacctc cgagagcctg gatgtgatgg cgtcacagaa gagaccctcc 60
cagaggcacg gatccaagta cctggccaca gcaagtacca tggaccatgc caggcatggc
120 ttcctcccaa ggcacagaga cacgggcatc cttgactcca tcgggcgctt
ctttggcggt 180 gacaggggtg cgccaaagcg gggctctggc aaggactcac
accacccggc aagaactgct 240 cactatggct ccctgcccca gaagtcacac
ggccggaccc aagatgaaaa ccccgtagtc 300 cacttcttca agaacattgt
gacgcctcgc acaccacccc cgtcgcaggg aaaggggaga 360 ggactgtccc
tgagcagatt tagctggggg gccgaaggcc agagaccagg atttggctac 420
ggaggcagag cgtccgacta taaatcggct cacaagggat tcaagggagt cgatgcccag
480 ggcacgcttt ccaaaatttt taagctggga ggaagagata gtcgctctgg
atcacccatg 540 gctagacgct gaaaacccac ctggttccgg aatcctgtcc
tcagcttctt aatataactg 600 ccttaaaact ttaatcccac ttgcccctgt
tacctaatta gagcagatga cccctcccct 660 aatgcctgcg gagttgtgca
cgtagtaggg tcaggccacg gcagcctacc ggcaatttcc 720 ggccaacagt
taaatgagaa catgaaaaca gaaaacggtt aaaactgtcc ctttctgtgt 780
gaagatcacg ttccttcccc cgcaatgtgc ccccagacgc acgtgggtct tcagggggcc
840 aggtgcacag acgtccctcc acgttcaccc ctccaccctt ggactttctt
ttcgccgtgg 900 ctcggcaccc ttgcgctttt gctggtcact gccatggagg
cacacagctg cagagacaga 960 gaggacgtgg gcggcagaga ggactgttga
catccaagct tcctttgttt ttttttcctg 1020 tccttctctc acctcctaaa
gtagacttca tttttcctaa caggattaga cagtcaagga 1080 gtggcttact
acatgtggga gctttttggt atgtgacatg cgggctgggc agctgttaga 1140
gtccaacgtg gggcagcaca gagagggggc cacctcccca ggccgtggct gcccacacac
1200 cccaattagc tgaattcgcg tgtggcagag ggaggaaaag gaggcaaacg
tgggctgggc 1260 aatggcctca cataggaaac agggtcttcc tggagatttg
gtgatggaga tgtcaagcag 1320 gtggcctctg gacgtcaccg ttgccctgca
tggtggcccc agagcagcct ctatgaacaa 1380 cctcgtttcc aaaccacagc
ccacagccgg agagtccagg aagacttgcg cactcagagc 1440 agaagggtag
gagtcctcta gacagcctcg cagccgcgcc agtcgcccat agacactggc 1500
tgtgaccggg cgtgctggca gcggcagtgc acagtggcca gcactaaccc tccctgagaa
1560 gataaccggc tcattcactt cctcccagaa gacgcgtggt agcgagtagg
cacaggcgtg 1620 cacctgctcc cgaattactc accgagacac acgggctgag
cagacggccc ctgtgatgga 1680 gacaaagagc tcttctgacc atatccttct
taacacccgc tggcatctcc tttcgcgcct 1740 ccctccctaa cctactgacc
caccttttga ttttagcgca cctgtgattg ataggccttc 1800 caaagagtcc
cacgctggca tcaccctccc cgaggacgga gatgaggagt agtcagcgtg 1860
atgccaaaac gcgtcttctt aatccaattc taattctgaa tgtttcgtgt gggcttaata
1920 ccatgtctat taatatatag cctcgatgat gagagagtta caaagaacaa
aactccagac 1980 acaaacctcc aaatttttca gcagaagcac tctgcgtcgc
tgagctgagg tcggctctgc 2040 gatccatacg tggccgcacc cacacagcac
gtgctgtgac gatggctgaa cggaaagtgt 2100 acactgttcc tgaatattga
aataaaacaa taaactttt 2139 3 581 DNA Homo sapiens 3 taatatctag
ggktttgact ctgacccgtg ttggggctct cacttcatgg cttctcacgc 60
ttgtgctgca tatcccacac caattagacc caaggatcag ttggaagttt ccaggacatc
120 ttcattttat ttccaccctc aatccacatt tccagatgtc tctgcagcaa
agcgaaattc 180 caggcaagcc ttagggaaaa aaggaaaaac aaagaaaatg
aaacaattgg cagtgaaagg 240 cagaaagaga agatggagcc cttagagaag
ggagtatccc tgagtaggtg gggaaaaggg 300 gaggagaagg ggaggaggag
aggaggagga aagcaggcct gtccctttaa gggggttggc 360 tgtcaatcag
aaagcccttt tcattgcagg agaagaggac aaagatactc agagagaaaa 420
agtaaaagac cgaagaagga ggctggagag accaggatcc ttccagctga acaaagtcag
480 ccacaaagca gactagccag ccggctacaa ttggagtcag agtcccaaag
acatgggtaa 540 gtttcaaaaa ctttagcatt gaagattcaa gaggacacag g 581 4
1762 DNA Homo sapiens 4 ctgctttcag agcctgtgac ttcttgtgtg cctctcctgt
ttctcagcaa catggcatag 60 ggcctgggat accaggtctg gggatctcag
ggactcttag cactttaaga cacatgtgtt 120 cccaggccct ggtgtgttcc
tctagtgcca gaaagatgtt tcatgctttg ctgactttgt 180 ataaagtctg
tttgtagctg ttttgacaga atctcagcgt ataactgagg gtggggacat 240
tagccaagct gcattatagg aggacaaaac tgccatacaa agtgtccaaa atcattaagc
300 ctgcattttt attattggga gtaatatcaa acctcctatt ttccaatttt
catttcttgt 360 cctgtgctag ctccatcctg tttggactgc tcctcccata
tgtaaactaa gaagaatcaa 420 gcattctttg caacaaatac acacgatgct
caaaaatgtc caggagcatc caatttccaa 480 agtttcctcc acctggaatg
ctcttcatgc taaaatcctg tctgacaata ccagcatctc 540 tggcctgcac
tcatcccttc ctggaactcc aagtgcattt accctctgtt accacttact 600
tggctgcctg aattgttagt tgaaaatatt aggtctactt agctaattct tcctcaggaa
660 attaaagact cccatatggc agagtctgtg tcttttctct cttcatatcc
cgtataacac 720 ccagcataat gctgggcata tagtgagtat tccataaata
gttgatgaat gactaaaata 780 agcaagcaaa caaacagact agaacaataa
gaaagaaggg actggatttc ataatctctc 840 tggcttgcta tttgaattgc
tgaattatta ttatttatta aatatttttt aaattctggc 900 aataaaaggt
aaggatttat tttctttctt tctttttttt tttcttgaga cagagtctcg 960
ctcttactgc ccaggctgga gtacaatggc gcaatcttgg ctcacggcaa cctccgcctc
1020 ctcctgggtt taacagattc tcctgtctca gcctcctgag tagctgggat
tacaggcata 1080 cgcccatgcc cggctaattt ttgtattttt agtagagacg
gggttttgcc atgttggcca 1140 ggctggtctt gaactcctga cctcatgtga
tccacctgcc tcagcctccc aaagtgctgg 1200 gattacaggc atgcgccacc
gtgcccggcc aaagatttat tttcaagaat gaaacaaagt 1260 aaggattctg
ggtcaatctc acatgctgaa agccaaaacc tctagccgct cctgcttttt 1320
gacttcggag tgcccactat ctccgagcct gtgagcacag ggcctggcag aggggtttga
1380 gtggcatgag ctacctactg gatgtgcctg actgtttccc cttcttcttc
cccaggcttg 1440 ttagagtgct gtgcaagatg tctggtaggg gccccctttg
cttccctggt ggccactgga 1500 ttgtgtttct ttggggtggc actgttctgt
ggctgtggac atgaagccct cactggcaca 1560 gaaaagctaa ttgagaccta
tttctccaaa aactaccaag actatgagta tctcatcaat 1620 gtgtaagtac
ctgccctccc acacagaccc atcttttttt tccctctctc catcctggag 1680
atagagaact cttcagtacc ttagtaacta gcaggggact ggggtggagc cagaccggat
1740 tcccgagtct tccctctgtg ca 1762 5 828 DNA Homo sapiens 5
ctagaaaatc cctagccttg ttaaggtgct cgctctggtg tatacctcac ttatgtcggg
60 aaagaagcca ggtcttcaat taataagatt ccctggtctc gtttgtctac
ctgttaatgc 120 aggatccatg ccttccagta tgtcatctat ggaactgcct
ctttcttctt cctttatggg 180 gccctcctgc tggctgaggg cttctacacc
accggcgcag tcaggcagat ctttggcgac 240 tacaagacca ccatctgcgg
caagggcctg agcgcaacgg taacaggggg ccagaagggg 300 aggggttcca
gaggccaaca tcaagctcat tctttggagc gggtgtgtca ttgtttggga 360
aaatggctag gacatcccga caaggtgatc atcctcagga ttttgtggca ataacaaggg
420 gtgggggaaa attgggcgcg agtctgtggc ctcgtcccca cccaaggctg
ggtcctctct 480 aggggcctgg catttgagtg aggaagcgat ggctgcagcc
gaacgagaag gtcaggaaga 540 acgtggtgcc cagctggctt agcctcacct
ttcaaaggtt ccctaagcaa atttcttctc 600 aaaacagaaa gcatgagttt
tgtgggatgc tttgtacaat cagaccattt ctaagccatc 660 tgttggtatc
cctttgttcc cttcctagta ggtaccacaa gagtggatct aactggacaa 720
gagtctaaaa tgctgctcat gtgattgaga cttgggcacc tgagctraga gggaggatgg
780 ataataaaaa ttaaataata actccaaggt aaatttacaa tgttctgg 828 6 1140
DNA Homo sapiens 6 gatcctcctc attcttcccc tacccattcc ccccaccctc
cgttatactg gggccagtta 60 tctagtagat actgccaatt acccttggca
gaggtgccct gctcactaat tttatttggg 120 ggagmgccct ggaacctggt
tttaatgtct ggcacacgcc acttccagga tctcccagtt 180 tgtgtttcta
catctgcagg ctgatgctga tttctaacca acccatgtca atcattttag 240
tttgtgggca tcacctatgc cctgaccgtt gtgtggctcc tggtgtttgc ctgctctgct
300 gtgcctgtgt acatttactt caacacctgg accacctgcc agtctattgc
cttccccagc 360 aagacctctg ccagtatagg cagtctctgt gctgatgcca
gaatgtatgg tgagttaggg 420 tacgggtgct ttggctctcc tacccactat
ggaagcacta tatatttggt tattttctta 480 gtgtaaggag ggtggtgatt
atgagaaaaa tataagatga tgaatgattg ggtcttagtt 540 tattaatcct
tccctactga aaccagagag gtttcttccc ccggaaggga acttggaagt 600
ggtgggagtt ttcttggcca ttcacattgg cctactctag ttgactgctg ttcacaaccc
660 caaagcagca catttcaata acaaacacaa ggttdsacca ctgttcaata
ccaccttctc 720 ttttttgtaa acctgtagaa aagaggatcc taattgttgg
tagmatccaa mtttacagcc 780 aggataatta gagatggaag aagggctctg
ggggaaagtc tccatgtggc cccgtaactc 840 cataaagctt accctgcttg
ctttttgtgt cttacttagg tgttctccca tggaatgctt 900 tccctggcaa
ggtttgtggc tccaaccttc tgtccatctg caaaacagct gaggtgagtg 960
ggttatttgg gttattttac aagggagtag ctaataccat acaaattaca cccatggcct
1020 tcaattttaa ggactgaaag tttccctttg ctggattttg aattagccga
ttgccttcta 1080 caacatgttg gctaagtgtg cctgagccaa tgagcataga
aggtaaaaca cctcttttct 1140 7 295 DNA Homo sapiens misc_feature
(42)..(43) n at positions 42 and 43 is unknown 7 aattagcaca
cagaaaggat atccaacaca tacaaagctg tnntcatgga ctacactgga 60
gcatattact gctgttgcaa gaaacatttc ttcttcctct tttcattttc ctgcagttcc
120 aaatgacctt ccacctgttt attgctgcat ttgtgggggc tgcagctaca
ctggtttccc 180 tggtgagttg actttgaatg atcttggcaa gtaaataggc
ctgagatagt tgtgggtaca 240 gctattctga aaggcaagaa ggtagactgc
ttccatcctt gaaatgctgg aggga 295 8 2940 DNA Homo sapiens 8
aattctatat actatcacta tggctccact ttggatactc tccagtggat ttagttactc
60 atatggaaat acctgggagg acctcctaac attattagaa ttgttatgat
tataatacaa 120 ygctatgtcc caggtcttgc tgatagtgct acagtgccct
gtgaatgtag tgtgctcatt 180 gtgcagatta aaaacctaag gcactgaagg
gtgaagtgat ttatctgaag ttattttata 240 aagcagtgat cagacaasct
gagctcacag aactccctgg cccctactgc tgaggtttcc 300 atacagagtc
aagtaatttc tcaccttgta aaacgaattg attcattaac caggggagag 360
ctctactgca tgatgtggct gtgtgtctac agcaagcacc ctatgactct aagtcactcg
420 gacatattga tgtggcaaag cccaaatatt gttcacttcc ctgaggaaaa
ctcagtgcta 480 gatcaaacag aggtgtggaa taaatcttta tgatttgatt
ctctgggcct gggccatgag 540 acccatgatg cctcagagac atcggacttc
cagtcaagtg tatatggaga aagccaagcc 600 tgggatgtac tgctttttgc
agagcatggg tttttccctt atttagttat gattttattt 660 ctacccttcc
tcattcccaa agggatttga ggagggagtg ctttcttttc tactctcatt 720
cacattctct cttctgttcc ctacagctca ccttcatgat tgctgccact tacaactttg
780 ccgtccttaa actcatgggc cgaggcacca agttctgatc ccccgtagaa
atcccccttt 840 ctctaatagc gaggctctaa ccacacagcc tacaatgctg
cgtctcccat cttaactctt 900 tgcctttgcc accaactggc cctcttctta
cttgatgagt gtaacaagaa aggagagtct 960 tgcagtgatt aaggtctctc
tttggactct cccctcttat gtacctcttt tagtcatttt 1020 gcttcatagc
tggttcctgc tagaaatggg aaatgcctaa taatatgact tcccaactgc 1080
aagtcacaaa ggaatggagg ctctaattga attttcaagc atctcctgag gatcagaaag
1140 taatttcttc tcaaagggta cttccactga tggaaacaaa gtggaaggaa
agatgctcag 1200 gtacagagaa ggaatgtctt tggtcctctt gccatctata
ggggccaaat atattctctt 1260 tggtgtacaa aatggaattc attctgcgtc
tctctattac actgaagata gaagaaaaaa 1320 gaatgtcaga aaaacaataa
gagcgtttgc ccaaatctgc ctattgcagc tgggagaagg 1380 gggtcaaagc
aaggatcttt cacccacaga aagagagcac tgaccccgat ggcgatggac 1440
tactgaagcc ctaactcagc caaccttact tacagcataa gggagcgtag aatctgtgta
1500 gacgaagggg gcatctggcc ttacacctcg ttagggaaga gaaacagggt
cttgtcagca 1560 tcttctcact cccttctcct tgataacagc taccatgaca
accctgtggt ttccaaggag 1620 ctgagaatag aaggaaacta gcttacatga
gaacagactg gcctgaggag cagcagttgc 1680 tggtggctaa tggtgtaacc
tgagatggcc ctctggtaga cacaggatag ataactcttt 1740 ggatagcatg
tctttttttc tgttaattag ttgtgtactc tggcctctgt catatcttca 1800
caatggtgct catttcatgg ggtattatcc attcagtcat cgtaggtgat ttgaaggtct
1860 tgatttgttt tagaatgatg cacatttcat gtattccagt ttgtttatta
cttatttggg 1920 gttgcatcag aaatgtctgg agaataattc tttgattatg
actgtttttt aaactaggaa 1980 aattggacat taagcatcac aaatgatatt
aaaaattggc tagttgaatc tattgggatt 2040 ttctacaagt attctgcctt
tgcagaaaca gatttggtga atttgaatct caatttgagt 2100 aatctgatcg
ttctttctag ctaatggaaa atgattttac ttagcaatgt tatcttggtg 2160
tgttaagagt taggtttaac ataaaggtta ttttctcctg atatagatca cataacagaa
2220 tgcaccagtc atcagctatt cagttggtaa gcttccagtc atcagctatt
cagttggtaa 2280 gcttcccagg aaaaaggaca ggcagaaaga gtttgagacc
tgaatagctc ccagatttca 2340 gtcttttaat gtttttgtta actttgggtt
aaaaaaaaaa aaagtctgat tggttttaat 2400 tgaaggaaag atttgtacta
cagttctttt gttgtaaaga gttgtgttgt tcttttcccc 2460 caaagtggtt
tcagcaatat ttaaggagat gtaagagctt tacaaaaaga cacttgatac 2520
ttgttttcaa accagtatac aagataagct tccaggctgc atagaaggag gagagggaaa
2580 atgttttgta agaaaccaat caagataaag gacagtgaag taatccgtac
cttgtgtttt 2640 gttttgattt aataacataa caaataacca acccttccct
gaaaacctca catgcataca 2700 tacacatata tacacacaca aagagagtta
atcaactgaa agtgttcctt catttctgat 2760 atagaattgc aattttaaca
cacataaagg ataaactttt agaaacttat cttacaaagt 2820 gtattttata
aaattaaaga aaataaaatt aagaatgttc tcaatcaaac atcgtgtcct 2880
ttgagtgaat tgttctattt gacttcacaa tagaaactta ataatcgtac cttctcaaga
2940 9 17538 DNA Homo sapiens 9 atggaaatgt tctgtatttg tgttgtctga
tgagataacc actaactgta gtgctattga 60 gcatttgaaa catggctagt
gtaatcaatg aaccaaattt ttaattttat ttaattgtaa 120 ttaattttaa
gtggccacat gcagggagtg actgctgcat tggacagcac ggctctaaat 180
tgagcctttt ttccttattt ggtgaggcat acttgcctta agattgggaa gtctattttt
240 ggaacctgct accaatgctg gtctcacact tgcaattctc agctgagcca
agaggtgaga 300 gaaaggtcat tttccattcc aagatctcac tctcccctgt
gacactgagg aaactggcaa 360 gtgatgtgaa ggctggagag cgtgtcctgt
atgctggctc tgtcccttct gcctgtgttg 420 actgacatag ttagttgctg
cccttgctgg tctcccttcc tccaaccttg cctctctgag 480 cacacctgac
attcatctca tgacttccct aaaaacattc tttgggaaca agaaactaac 540
aaatcccaag tgacctatca catatacaaa catacagggc agagtttgga ttcgcggtag
600 aagaaaggga ggttagacat taagaagaat ggtctggtga tgacagttgt
gagataatag 660 aaacaggaaa aagaaatcta agttttcttt ctttttttaa
gaaccaataa taatttctct 720 cttttgacta gtcagtaggg ctggggtgga
ttggaggaag cttacatatt ccatgaacaa 780 gcctcttcct aaggtcctgt
aagtgatcct gccccactga ttagccccta gaagaccctt 840 caaaggttgg
atctccagga gggagtgggg gaggaaagcc ctgtaccagg cagcctctgc 900
tccattgctc tgggggggtg gggaagacaa accctggtca tcccctcagt ctgtagccct
960 tttgtgtgag tgcctggcaa gggtgacgtg gggctgtttc tgcgggcaca
gctgcagcaa 1020 ttaccggagt ggaggcaggg cccaggcagc actgccctcc
aagatcttcc cttgggcttt 1080 tcagcagtaa ggggacatgc accccaaggg
cctccacttg gcctgacctt gctgcggggg 1140 ctctctgtcc ccaggaacag
tagagatggc aagcttatcg agaccctctc tgcccagctg 1200 cctctgctcc
ttcctcctcc tcctcctcct ccaagtgtct tccagctatg caggtaagac 1260
atgttttttt tcctgccctg gggagaccct gaaaacagaa aggctagttt cctgggggtt
1320 agctccttca aacatcctca agttggtata ttatctttct aaaacataga
cctactgaca 1380 tgcctccctt cctcagaaac cttccgtggg tggttcttac
agccttcaag atggagtcca 1440 gactcttttt tttttttggg acagagtctc
cctctgttgc tcaggctgga gtgcagtggc 1500 atgatctcgg ctcactgcaa
cctcagcctc cctggttcaa gcgattctcc tgacttggcc 1560 tcccaagtag
cggagactac aggcgcctgc caccacaccc agctaaattt gttcttttct 1620
ttcttttttt ttttttttgg gattttagga cagacggggt ttcacatgtt ggccaggatg
1680 gtctcgatct cttgacctgc tgatccgccc gcctcagctt cccaaagtac
tgggattatg 1740 ggcgtgagcc actgcactag gcctaatttt tttattttta
gtagagatgg ggtttcacca 1800 tgttggccag gctggtctgg aacccctgac
ctcaagtggt ctgccctcct cagcctccca 1860 aagttctgag attacaggca
tgagccattg cgtctgaccc agactcctta atgtgactaa 1920 ctccaggctt
tccttggact acttcttact tgtctttcca gctttgtctt ttcacctctc 1980
caattgagat aaaataataa caacctcttg gagttctcat caggattaca tgaaatgaga
2040 tatgtaacat gcttagcagt gcctgtccat agtaaatctc aataaatgtt
tgtggaatta 2100 taatatcttg tcatgtttga gactttgctc tgcataatca
ggcaccagta ggtttttata 2160 aaggaacccg tctgtcacgt gcagaggaga
aataaacaga aagtttccca tcctcaggga 2220 gccacctgac tgacagaggc
acagtgcatc cactctccag gtctagggga gaaagcagcc 2280 ttatttctta
gtagctcaga atctgacttg agaaacacat ccacatagaa aaaaacaagg 2340
aactttttcg ggtcagggtc cgggacccac agtgaggtgg aagatacagg ggaaggaaga
2400 gggaaataga gccatcccca gggtggaaga tctcagaaga gaatttggga
aacaaggtat 2460 gaacaaggac tgaatagtga gaagtgatgg agagacagct
aaagtagatg gagtgtcaaa 2520 accaaaacct ctaagggtag aataggcagc
aatttggcca agtcctaaca gggaggccca 2580 taggaggatt caacctcaag
atgctgtgcc acattccaag agggaaccta aaggctgggc 2640 tgaagagtca
gagatggcta cagctggcaa aaagatgggc agatgctgag aggagatgat 2700
tgctaaaatg ttctgtccag gacattcaca gtatctctat aaccagagtc ttttttgtcg
2760 ttgttgttct caagaaggaa acttgaggcc gggtgtggtg gtttatgccc
ataatcccag 2820 cgctttgggg ccaaggcagg cggatcacct gaggtcagga
gttcgagacc agcctggcca 2880 acagtgtgaa acctcatctt tactaaaaat
acaaaaatta gctggatgcg gcggtaggtg 2940 cctgtaatgc cagctactcg
ggaggctgag gcaggagaat cacttgaacc tgggaggcgg 3000 aggttgcagg
gaggcggagg ttgcagtgag ccaagattgc accactgcac tccagcctgg 3060
gcgacagaga gtaagactgt ctcaaaaaat aaatgaataa ataaaaagga agaagaagaa
3120 gaagaacaat tgcaatcctc cctggctcta gaatgtcatt taaaagtcga
gtgtcttctt 3180 ccttccctgt tttgaagcag cccttctcat gacaggcttg
cttgccaagg ttccctctga 3240 ccttaaatct cttccttttg gtgtcttgga
cagggcagtt cagagtgata ggaccaagac 3300 accctatccg ggctctggtc
ggggatgaag tggaattgcc atgtcgcata tctcctggga 3360 agaacgctac
aggcatggag gtggggtggt accgcccccc cttctctagg gtggttcatc 3420
tctacagaaa tggcaaggac caagatggag accaggcacc tgaatatcgg ggccggacag
3480 agctgctgaa agatgctatt ggtgagggaa aggtgactct caggatccgg
aatgtaaggt 3540 tctcagatga aggaggtttc acctgcttct tccgagatca
ttcttaccaa gaggaggcag 3600 caatggaatt gaaagtagaa ggtgagtagt
gccatataat attaggtatt aactgttggg 3660 tggccaagaa caattattct
ctcaactgag atgagatccc tcaacccaaa catctcagtc 3720 ctgggaatga
tttccataaa aatgtacaca tcaataaaca gaaactcatg cttagggatg 3780
tctgttgcat cattattcag agtagcaagg aaattgggat caaaatcaat gcctttgagt
3840 aggtaagtga cagaatgaac aatggtagcc atactgtgaa tattatgcag
ggattaaaaa 3900 gattatttta gcactaggcc agatggtttg gggggctcct
ctaaggtatt attgagtgat 3960 aagagcaagc tgctgtagga tacaaaaaca
aaaacaaaac cctagggcat ggtggtttgc 4020 ctcgcagcta ctcaggaggc
tgagacggga ggctggcttg agcccagggg tttgcagtta 4080 cagtgagcta
tgattgcacc actgcactcc aacccgggtg acagagcaaa gaccttcacc 4140
cccactccct acccgtctct aaaaaaaaca aaaacaaaaa caaaaaaacc cttgggccca
4200 gcgccgtggc tcacgcctgt aatcccagca ctgtgggagg ccgaggtggg
cagatcacaa 4260 ggtcaggaga tcgagaccat cctggctaaa acggtgaaac
cccgtctcta ctaaaaatac 4320 aaaaaaaaaa aaaaaattta
gccaggcatg gtagcaggcg cctgtagtcc cagctactcg 4380 ggaggctgag
gcaggagaat ggcgtgaacc cggaagcgga ggttgcagtg agccaaaatc 4440
cttccactgc actccagcat gggggacaca gcgagactcc gtctcaaaaa aaaaaaaaaa
4500 accctgtatt tgtgagcgca cacacacaca cacacacaca cacacctgtg
cttggtccta 4560 gtgaataagc aagtaaatca aatgtctaaa tataattata
gaaaggagat gtcacctttt 4620 ggctgtacct ccactatttc attctgcaga
attgcagaat ttcttttttt tttcctttct 4680 ttcttttctt tttttttttg
acacagagtc tcgctctgta acccaggctg gagtgcaatg 4740 gcgccctccg
cctcctgggt tcaagtgatt ctcctgcctc agcctcccga gtagctggga 4800
ttacaggtgc ccaccaccac acccagctaa tttttgtatt tttagtagag acagggtttc
4860 accaggttgt caaggttggt ctcaaactcc tgacctcagg tgatccactc
gcctcagact 4920 cccaaagtgc tgggattaca ggcatgagcc atggtgcccg
gcctcagaat ttcattttca 4980 acatgttttg catgatgggt gattttggag
aatatttttt gctctatcgc aggatgatta 5040 agatgtggac aaggtgaagc
cgatggaggg ggagctttga aagttacttg ctatttaatt 5100 gaggaactaa
actgctttga gagcctgggg gtcagatcct ctgccttttc ctcctcccca 5160
cctgcagtgc aaacatcaga caattgatca ctattgtatc ttggaggtgg gagtgaccat
5220 tgcagtgctg ggaccagaag atggcattgt atgtggaaca acaaagcact
atttctagag 5280 actgcctgca gggatatgga aatagcttta tgtgtctcag
aatgttcttc atacagctgt 5340 ttttattggg gaaattctac ttgccgaaaa
gtttgatagt gagaccctct ccagtttgca 5400 gatttttctc cttcctgctc
aacaacttcc tagctcagta actgcctctc ccaacaaact 5460 ccctcagttt
caccacacca aaaaaggaag acaagccggt tgcggtggct cacacctata 5520
atcccaaaac tttgggaggc cgaggcgggt ggatccacct gaggtcggga gttcgagact
5580 agcctgacca acatggagaa accctgtctc tactaaaaac acaaaattag
cctggcgtgg 5640 tggcgcattc ctgtaatccc agctgggagg ctgaggcagg
agaatcgctt gaaccccgga 5700 ggcggaggtt gcagtgagcc aagatcgttc
cattacactc cagtctgggc aagaaaagtg 5760 gaactccatc tccaaaaaaa
aaaaaaaaaa aacaaggaag acaaaaagaa aagcagctaa 5820 agactttgcc
tcaggggaga aagttctctt ttgggttgct atccacattc caacctcctg 5880
ttcccacctc ttcgtctgca tgcctaagaa actgttttac aagtaaataa gggacgcttt
5940 gtctaggctt tggagccagg aagttgagac aaatttagga atgagatgaa
gtaatggtat 6000 tattgcaagt ctcaggtgta actacctctg ctctttctct
gaagagtttc taatttctct 6060 tgtttactta tttttttctt gtcatttttg
ggattttatt actagttgtc tctaatcctt 6120 tctttaaatt cttcattatg
aaacataaaa acaaatgcca ggcgcggcag ctcacgcctg 6180 taatcccagc
actttgggag gccgaagcgg gcagatcacc cgggtcagga gttcgagacc 6240
agcctgatca acatggagaa accccgtctc tactaaaaaa tacaaaatta gctaggcgtg
6300 gtggcacatg ccagtaatcc cagctacttg agagactgag gcaggagaat
cgcttgaacc 6360 gggaggcaga ggttgcggtg agccaagatc gcgccattgc
actccagcct gggcaacaag 6420 agcaaaactc tgtctcaaaa aaaaaaaacc
acatacaaac cagagataat attataatga 6480 gcctccaagt gcctaccacc
ttgctgcagc acttgtcaat ccagggacca cccacctcac 6540 cggctcccca
ctcattacca ccctccccta ctcaattact gaggtaaatc ctaggcagca 6600
tgatcatttc ttttttttct ttttatttat tttgagacag gatctgtctc tgtcacccag
6660 gctggagtgt agtggcatat ctctgctcac tgcagcctct gcctcccggg
cagaagccat 6720 cctcccacct cagcctacat agtagctggg accacaggca
cacaccacca cacactgcta 6780 atgttttgta ttttttgtag agactgggtt
ttaccatgtt gatcaggctg gtctcaaact 6840 cctaggctca agcaatcctc
ccacctcggc ctcccaaagt gctagaatta caggcgcgag 6900 ccactgcacc
cagcgaagaa cactttttaa aaaataaata ggccgggcgc ggtggctcac 6960
acctgtaatc ccagtacttt gggagcccaa ggagggcgaa tcatgaggtc aagagattga
7020 gaccatccta agtaacatgg tgaaacccca tttctactac aaatacaaaa
acaaaattag 7080 cctggcgtgg tggcaggcgc ctgtagtccc agctacttgg
gagctgaggc aggagaatgg 7140 agtgaacccg ggaggcggag cttgcagtga
gctgagatca tgccactgca ctcccccctg 7200 gggcaacaga gtgagactcc
caaaaaaaaa aaaaaaagcc ccccctcccc acacacaata 7260 atataaataa
ataaataacc acaatactat tatcacatct tacaaactca acaaaaattt 7320
cttaatatca tcaaataccc agtttgtgtt caaattttcc tgattgtttc ataaatatac
7380 tcttacagtt ggtttctttt agcgagattc aaatgagacc cacctgttga
cctttgccct 7440 tagggtttcc cagggtctga attttgttga cgacattccc
atgttgctat gtaatacggt 7500 cctccatgcc ctgtgttttt ctgtaaactg
atagatgtgg aggtgcaatg acatttgtgt 7560 ttgatttact ttggcaaata
tagttcatca gtgatactct atacttcttg ttgctttaca 7620 tccggaggct
gataatgtct gcttttctct cttttctaat tatttgtgaa aggaaaaatg 7680
tggggggttg ggagaaaaaa acccttaagt acatactcgc taaatcacat tgctacaggt
7740 aacttccatt aagaacttga aagtaaaggt agctgcattt tcccctaggg
aacacaatga 7800 tagacaggag ccttagtcta cagcttgaag gattgtaatt
atacctaagc aaccctcctg 7860 gaccagttta atgttattag ctgtgatgta
tccctacctt tgatgtcatt atccttactt 7920 agctccctta aagcagagat
caagatgaaa agggcttcag ctgcagcatg gcacatggag 7980 attagagtgg
ggcttttgga tgctgaggag cagacctaga atgggaaata gatgggagcc 8040
acagaagtga aggtccccct ccctcattgc tcaacctact ccacatctcc aggtctgcac
8100 atctgttcag ttactgaatc ctgtgtaagc taccttcttt ttcttttttc
ttttatttat 8160 ttatttattt tttttttgag atggagtttt gctcttgtta
cccaggctgg agtgcaatgg 8220 tgcaatctcg gctcactgca ccctccaact
cccaggttca tgcaattctc ctccctcagc 8280 cttccaagta gctgggatta
caggctgcac caccatgtct ggctaatttt tgaaaaatca 8340 gtagagagag
ggtttcacca tgttggccaa gccggtctcg aactcctgac ctcaagtgat 8400
ccacccacct tggcctccca aaatgctggg attacaggtg tgagccacca tgcccgctgt
8460 aaactacctt cttaaaagct ctagaagagg gcttttaacc ttttgttgtg
tgtcatgcac 8520 cttccgcaag ctgatgaagt tgatagaccc atctcagaat
tttttttttt tttttgagac 8580 agtgtctcac tctgtcaccc aggattggtt
gcagtggcac gatcatgggt cattgcagcc 8640 tccacctccc aggctcaagt
gatcctcctg actcagcctc ttgaatagct gagaccacag 8700 gcttgtgtca
ccatgcccag gtaattttta attttttttc gtagaggcag ggtctcacat 8760
tatgttgccc agtctggcct cgagaactcc tgggctcaag caatcttcct gccttgggct
8820 cccaaagtgg tgggattaca ggggagagcc accacaccta gccaggagga
tgttttaaat 8880 acaccaaata aaacatttat acccaaatac agttatccaa
atattaaatt aacaagagtt 8940 agggtgaccc tattaattag tgtaatttcc
aaatagtaat gaacataagt gatagtttga 9000 gatttctgtg acttttctaa
tgtgacgtga aaatatttgt gatttttctt tttctttttt 9060 ttttttgaga
tggagtttcg ctcttgttgc ccaggctgga gtgcaatggc aagatctcgg 9120
ctcacctcaa cctccgcctc ctgggttcaa gcgattctcc tgcctcagcc tcttgagtag
9180 ctgggattac aggactgtgc caccacgtcc agctaatttt gtatttttag
tagaaacagg 9240 gtttctccat gttggtcagg ctggtcttga actcccaacc
tcaggcgatc cgcccgcctc 9300 ggcctcccaa agtgctggga ttacaggtgt
gagccaccgc acctggccaa tatttgtgat 9360 ttttattgac gacaaagtca
aaggttctct tcatattatt gtggtgtatc gcctacaagc 9420 ataattaaaa
taaacactaa atttcagttt aaagtttact gaaaataaat atgtattttt 9480
tattccctat ttaagctttg aatcccctga cttcctatac cattaccact gtcctagttc
9540 aggttcatgt tgttttttac tttaattgtt atcacagtct cttaacattt
ctccctatgt 9600 tctccagtcc tgtaggtgct aaatctgacg tggtcacttc
tcagcttgga atccttcagt 9660 gcaccaccac agccttgaac tacatatttg
aaatacatat ttattttcag taaactttaa 9720 actgaaattt agtgtttatt
ttaattatgc ttgtaggcga tacaccacaa taatatgaag 9780 agaacctttg
actttgtcgt caataaaaag tcccttgagg ggacttcaga tgtaagtccc 9840
ttagctgctc gttaaaactc ccccaggctg acccaataca caatcttgac tttaaaccac
9900 ttgtcattct aaatcactag catttcctgg aaaaaaaagc catttttcct
tcagggctaa 9960 gctcagggac caattctgtg tcaccttctt tgaatcctga
tgatattcac ttctttattt 10020 gacctgattt attgggcccc agacaccatg
ctgagtgttg gggattcagc tctggacaat 10080 gtcaaatgtc agtcctgcct
ttcagatcct ttctactggg tgagccctgg agtgctggtt 10140 ctcctcgcgg
tgctgcctgt gctcctcctg cagatcactc ttggcctcgt cttcctctgc 10200
ctgcagtaca gactgagagg tacagggcag agggtgggtg gatcaggatc ctttctttaa
10260 atgagctggc ttcttggagc tacaccactt aacatgtatt tgtgagtgac
ttctgggttc 10320 agaagttctt ctcactattg agtgataaag aaaaaaaata
actccatgat gaaagagttt 10380 tacatcttac ggaatgcttt catatgaata
atcggaccta gcatttccct atgagctaac 10440 tatgccatat agtaacccca
ttttacagag gatacaactg aggccaggag tagttcagtg 10500 acttactcaa
accgatataa cttataagtg gtagagctga ggcctctgta tcatacctag 10560
cagctccatg caacttggga gagtgtgagc ttcgaagtca gacaggtcta ggctattagg
10620 agttttgaat aaagatactg aagtgaaagt ctctaccaca cagtaggcgt
tcgaaaattg 10680 tttcctcttt ctccattcaa cactgaggac tcaggttcag
ctgctgatga agctcctctt 10740 ttttgcctag agctttcatt ctgagccttc
tcctcctacc aagtgtctcc ccaatgccag 10800 agcaggaaga gtcttcactc
ctcccaatgc cccacctccc atttgttact aagaggagag 10860 gagaaagtag
caaggagggt atggggaatg ttctggggga atgggtgttg gtgcgatcaa 10920
caacaaagtc ctttctctca ccttgaattc atcccagatg cctgcttgtt tacttcttcc
10980 acacaaaaaa aggccttcag ccctcatggc tgagcagaaa gaatctgaat
gttagagtca 11040 ggcagcctgg gtttgaattc catctcaggt actgaactct
atagcaaaat tcttagattc 11100 tccaagcttc agttgccttg tctgtcaaat
agagaaaaca tccttcgtcc taaattgtag 11160 ggaggattaa agtcatgcaa
agtgcctact acaaatccag tcacaaagta gctagctact 11220 cactaaatgt
tcagctcctc cctcctcatt cagatgggaa gtggctttag ataaacaaag 11280
tggcaacgca gtgggctgga gcagctctgt gaactgagaa tccaagaaaa ggggcgaaga
11340 gcagctggga tgtattggat gcttgtgctg gcttggagca ttgctcacat
tctttattcg 11400 ctattgtatc tagactatag ctagagaaag agccgcaacc
attggcttta aatccagtgc 11460 tcttcctact ctcctgaggt tgtttccagg
ctgcagagaa atagcctgca caaggggccc 11520 aggcgctggg tgtgggaggg
tccccaccga gagccagaac atgcaggaac taaaatgttg 11580 cctttttcta
ttttaggaaa acttcgagca gagataggtg agttccagtc atcgtttctc 11640
ccaattcttg ccttttggtt ttttggcata acggaaatgg tcccattctt ggaccgtctc
11700 tccctctcaa taccctgttt tcccctcagt ttccctttct ctacagtggg
tgtgtcgtgc 11760 ctagaacaag ttttaagtaa ttaaataaca aagactcagg
ataaaaggat cctttttgga 11820 gtgccctact aaatccattt ccatttgttt
ctctttcaga gaatctccac cggacttttg 11880 gtaagttccg gcatgtctag
gccctcccag gtcaacttgg tatttcactc tagttccagt 11940 cacctggggg
aacaaggacc cctggctcct ggttgagtcc cttcctctct tctcttttct 12000
ttctttaaat aagaagtcat ttgcatttag gattggtaaa atcataataa aaatactcat
12060 gtactgtttt tatgtgccag gcactattct aactacttta caaaaacgtt
atcttattct 12120 gtttaactcc ttatgcacat gatctctctt ttcaggaatg
ccaaaacaga ggtaaataga 12180 tcgtttacac gtaaacctga tgtctggttg
gggaggtgaa acaaacagaa acaagacaca 12240 actgtatcac ctgtacttat
atttctgctt tacaaactca ggatgtttcc atgagtacag 12300 aacatgacta
atcagagaag acctcataga ggaatagaaa agccaccaag ccccactagg 12360
aattgacccc tcaaggacat ggtttctagc ctttttgttc actgcagatt gcccaatgcc
12420 taaagataat ggcaacagaa gagcacccaa atatttgtta gataaatgtt
gcagacacta 12480 gaaggtgtca ttagggcaca gatggtacct tctctgagca
aacttccttc acagctcctc 12540 ctcccgaggc tgtaggtgac tctactcttg
tcacctggca cacagagttc tatcgtacga 12600 tttaggaaat tagaccagtg
tgtggaccac acacacacac atctttacac acccaaagag 12660 gaggaatagt
atctttgttt tggaggactt gactatgaaa ggtcttaact cctttttgta 12720
ccatgaatct ctctggcact ccagtgaagt ctaaaggacc cctttgcaga atgtttttaa
12780 atatacacat aaaatagaac acataggatt gcaaaaacaa tcattgtact
aaaatacagt 12840 tatcaaccga taatcacatt tgtgatatag taacataaat
gtttcttttt tttttttttg 12900 gaggcagagt ttggctcttg tcacccaggc
tggagtgcaa tggcgcgatc taggctcact 12960 gaaacctctg cctcccgggt
tcaagcgatt ctcagcctcc tgagtagctg ggattacagg 13020 tgcccgccac
cacacccagc taatttttgt atttttagta gagactaggt ttcaccaggt 13080
tggccaggct ggcctcgaac tcctgacctc aggtgatcca cctgccttgg cctcccaaag
13140 tgctgggatt acgggcatga gccaccgtgc ccggccataa atatttcttt
agccaaagta 13200 atacattaag taatgtagca gcaagtctaa taacctgtaa
tttctttctt tctttctttc 13260 tttctttttt tttgagatga agtttttttg
agatggagtg caatggcaca atctcggctc 13320 actgcaacct ccacctcctg
ggttcaagcg attctcctgc ctcagcctcc caagttgctg 13380 gaactacagg
cgcatgccac catgcccagc taatttttgt atttttagta gagacggggt 13440
ttcaccatgt tggccaggct ggtcttgaac ccctgacctc aggtgatctg cctgccttgg
13500 ccttccaaag tgctgggatt acaggcatga gccaccaggc ccagcccaat
aacctttaat 13560 ttcaacatac taataaacat aaacagtatt tcaagatttc
tgcaataact ctaatgggaa 13620 tgaaaacatc tgtggcttcc attggtaatt
aagtcacagg tactgctcat attgtggtta 13680 gttgtaaaat gttttggttt
gttttgtttt ttccaagact tgggggaatg ggtgttggtg 13740 ggatcaacaa
gagtcttgct ctgtggccca ggctggagtg caggggcagg atcttggctc 13800
actgcaacct ccgcctccca ggttcaagcg attctcctgc ctcagcctcc tgagtagctg
13860 gcattacagg catgtgccac cacgcccagc taatttttac atttttagta
gagatggggt 13920 ttcaccatgt tggcctggct ggtcttgaac tcttggcctc
atgatccacc cgtctcggac 13980 tcccagagtg ttgggattac aggcatgagc
caccacacct ggcagttgtt acatttttaa 14040 tgaaagaaaa tgttaaatcc
agttattgaa aataaggagg cagtactttt ctcatccaag 14100 ttcatggact
ttctgaattt tgtccccaga gtcctttggt gttctaggac cccaggttaa 14160
ggaacccaaa aagacaggtg ggtggggcat gagggggaac acatgttaat ccctgtttgt
14220 tctggtgaac aattcagatc cccactttct gagggtgccc tgctggaaga
taaccctgtt 14280 tgtaattgtg ccggttcttg gacccttggt tgccttgatc
atctgctaca actggctaca 14340 tcgaagacta gcaggtgcag tggctgggca
gcaggcaaga ccaccaaata gtgggggacc 14400 aagtcagctc tgaatgggaa
gccaaaagag aatagaacca ggactcaaga ttaggggagc 14460 tgggatttcc
ttattcctct gtccccatgc ccaaccccag gctcttctga gaaactgtga 14520
agagaaccac ttactggatc tgtgggatcc cccagtggaa agggcagtgt gggtcactcc
14580 aaatgtccat agggaggatg tggggaaggt gctattcatc ttccactaat
cacatatttg 14640 tttctttttg ttttcagggc aattccttga agagctacgt
aagttctctt ctctctgtta 14700 taagcagaga ataaaaagcc aggaaaggga
gacagaagca acaagaggaa gaggcgggct 14760 attgagggat cacattccca
gaggaaagga ggagctggag agcctgggtg gagggaagac 14820 tcctcctggg
aggtagaggg caaagaagcc agctgttaga gacacattta caggtggcag 14880
agaagctgga ggcactccta tctgccacct gatccattcc tccttcactg cccctaagca
14940 ggaatccaac cctagctggt ctcattgccc attccacagc aactgcccag
tgcctcacct 15000 ctcagatcaa ccattgaggc aggaatggag acaagatgac
cccaagggct tttcttctcc 15060 ctagttcaat ggttttatga tacaaactac
tgacatacgt ttttcaagtt attttctcct 15120 tcttctagga aatcccttct
gagtgatgtc acatcttggc aggggtggag gagagcctgg 15180 ttgcccaggg
atttgtcctt ggggacatct catccatcaa gttgcacact cactggcatc 15240
tttgctatgg ggacattcca atttgcactt tcaggaacac tctgaattcc aagtagaatt
15300 gatttccctt cttctgtcat ctaccttttc tcttcatttt cccattttta
ttacccttct 15360 ttccatttct ctctccagtc ttccacctgg aagccctctc
tggctaagga caggcaggtg 15420 cccctctctc catcagagga cacctgtact
ggagagcaac acaggatggt ctctgccatg 15480 aactggaggc caggaatctc
ctcactgaaa attacagtat ggtaactttg caaatggtgg 15540 ttgtttcttc
caagactcca gccctgattg cgcaaaactg aaaggcatgt gaagggaagg 15600
aagaggaaga gtgcaaaaca ttgaagagag agctgagtga gctgaagagt gaggatatga
15660 gtagccccaa cccaaacctg gagatgggga gaaacctaca gaatactagc
cagagctcct 15720 ccttgtcttg gcagcctact agggacctgg ggaagcaaaa
acgaaagctg ggcaacatgc 15780 ctgctttaga atgttttcct tctacttaca
catcttccac aggtctcaga atctttcctt 15840 cctctcatcc ttttctccta
tctacatatc tatcagagta tccactgttt attcaacaac 15900 tactacttga
tggtcagaca caaacaaaca agctaggtgc taattaataa agatacgagt 15960
tttggccggg tgcggtggct cacgcctgta atcccagcac tttgggaggc cgaggcgggc
16020 gaatcacgag gtcaggagtt caagaccagc ctggccaaca tggtgaaacc
ccatctctac 16080 taaaaataca aacaattaac tgagcatagt ggtgggcacc
tataatacca gctactccgg 16140 aggctgaggc aggagaatcg cttgaaccca
ggaggcagag gttgcagtga gctgagatcg 16200 cgccactgca ctctagccgg
agtgacagag taagactctg tctcaaaaat aaataaataa 16260 ataaataaat
aaataaataa ataaataaaa aataataata caagttttca taagcacact 16320
tctaacccct tgtcttttat gtatttcctt ccttatccac gcacctgtct ccctctactc
16380 cagcctcatt accccagagg tcagtcctca ggaaaactaa acacaaagaa
agagctcagt 16440 cagaaaggcc atttatttat gtttcaagat gctcactgcc
tcctttgttt tgtctccttt 16500 gcaggccttc tctcttaggc ctcttctcct
gggggtatgg atcctggggg gagattgatc 16560 acctccatgc ttccattcct
ccccagccat agtggggaca tcatgagaga agccaagcca 16620 ctggcccagg
atcacccggc atttatggtg gctgctctgg cacaggtcct tgcctttata 16680
gcccctccag tgatccataa ggccctcttt ctccccaaag gagaggtcac agatagggca
16740 aaggtagctc ttctgcttcc agtgggtctg ctggtgtctg accagcctgg
aaaatgagct 16800 gaaagacttg ctgcaatgga agcagtagtt gggcggctct
gtgaggtggc ccttctggtg 16860 tctggagaga taggatttct tgctaaaagt
caaagaacaa tgggggcaac agaagacatt 16920 gagtcttgag ggcttcactg
gatgagagtt ggatctggca tcctgacaga gggttccagt 16980 gatgggtgcc
tgggtcctgg tcacaggtgc ttggttctta agtacagatg cctggttctg 17040
ggccatagga ccctcagttc taaatatggg ttcctgggac ctggccactg gtgcatggtt
17100 cacatccaaa agcccctgga tggacctctg gcttctggcg atgggtgtct
ggaattcagc 17160 ctgggtgcct ggaatcctca aagtacactc ctggtttcca
tccactggct cctggttttg 17220 gtgtatcttc tggtggcgtt tgagctcaga
ctggtcccgg aagctcttcc cacacacaga 17280 gcatgaatgg ggccggtaac
ccagatggac gcggcggtga cgacttagtc cagaagcatc 17340 acagtaggtc
ttgtcacaga gcgtgcaaca gaagggcctc tccccaagat gcatgcgtct 17400
gtgatagctg agggacttgg ggctccgaaa caacttccca cactgactgc agctgttagt
17460 cagcttggga ttgtgaacaa actggtggct atagaggtag gagcgcctgc
tgaaacattt 17520 ggcacaggtg tagcaaaa 17538 10 327 DNA Rattus
norvegicus 10 tttgtatgtc attgcaggat tcatgctttc cagtgtgtca
tctatggaac tgcctctttc 60 ttcttccttt atggggccct cctgctggct
gagggcttct acaccaccgg cgctgtcagg 120 cagatctttg gcgactacaa
gaccaccatc tgcggcaagg gcctgagcgc aacggtaaca 180 gggggccaga
aggggagggg ttacagaggc caacatcaag ctcattcttt ggagcgggtg 240
tgtcattgtt tgggaaaatg gctaggacat cccgacaagg tgatcatcct caggattttg
300 tggcaataac aaggggtggg gggacaa 327 11 2013 DNA Rattus norvegicus
11 ctgtatcagt gctcctcgtc gcctcactgt acttcacgga agagacttgg
ttgactggcc 60 acttggagcg gaatcaggag acattcccaa ctcagagaga
ctgagcccta gctcgcccac 120 ttgctggaca agatgatatt ccttaccacc
ctgcctctgt tttggataat gatttcagct 180 tctcgagggg ggcactgggg
tgcctggatg ccctcgtcca tctcagcctt cgagggcacg 240 tgtgtctcca
tcccctgccg tttcgacttc ccggatgagc tcagaccggc tgtggtacat 300
ggcgtctggt atttcaacag tccctacccc aagaactacc cgccagtggt cttcaagtcc
360 cgcacacaag tggtccacga gagcttccag ggccgtagcc gcctgttggg
agacctgggc 420 ctacgaaact gcaccctgct tctcagcacg ctgagccctg
agctgggagg gaaatactat 480 ttccgaggtg acctgggcgg ctacaaccag
tacaccttct cggagcacag cgtcctggac 540 atcatcaaca cccccaacat
cgtggtgccc ccagaagtgg tggcaggaac ggaagtagag 600 gtcagctgca
tggtgccgga caactgccca gagctgcgcc ctgagctgag ctggctgggc 660
cacgaggggc taggggagcc cactgttctg ggtcggctgc gggaggatga aggcacctgg
720 gtgcaggtgt cactgctaca cttcgtgcct actagagagg ccaacggcca
ccgtctgggc 780 tgtcaggctg ccttccccaa caccaccttg cagttcgagg
gttacgccag tctggacgtc 840 aagtaccccc cggtgattgt ggagatgaat
tcctctgtgg aggccattga gggctcccac 900 gtcagcctgc tctgtggggc
tgacagcaac ccgccaccgc tgctgacttg gatgcgggat 960 gggatggtgt
tgagggaggc agttgctgag agcctgtacc tggatctgga ggaggtgacc 1020
ccagcagagg acggcatcta tgcttgcctg gcagagaatg cctatggcca ggacaaccgc
1080 acggtggagc tgagcgtcat gtatgcacct tggaagccca cagtgaatgg
gacggtggtg 1140 gcggtagagg gggagacagt ctccatcctg tgttccacac
agagcaaccc ggaccctatt 1200 ctcaccatct tcaaggagaa gcagatcctg
gccacggtca tctatgagag tcagctgcag 1260 ctggaactcc ctgcagtgac
gcccgaggac gatggggagt actggtgtgt agctgagaac 1320 cagtatggcc
agagagccac cgccttcaac ctgtctgtgg agtttgctcc cataatcctt 1380
ctggaatcgc actgtgcagc
ggccagagac accgtgcagt gcctgtgtgt ggtaaaatcc 1440 aacccggaac
cctccgtggc ctttgagctg ccttcccgca acgtgactgt gaacgagaca 1500
gagagggagt ttgtgtactc agagcgcagc ggcctcctgc tcaccagcat cctcacgctc
1560 cggggtcagg cccaagcccc accccgcgtc atttgtacct ccaggaacct
ctacggcacc 1620 cagagcctcg agctgccttt ccagggagca caccgactga
tgtgggccaa aatcggccct 1680 gtgggtgctg tggtcgcctt tgccatcctg
attgccattg tctgctacat cacccagaca 1740 agaagaaaaa agaacgtcac
agagagcccc agcttctcag cgggagacaa ccctcatgtc 1800 ctgtacagcc
ccgaattccg aatctctgga gcacctgata agtatgagag tgagaagcgc 1860
ctggggtccg agaggaggct gctgggcctt aggggggaac ccccagaact ggacctcagt
1920 tattcccact cagacctggg gaaacgaccc accaaggaca gctacaccct
gacagaggag 1980 ctggctgagt acgcagaaat ccgagtcaag tga 2013 12 171
PRT Homo sapiens 12 Met Ala Ser Gln Lys Arg Pro Ser Gln Arg His Gly
Ser Lys Tyr Leu 1 5 10 15 Ala Thr Ala Ser Thr Met Asp His Ala Arg
His Gly Phe Leu Pro Arg 20 25 30 His Arg Asp Thr Gly Ile Leu Asp
Ser Ile Gly Arg Phe Phe Gly Gly 35 40 45 Asp Arg Gly Ala Pro Lys
Arg Gly Ser Gly Lys Asp Ser His His Pro 50 55 60 Ala Arg Thr Ala
His Tyr Gly Ser Leu Pro Gln Lys Ser His Gly Arg 65 70 75 80 Thr Gln
Asp Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr 85 90 95
Pro Arg Thr Pro Pro Pro Ser Gln Gly Lys Gly Arg Gly Leu Ser Leu 100
105 110 Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro Gly Phe Gly
Tyr 115 120 125 Gly Gly Arg Ala Ser Asp Tyr Lys Ser Ala His Lys Gly
Phe Lys Gly 130 135 140 Val Asp Ala Gln Gly Thr Leu Ser Lys Ile Phe
Lys Leu Gly Gly Arg 145 150 155 160 Asp Ser Arg Ser Gly Ser Pro Met
Ala Arg Arg 165 170 13 274 PRT Homo sapiens 13 Met Gly Leu Leu Glu
Cys Cys Ala Arg Cys Leu Val Gly Ala Pro Phe 1 5 10 15 Ala Ser Leu
Val Ala Thr Gly Leu Cys Phe Phe Gly Val Ala Leu Phe 20 25 30 Cys
Gly Cys Gly His Glu Ala Leu Thr Gly Thr Glu Lys Leu Ile Glu 35 40
45 Thr Tyr Phe Ser Lys Asn Tyr Gln Asp Tyr Glu Tyr Leu Ile Asn Val
50 55 60 Ile His Ala Phe Gln Tyr Val Ile Tyr Gly Thr Ala Ser Phe
Phe Phe 65 70 75 80 Leu Tyr Gly Ala Leu Leu Leu Ala Glu Gly Phe Tyr
Thr Thr Gly Ala 85 90 95 Val Arg Gln Ile Phe Gly Asp Tyr Lys Thr
Thr Ile Cys Gly Lys Gly 100 105 110 Leu Ser Ala Thr Val Thr Gly Gly
Gln Lys Gly Arg Gly Ser Arg Gly 115 120 125 Gln His Gln Ala His Ser
Leu Glu Arg Val Cys His Cys Leu Gly Lys 130 135 140 Trp Leu Gly His
Pro Asp Lys Ile Thr Tyr Ala Leu Thr Val Val Trp 145 150 155 160 Leu
Leu Val Phe Ala Cys Ser Ala Val Pro Val Tyr Ile Tyr Phe Asn 165 170
175 Thr Trp Thr Thr Cys Gln Ser Ile Ala Phe Pro Ser Lys Thr Ser Ala
180 185 190 Ser Ile Gly Ser Leu Cys Ala Asp Ala Arg Met Tyr Gly Val
Leu Pro 195 200 205 Trp Asn Ala Phe Pro Gly Lys Val Cys Gly Ser Asn
Leu Leu Ser Ile 210 215 220 Cys Lys Thr Ala Glu Phe Gln Met Thr Phe
His Leu Phe Ile Ala Ala 225 230 235 240 Phe Val Gly Ala Ala Ala Thr
Leu Val Ser Leu Leu Thr Phe Met Ile 245 250 255 Ala Ala Thr Tyr Asn
Phe Ala Val Leu Lys Leu Met Gly Arg Gly Thr 260 265 270 Lys Phe 14
247 PRT Homo sapiens 14 Met Ala Ser Leu Ser Arg Pro Ser Leu Pro Ser
Cys Leu Cys Ser Phe 1 5 10 15 Leu Leu Leu Leu Leu Leu Gln Val Ser
Ser Ser Tyr Ala Gly Gln Phe 20 25 30 Arg Val Ile Gly Pro Arg His
Pro Ile Arg Ala Leu Val Gly Asp Glu 35 40 45 Val Glu Leu Pro Cys
Arg Ile Ser Pro Gly Lys Asn Ala Thr Gly Met 50 55 60 Glu Val Gly
Trp Tyr Arg Pro Pro Phe Ser Arg Val Val His Leu Tyr 65 70 75 80 Arg
Asn Gly Lys Asp Gln Asp Gly Asp Gln Ala Pro Glu Tyr Arg Gly 85 90
95 Arg Thr Glu Leu Leu Lys Asp Ala Ile Gly Glu Gly Lys Val Thr Leu
100 105 110 Arg Ile Arg Asn Val Arg Phe Ser Asp Glu Gly Gly Phe Thr
Cys Phe 115 120 125 Phe Arg Asp His Ser Tyr Gln Glu Glu Ala Ala Met
Glu Leu Lys Val 130 135 140 Glu Asp Pro Phe Tyr Trp Val Ser Pro Gly
Val Leu Val Leu Leu Ala 145 150 155 160 Val Leu Pro Val Leu Leu Leu
Gln Ile Thr Leu Gly Leu Val Phe Leu 165 170 175 Cys Leu Gln Tyr Arg
Leu Arg Gly Lys Leu Arg Ala Glu Ile Glu Asn 180 185 190 Leu His Arg
Thr Phe Asp Pro His Phe Leu Arg Val Pro Cys Trp Lys 195 200 205 Ile
Thr Leu Phe Val Ile Val Pro Val Leu Gly Pro Leu Val Ala Leu 210 215
220 Ile Ile Cys Tyr Asn Trp Leu His Arg Arg Leu Ala Gly Gln Phe Leu
225 230 235 240 Glu Glu Leu Arg Asn Pro Phe 245 15 18 PRT Rattus
norvegicus 15 Ala Pro Lys Arg Gly Ser Gly Lys Asp Ser His Thr Arg
Thr Thr His 1 5 10 15 Tyr Gly 16 23 PRT Homo sapiens 16 Val Leu Gly
Gly Gly Cys Ala Leu Leu Arg Cys Pro Ala Leu Asp Ser 1 5 10 15 Leu
Thr Pro Ala Asn Glu Asp 20 17 4684 DNA Rattus norvegicus CDS
(253)..(3744) 17 attgctcgtc tgggcggcgg cggcggctgc agcctgggac
agggcgggtg gcacatctcg 60 atcgcgaagg caggagaagc agtctcattg
ttccgggagc cgtcgcctct gcaggttctt 120 cggctcggct cggcacgact
cggcctgcct ggcccctgcc agtcttgccc aacccccaca 180 accgcccgcg
actctgagga gaagcggccc tgcggcggct gtagctgcag catcgtcggc 240
gacccgccag cc atg gaa gac ata gac cag tcg tcg ctg gtc tcc tcg tcc
291 Met Glu Asp Ile Asp Gln Ser Ser Leu Val Ser Ser Ser 1 5 10 acg
gac agc ccg ccc cgg cct ccg ccc gcc ttc aag tac cag ttc gtg 339 Thr
Asp Ser Pro Pro Arg Pro Pro Pro Ala Phe Lys Tyr Gln Phe Val 15 20
25 acg gag ccc gag gac gag gag gac gag gag gag gag gag gac gag gag
387 Thr Glu Pro Glu Asp Glu Glu Asp Glu Glu Glu Glu Glu Asp Glu Glu
30 35 40 45 gag gac gac gag gac cta gag gaa ctg gag gtg ctg gag agg
aag ccc 435 Glu Asp Asp Glu Asp Leu Glu Glu Leu Glu Val Leu Glu Arg
Lys Pro 50 55 60 gca gcc ggg ctg tcc gca gct gcg gtg ccg ccc gcc
gcc gcc gcg ccg 483 Ala Ala Gly Leu Ser Ala Ala Ala Val Pro Pro Ala
Ala Ala Ala Pro 65 70 75 ctg ctg gac ttc agc agc gac tcg gtg ccc
ccc gcg ccc cgc ggg ccg 531 Leu Leu Asp Phe Ser Ser Asp Ser Val Pro
Pro Ala Pro Arg Gly Pro 80 85 90 ctg ccg gcc gcg ccc cct gcc gct
cct gag agg cag cca tcc tgg gaa 579 Leu Pro Ala Ala Pro Pro Ala Ala
Pro Glu Arg Gln Pro Ser Trp Glu 95 100 105 cgc agc ccc gcg gcg ccc
gcg cca tcc ctg ccg ccc gct gcc gca gtc 627 Arg Ser Pro Ala Ala Pro
Ala Pro Ser Leu Pro Pro Ala Ala Ala Val 110 115 120 125 ctg ccc tcc
aag ctc cca gag gac gac gag cct ccg gcg agg ccc ccg 675 Leu Pro Ser
Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro 130 135 140 cct
ccg ccg cca gcc ggc gcg agc ccc ctg gcg gag ccc gcc gcg ccc 723 Pro
Pro Pro Pro Ala Gly Ala Ser Pro Leu Ala Glu Pro Ala Ala Pro 145 150
155 cct tcc acg ccg gcc gcg ccc aag cgc agg ggc tcc ggc tca gtg gat
771 Pro Ser Thr Pro Ala Ala Pro Lys Arg Arg Gly Ser Gly Ser Val Asp
160 165 170 gag acc ctt ttt gct ctt cct gct gca tct gag cct gtg ata
ccc tcc 819 Glu Thr Leu Phe Ala Leu Pro Ala Ala Ser Glu Pro Val Ile
Pro Ser 175 180 185 tct gca gaa aaa att atg gat ttg atg gag cag cca
ggt aac act gtt 867 Ser Ala Glu Lys Ile Met Asp Leu Met Glu Gln Pro
Gly Asn Thr Val 190 195 200 205 tcg tct ggt caa gag gat ttc cca tct
gtc ctg ctt gaa act gct gcc 915 Ser Ser Gly Gln Glu Asp Phe Pro Ser
Val Leu Leu Glu Thr Ala Ala 210 215 220 tct ctt cct tct cta tct cct
ctc tca act gtt tct ttt aaa gaa cat 963 Ser Leu Pro Ser Leu Ser Pro
Leu Ser Thr Val Ser Phe Lys Glu His 225 230 235 gga tac ctt ggt aac
tta tca gca gtg tca tcc tca gaa gga aca att 1011 Gly Tyr Leu Gly
Asn Leu Ser Ala Val Ser Ser Ser Glu Gly Thr Ile 240 245 250 gaa gaa
act tta aat gaa gct tct aaa gag ttg cca gag agg gca aca 1059 Glu
Glu Thr Leu Asn Glu Ala Ser Lys Glu Leu Pro Glu Arg Ala Thr 255 260
265 aat cca ttt gta aat aga gat tta gca gaa ttt tca gaa tta gaa tat
1107 Asn Pro Phe Val Asn Arg Asp Leu Ala Glu Phe Ser Glu Leu Glu
Tyr 270 275 280 285 tca gaa atg gga tca tct ttt aaa ggc tcc cca aaa
gga gag tca gcc 1155 Ser Glu Met Gly Ser Ser Phe Lys Gly Ser Pro
Lys Gly Glu Ser Ala 290 295 300 ata tta gta gaa aac act aag gaa gaa
gta att gtg agg agt aaa gac 1203 Ile Leu Val Glu Asn Thr Lys Glu
Glu Val Ile Val Arg Ser Lys Asp 305 310 315 aaa gag gat tta gtt tgt
agt gca gcc ctt cac agt cca caa gaa tca 1251 Lys Glu Asp Leu Val
Cys Ser Ala Ala Leu His Ser Pro Gln Glu Ser 320 325 330 cct gtg ggt
aaa gaa gac aga gtt gtg tct cca gaa aag aca atg gac 1299 Pro Val
Gly Lys Glu Asp Arg Val Val Ser Pro Glu Lys Thr Met Asp 335 340 345
att ttt aat gaa atg cag atg tca gta gta gca cct gtg agg gaa gag
1347 Ile Phe Asn Glu Met Gln Met Ser Val Val Ala Pro Val Arg Glu
Glu 350 355 360 365 tat gca gac ttt aag cca ttt gaa caa gca tgg gaa
gtg aaa gat act 1395 Tyr Ala Asp Phe Lys Pro Phe Glu Gln Ala Trp
Glu Val Lys Asp Thr 370 375 380 tat gag gga agt agg gat gtg ctg gct
gct aga gct aat gtg gaa agt 1443 Tyr Glu Gly Ser Arg Asp Val Leu
Ala Ala Arg Ala Asn Val Glu Ser 385 390 395 aaa gtg gac aga aaa tgc
ttg gaa gat agc ctg gag caa aaa agt ctt 1491 Lys Val Asp Arg Lys
Cys Leu Glu Asp Ser Leu Glu Gln Lys Ser Leu 400 405 410 ggg aag gat
agt gaa ggc aga aat gag gat gct tct ttc ccc agt acc 1539 Gly Lys
Asp Ser Glu Gly Arg Asn Glu Asp Ala Ser Phe Pro Ser Thr 415 420 425
cca gaa cct gtg aag gac agc tcc aga gca tat att acc tgt gct tcc
1587 Pro Glu Pro Val Lys Asp Ser Ser Arg Ala Tyr Ile Thr Cys Ala
Ser 430 435 440 445 ttt acc tca gca acc gaa agc acc aca gca aac act
ttc cct ttg tta 1635 Phe Thr Ser Ala Thr Glu Ser Thr Thr Ala Asn
Thr Phe Pro Leu Leu 450 455 460 gaa gat cat act tca gaa aat aaa aca
gat gaa aaa aaa ata gaa gaa 1683 Glu Asp His Thr Ser Glu Asn Lys
Thr Asp Glu Lys Lys Ile Glu Glu 465 470 475 agg aag gcc caa att ata
aca gag aag act agc ccc aaa acg tca aat 1731 Arg Lys Ala Gln Ile
Ile Thr Glu Lys Thr Ser Pro Lys Thr Ser Asn 480 485 490 cct ttc ctt
gta gca gta cag gat tct gag gca gat tat gtt aca aca 1779 Pro Phe
Leu Val Ala Val Gln Asp Ser Glu Ala Asp Tyr Val Thr Thr 495 500 505
gat acc tta tca aag gtg act gag gca gca gtg tca aac atg cct gaa
1827 Asp Thr Leu Ser Lys Val Thr Glu Ala Ala Val Ser Asn Met Pro
Glu 510 515 520 525 ggt ctg acg cca gat tta gtt cag gaa gca tgt gaa
agt gaa ctg aat 1875 Gly Leu Thr Pro Asp Leu Val Gln Glu Ala Cys
Glu Ser Glu Leu Asn 530 535 540 gaa gcc aca ggt aca aag att gct tat
gaa aca aaa gtg gac ttg gtc 1923 Glu Ala Thr Gly Thr Lys Ile Ala
Tyr Glu Thr Lys Val Asp Leu Val 545 550 555 caa aca tca gaa gct ata
caa gaa tca ctt tac ccc aca gca cag ctt 1971 Gln Thr Ser Glu Ala
Ile Gln Glu Ser Leu Tyr Pro Thr Ala Gln Leu 560 565 570 tgc cca tca
ttt gag gaa gct gaa gca act ccg tca cca gtt ttg cct 2019 Cys Pro
Ser Phe Glu Glu Ala Glu Ala Thr Pro Ser Pro Val Leu Pro 575 580 585
gat att gtt atg gaa gca cca tta aat tct ctc ctt cca agc gct ggt
2067 Asp Ile Val Met Glu Ala Pro Leu Asn Ser Leu Leu Pro Ser Ala
Gly 590 595 600 605 gct tct gta gtg cag ccc agt gta tcc cca ctg gaa
gca cct cct cca 2115 Ala Ser Val Val Gln Pro Ser Val Ser Pro Leu
Glu Ala Pro Pro Pro 610 615 620 gtt agt tat gac agt ata aag ctt gag
cct gaa aac ccc cca cca tat 2163 Val Ser Tyr Asp Ser Ile Lys Leu
Glu Pro Glu Asn Pro Pro Pro Tyr 625 630 635 gaa gaa gcc atg aat gta
gca cta aaa gct ttg gga aca aag gaa gga 2211 Glu Glu Ala Met Asn
Val Ala Leu Lys Ala Leu Gly Thr Lys Glu Gly 640 645 650 ata aaa gag
cct gaa agt ttt aat gca gct gtt cag gaa aca gaa gct 2259 Ile Lys
Glu Pro Glu Ser Phe Asn Ala Ala Val Gln Glu Thr Glu Ala 655 660 665
cct tat ata tcc att gcg tgt gat tta att aaa gaa aca aag ctc tcc
2307 Pro Tyr Ile Ser Ile Ala Cys Asp Leu Ile Lys Glu Thr Lys Leu
Ser 670 675 680 685 act gag cca agt cca gat ttc tct aat tat tca gaa
ata gca aaa ttc 2355 Thr Glu Pro Ser Pro Asp Phe Ser Asn Tyr Ser
Glu Ile Ala Lys Phe 690 695 700 gag aag tcg gtg ccc gaa cac gct gag
cta gtg gag gat tcc tca cct 2403 Glu Lys Ser Val Pro Glu His Ala
Glu Leu Val Glu Asp Ser Ser Pro 705 710 715 gaa tct gaa cca gtt gac
tta ttt agt gat gat tcg att cct gaa gtc 2451 Glu Ser Glu Pro Val
Asp Leu Phe Ser Asp Asp Ser Ile Pro Glu Val 720 725 730 cca caa aca
caa gag gag gct gtg atg ctc atg aag gag agt ctc act 2499 Pro Gln
Thr Gln Glu Glu Ala Val Met Leu Met Lys Glu Ser Leu Thr 735 740 745
gaa gtg tct gag aca gta gcc cag cac aaa gag gag aga ctt agt gcc
2547 Glu Val Ser Glu Thr Val Ala Gln His Lys Glu Glu Arg Leu Ser
Ala 750 755 760 765 tca cct cag gag cta gga aag cca tat tta gag tct
ttt cag ccc aat 2595 Ser Pro Gln Glu Leu Gly Lys Pro Tyr Leu Glu
Ser Phe Gln Pro Asn 770 775 780 tta cat agt aca aaa gat gct gca tct
aat gac att cca aca ttg acc 2643 Leu His Ser Thr Lys Asp Ala Ala
Ser Asn Asp Ile Pro Thr Leu Thr 785 790 795 aaa aag gag aaa att tct
ttg caa atg gaa gag ttt aat act gca att 2691 Lys Lys Glu Lys Ile
Ser Leu Gln Met Glu Glu Phe Asn Thr Ala Ile 800 805 810 tat tca aat
gat gac tta ctt tct tct aag gaa gac aaa ata aaa gaa 2739 Tyr Ser
Asn Asp Asp Leu Leu Ser Ser Lys Glu Asp Lys Ile Lys Glu 815 820 825
agt gaa aca ttt tca gat tca tct ccg att gag ata ata gat gaa ttt
2787 Ser Glu Thr Phe Ser Asp Ser Ser Pro Ile Glu Ile Ile Asp Glu
Phe 830 835 840 845 ccc acg ttt gtc agt gct aaa gat gat tct cct aaa
tta gcc aag gag 2835 Pro Thr Phe Val Ser Ala Lys Asp Asp Ser Pro
Lys Leu Ala Lys Glu 850 855 860 tac act gat cta gaa gta tcc gac aaa
agt gaa att gct aat atc caa 2883 Tyr Thr Asp Leu Glu Val Ser Asp
Lys Ser Glu Ile Ala Asn Ile Gln 865 870 875 agc ggg gca gat tca ttg
cct tgc tta gaa ttg ccc tgt gac ctt tct 2931 Ser Gly Ala Asp Ser
Leu Pro Cys Leu Glu Leu Pro Cys Asp Leu Ser 880 885 890 ttc aag aat
ata tat cct aaa gat gaa gta cat gtt tca gat gaa ttc 2979 Phe Lys
Asn Ile Tyr Pro Lys Asp Glu Val His Val Ser Asp Glu Phe 895 900 905
tcc gaa aat agg tcc agt gta tct aag gca tcc ata tcg cct tca aat
3027 Ser Glu Asn Arg Ser Ser Val Ser Lys Ala Ser Ile Ser Pro Ser
Asn 910 915 920 925 gtc tct gct ttg gaa cct cag aca gaa atg ggc agc
ata gtt aaa tcc 3075 Val Ser Ala Leu Glu Pro Gln Thr Glu Met Gly
Ser Ile Val Lys Ser 930 935 940 aaa tca ctt acg aaa gaa gca gag aaa
aaa ctt cct tct gac aca gag 3123 Lys Ser Leu Thr Lys Glu Ala Glu
Lys Lys Leu Pro Ser Asp Thr Glu 945 950 955 aaa gag gac aga tcc ctg
tca
gct gta ttg tca gca gag ctg agt aaa 3171 Lys Glu Asp Arg Ser Leu
Ser Ala Val Leu Ser Ala Glu Leu Ser Lys 960 965 970 act tca gtt gtt
gac ctc ctc tac tgg aga gac att aag aag act gga 3219 Thr Ser Val
Val Asp Leu Leu Tyr Trp Arg Asp Ile Lys Lys Thr Gly 975 980 985 gtg
gtg ttt ggt gcc agc tta ttc ctg ctg ctg tct ctg aca gtg ttc 3267
Val Val Phe Gly Ala Ser Leu Phe Leu Leu Leu Ser Leu Thr Val Phe 990
995 1000 1005 agc att gtc agt gta acg gcc tac att gcc ttg gcc ctg
ctc tcg 3312 Ser Ile Val Ser Val Thr Ala Tyr Ile Ala Leu Ala Leu
Leu Ser 1010 1015 1020 gtg act atc agc ttt agg ata tat aag ggc gtg
atc cag gct atc 3357 Val Thr Ile Ser Phe Arg Ile Tyr Lys Gly Val
Ile Gln Ala Ile 1025 1030 1035 cag aaa tca gat gaa ggc cac cca ttc
agg gca tat tta gaa tct 3402 Gln Lys Ser Asp Glu Gly His Pro Phe
Arg Ala Tyr Leu Glu Ser 1040 1045 1050 gaa gtt gct ata tca gag gaa
ttg gtt cag aaa tac agt aat tct 3447 Glu Val Ala Ile Ser Glu Glu
Leu Val Gln Lys Tyr Ser Asn Ser 1055 1060 1065 gct ctt ggt cat gtg
aac agc aca ata aaa gaa ctg agg cgg ctt 3492 Ala Leu Gly His Val
Asn Ser Thr Ile Lys Glu Leu Arg Arg Leu 1070 1075 1080 ttc tta gtt
gat gat tta gtt gat tcc ctg aag ttt gca gtg ttg 3537 Phe Leu Val
Asp Asp Leu Val Asp Ser Leu Lys Phe Ala Val Leu 1085 1090 1095 atg
tgg gtg ttt act tat gtt ggt gcc ttg ttc aat ggt ctg aca 3582 Met
Trp Val Phe Thr Tyr Val Gly Ala Leu Phe Asn Gly Leu Thr 1100 1105
1110 cta ctg att tta gct ctg atc tca ctc ttc agt att cct gtt att
3627 Leu Leu Ile Leu Ala Leu Ile Ser Leu Phe Ser Ile Pro Val Ile
1115 1120 1125 tat gaa cgg cat cag gtg cag ata gat cat tat cta gga
ctt gca 3672 Tyr Glu Arg His Gln Val Gln Ile Asp His Tyr Leu Gly
Leu Ala 1130 1135 1140 aac aag agt gtt aag gat gcc atg gcc aaa atc
caa gca aaa atc 3717 Asn Lys Ser Val Lys Asp Ala Met Ala Lys Ile
Gln Ala Lys Ile 1145 1150 1155 cct gga ttg aag cgc aaa gca gat tga
aaaagcccca aacagaagtt 3764 Pro Gly Leu Lys Arg Lys Ala Asp 1160
catctttaaa ggggacactc acttgattac gggggtggga gggtcagggg tgagcccttg
3824 gtggccgtgc ggtttcagct ctttattttt agcagtgcac tgtttgagga
aaaattacct 3884 gtcttgactt cctgtgttta tcatcttaag tattgtaagc
tgctgtgtat ggatctcatt 3944 gtagtcacac ttgtcttccc caatgaggcg
cctggtgaat aaaggactcg gggaaagctg 4004 tgcattgtat ctgctgcagg
gtagtctagc tgtatgcaga gagttgtaaa gaaggcaaat 4064 ctgggggcag
ggaaaaccct tttcacagtg tactgtgttt ggtcagtgta aaactgatgc 4124
agatttttct gaaatgaaat gtttagatga gagcatacta ctaaagcaga gtggaaaact
4184 ctgtctttat ggtgtgttct aggtgtattg tgaatttact gttatattgc
caatataagt 4244 aaatatagac ctaatctata tatagtgttt cacaaagctt
agatctttaa ccttgcagct 4304 gccccacagt gcttgacctc tgagtcattg
gttatgcagt gtagtccaag cacataaact 4364 aggaagagaa atgtatttgt
aggagtgcta cctaccacct gttttcaaga aaatatagaa 4424 ctccaacaaa
aatatagaat gtcatttcaa agacttactg tatgtatagt taattttgtc 4484
acagactctg aaattctatg gactgaattt catgcttcca aatgtttgca gttatcaaac
4544 attgttatgc aagaaatcat aaaatgaaga cttataccat tgtggtttaa
gccgtactga 4604 attatctgtg gaatgcattg tgaactgtaa aagcaaagta
tcaataaagc ttatagatct 4664 taaaaaaaaa aaaaaaaaaa 4684 18 1163 PRT
Rattus norvegicus 18 Met Glu Asp Ile Asp Gln Ser Ser Leu Val Ser
Ser Ser Thr Asp Ser 1 5 10 15 Pro Pro Arg Pro Pro Pro Ala Phe Lys
Tyr Gln Phe Val Thr Glu Pro 20 25 30 Glu Asp Glu Glu Asp Glu Glu
Glu Glu Glu Asp Glu Glu Glu Asp Asp 35 40 45 Glu Asp Leu Glu Glu
Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly 50 55 60 Leu Ser Ala
Ala Ala Val Pro Pro Ala Ala Ala Ala Pro Leu Leu Asp 65 70 75 80 Phe
Ser Ser Asp Ser Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala 85 90
95 Ala Pro Pro Ala Ala Pro Glu Arg Gln Pro Ser Trp Glu Arg Ser Pro
100 105 110 Ala Ala Pro Ala Pro Ser Leu Pro Pro Ala Ala Ala Val Leu
Pro Ser 115 120 125 Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro
Pro Pro Pro Pro 130 135 140 Pro Ala Gly Ala Ser Pro Leu Ala Glu Pro
Ala Ala Pro Pro Ser Thr 145 150 155 160 Pro Ala Ala Pro Lys Arg Arg
Gly Ser Gly Ser Val Asp Glu Thr Leu 165 170 175 Phe Ala Leu Pro Ala
Ala Ser Glu Pro Val Ile Pro Ser Ser Ala Glu 180 185 190 Lys Ile Met
Asp Leu Met Glu Gln Pro Gly Asn Thr Val Ser Ser Gly 195 200 205 Gln
Glu Asp Phe Pro Ser Val Leu Leu Glu Thr Ala Ala Ser Leu Pro 210 215
220 Ser Leu Ser Pro Leu Ser Thr Val Ser Phe Lys Glu His Gly Tyr Leu
225 230 235 240 Gly Asn Leu Ser Ala Val Ser Ser Ser Glu Gly Thr Ile
Glu Glu Thr 245 250 255 Leu Asn Glu Ala Ser Lys Glu Leu Pro Glu Arg
Ala Thr Asn Pro Phe 260 265 270 Val Asn Arg Asp Leu Ala Glu Phe Ser
Glu Leu Glu Tyr Ser Glu Met 275 280 285 Gly Ser Ser Phe Lys Gly Ser
Pro Lys Gly Glu Ser Ala Ile Leu Val 290 295 300 Glu Asn Thr Lys Glu
Glu Val Ile Val Arg Ser Lys Asp Lys Glu Asp 305 310 315 320 Leu Val
Cys Ser Ala Ala Leu His Ser Pro Gln Glu Ser Pro Val Gly 325 330 335
Lys Glu Asp Arg Val Val Ser Pro Glu Lys Thr Met Asp Ile Phe Asn 340
345 350 Glu Met Gln Met Ser Val Val Ala Pro Val Arg Glu Glu Tyr Ala
Asp 355 360 365 Phe Lys Pro Phe Glu Gln Ala Trp Glu Val Lys Asp Thr
Tyr Glu Gly 370 375 380 Ser Arg Asp Val Leu Ala Ala Arg Ala Asn Val
Glu Ser Lys Val Asp 385 390 395 400 Arg Lys Cys Leu Glu Asp Ser Leu
Glu Gln Lys Ser Leu Gly Lys Asp 405 410 415 Ser Glu Gly Arg Asn Glu
Asp Ala Ser Phe Pro Ser Thr Pro Glu Pro 420 425 430 Val Lys Asp Ser
Ser Arg Ala Tyr Ile Thr Cys Ala Ser Phe Thr Ser 435 440 445 Ala Thr
Glu Ser Thr Thr Ala Asn Thr Phe Pro Leu Leu Glu Asp His 450 455 460
Thr Ser Glu Asn Lys Thr Asp Glu Lys Lys Ile Glu Glu Arg Lys Ala 465
470 475 480 Gln Ile Ile Thr Glu Lys Thr Ser Pro Lys Thr Ser Asn Pro
Phe Leu 485 490 495 Val Ala Val Gln Asp Ser Glu Ala Asp Tyr Val Thr
Thr Asp Thr Leu 500 505 510 Ser Lys Val Thr Glu Ala Ala Val Ser Asn
Met Pro Glu Gly Leu Thr 515 520 525 Pro Asp Leu Val Gln Glu Ala Cys
Glu Ser Glu Leu Asn Glu Ala Thr 530 535 540 Gly Thr Lys Ile Ala Tyr
Glu Thr Lys Val Asp Leu Val Gln Thr Ser 545 550 555 560 Glu Ala Ile
Gln Glu Ser Leu Tyr Pro Thr Ala Gln Leu Cys Pro Ser 565 570 575 Phe
Glu Glu Ala Glu Ala Thr Pro Ser Pro Val Leu Pro Asp Ile Val 580 585
590 Met Glu Ala Pro Leu Asn Ser Leu Leu Pro Ser Ala Gly Ala Ser Val
595 600 605 Val Gln Pro Ser Val Ser Pro Leu Glu Ala Pro Pro Pro Val
Ser Tyr 610 615 620 Asp Ser Ile Lys Leu Glu Pro Glu Asn Pro Pro Pro
Tyr Glu Glu Ala 625 630 635 640 Met Asn Val Ala Leu Lys Ala Leu Gly
Thr Lys Glu Gly Ile Lys Glu 645 650 655 Pro Glu Ser Phe Asn Ala Ala
Val Gln Glu Thr Glu Ala Pro Tyr Ile 660 665 670 Ser Ile Ala Cys Asp
Leu Ile Lys Glu Thr Lys Leu Ser Thr Glu Pro 675 680 685 Ser Pro Asp
Phe Ser Asn Tyr Ser Glu Ile Ala Lys Phe Glu Lys Ser 690 695 700 Val
Pro Glu His Ala Glu Leu Val Glu Asp Ser Ser Pro Glu Ser Glu 705 710
715 720 Pro Val Asp Leu Phe Ser Asp Asp Ser Ile Pro Glu Val Pro Gln
Thr 725 730 735 Gln Glu Glu Ala Val Met Leu Met Lys Glu Ser Leu Thr
Glu Val Ser 740 745 750 Glu Thr Val Ala Gln His Lys Glu Glu Arg Leu
Ser Ala Ser Pro Gln 755 760 765 Glu Leu Gly Lys Pro Tyr Leu Glu Ser
Phe Gln Pro Asn Leu His Ser 770 775 780 Thr Lys Asp Ala Ala Ser Asn
Asp Ile Pro Thr Leu Thr Lys Lys Glu 785 790 795 800 Lys Ile Ser Leu
Gln Met Glu Glu Phe Asn Thr Ala Ile Tyr Ser Asn 805 810 815 Asp Asp
Leu Leu Ser Ser Lys Glu Asp Lys Ile Lys Glu Ser Glu Thr 820 825 830
Phe Ser Asp Ser Ser Pro Ile Glu Ile Ile Asp Glu Phe Pro Thr Phe 835
840 845 Val Ser Ala Lys Asp Asp Ser Pro Lys Leu Ala Lys Glu Tyr Thr
Asp 850 855 860 Leu Glu Val Ser Asp Lys Ser Glu Ile Ala Asn Ile Gln
Ser Gly Ala 865 870 875 880 Asp Ser Leu Pro Cys Leu Glu Leu Pro Cys
Asp Leu Ser Phe Lys Asn 885 890 895 Ile Tyr Pro Lys Asp Glu Val His
Val Ser Asp Glu Phe Ser Glu Asn 900 905 910 Arg Ser Ser Val Ser Lys
Ala Ser Ile Ser Pro Ser Asn Val Ser Ala 915 920 925 Leu Glu Pro Gln
Thr Glu Met Gly Ser Ile Val Lys Ser Lys Ser Leu 930 935 940 Thr Lys
Glu Ala Glu Lys Lys Leu Pro Ser Asp Thr Glu Lys Glu Asp 945 950 955
960 Arg Ser Leu Ser Ala Val Leu Ser Ala Glu Leu Ser Lys Thr Ser Val
965 970 975 Val Asp Leu Leu Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val
Val Phe 980 985 990 Gly Ala Ser Leu Phe Leu Leu Leu Ser Leu Thr Val
Phe Ser Ile Val 995 1000 1005 Ser Val Thr Ala Tyr Ile Ala Leu Ala
Leu Leu Ser Val Thr Ile 1010 1015 1020 Ser Phe Arg Ile Tyr Lys Gly
Val Ile Gln Ala Ile Gln Lys Ser 1025 1030 1035 Asp Glu Gly His Pro
Phe Arg Ala Tyr Leu Glu Ser Glu Val Ala 1040 1045 1050 Ile Ser Glu
Glu Leu Val Gln Lys Tyr Ser Asn Ser Ala Leu Gly 1055 1060 1065 His
Val Asn Ser Thr Ile Lys Glu Leu Arg Arg Leu Phe Leu Val 1070 1075
1080 Asp Asp Leu Val Asp Ser Leu Lys Phe Ala Val Leu Met Trp Val
1085 1090 1095 Phe Thr Tyr Val Gly Ala Leu Phe Asn Gly Leu Thr Leu
Leu Ile 1100 1105 1110 Leu Ala Leu Ile Ser Leu Phe Ser Ile Pro Val
Ile Tyr Glu Arg 1115 1120 1125 His Gln Val Gln Ile Asp His Tyr Leu
Gly Leu Ala Asn Lys Ser 1130 1135 1140 Val Lys Asp Ala Met Ala Lys
Ile Gln Ala Lys Ile Pro Gly Leu 1145 1150 1155 Lys Arg Lys Ala Asp
1160 19 18 PRT Rattus norvegicus 19 Ser Tyr Asp Ser Ile Lys Leu Glu
Pro Glu Asn Pro Pro Pro Tyr Glu 1 5 10 15 Glu Ala 20 360 PRT Rattus
norvegicus 20 Met Glu Asp Ile Asp Gln Ser Ser Leu Val Ser Ser Ser
Thr Asp Ser 1 5 10 15 Pro Pro Arg Pro Pro Pro Ala Phe Lys Tyr Gln
Phe Val Thr Glu Pro 20 25 30 Glu Asp Glu Glu Asp Glu Glu Glu Glu
Glu Asp Glu Glu Glu Asp Asp 35 40 45 Glu Asp Leu Glu Glu Leu Glu
Val Leu Glu Arg Lys Pro Ala Ala Gly 50 55 60 Leu Ser Ala Ala Ala
Val Pro Pro Ala Ala Ala Ala Pro Leu Leu Asp 65 70 75 80 Phe Ser Ser
Asp Ser Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala 85 90 95 Ala
Pro Pro Ala Ala Pro Glu Arg Gln Pro Ser Trp Glu Arg Ser Pro 100 105
110 Ala Ala Pro Ala Pro Ser Leu Pro Pro Ala Ala Ala Val Leu Pro Ser
115 120 125 Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro Pro
Pro Pro 130 135 140 Pro Ala Gly Ala Ser Pro Leu Ala Glu Pro Ala Ala
Pro Pro Ser Thr 145 150 155 160 Pro Ala Ala Pro Lys Arg Arg Gly Ser
Gly Ser Val Val Val Asp Leu 165 170 175 Leu Tyr Trp Arg Asp Ile Lys
Lys Thr Gly Val Val Phe Gly Ala Ser 180 185 190 Leu Phe Leu Leu Leu
Ser Leu Thr Val Phe Ser Ile Val Ser Val Thr 195 200 205 Ala Tyr Ile
Ala Leu Ala Leu Leu Ser Val Thr Ile Ser Phe Arg Ile 210 215 220 Tyr
Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro 225 230
235 240 Phe Arg Ala Tyr Leu Glu Ser Glu Val Ala Ile Ser Glu Glu Leu
Val 245 250 255 Gln Lys Tyr Ser Asn Ser Ala Leu Gly His Val Asn Ser
Thr Ile Lys 260 265 270 Glu Leu Arg Arg Leu Phe Leu Val Asp Asp Leu
Val Asp Ser Leu Lys 275 280 285 Phe Ala Val Leu Met Trp Val Phe Thr
Tyr Val Gly Ala Leu Phe Asn 290 295 300 Gly Leu Thr Leu Leu Ile Leu
Ala Leu Ile Ser Leu Phe Ser Ile Pro 305 310 315 320 Val Ile Tyr Glu
Arg His Gln Val Gln Ile Asp His Tyr Leu Gly Leu 325 330 335 Ala Asn
Lys Ser Val Lys Asp Ala Met Ala Lys Ile Gln Ala Lys Ile 340 345 350
Pro Gly Leu Lys Arg Lys Ala Asp 355 360 21 199 PRT Rattus
norvegicus 21 Met Asp Gly Gln Lys Lys His Trp Lys Asp Lys Val Val
Asp Leu Leu 1 5 10 15 Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val Val
Phe Gly Ala Ser Leu 20 25 30 Phe Leu Leu Leu Ser Leu Thr Val Phe
Ser Ile Val Ser Val Thr Ala 35 40 45 Tyr Ile Ala Leu Ala Leu Leu
Ser Val Thr Ile Ser Phe Arg Ile Tyr 50 55 60 Lys Gly Val Ile Gln
Ala Ile Gln Lys Ser Asp Glu Gly His Pro Phe 65 70 75 80 Arg Ala Tyr
Leu Glu Ser Glu Val Ala Ile Ser Glu Glu Leu Val Gln 85 90 95 Lys
Tyr Ser Asn Ser Ala Leu Gly His Val Asn Ser Thr Ile Lys Glu 100 105
110 Leu Arg Arg Leu Phe Leu Val Asp Asp Leu Val Asp Ser Leu Lys Phe
115 120 125 Ala Val Leu Met Trp Val Phe Thr Tyr Val Gly Ala Leu Phe
Asn Gly 130 135 140 Leu Thr Leu Leu Ile Leu Ala Leu Ile Ser Leu Phe
Ser Ile Pro Val 145 150 155 160 Ile Tyr Glu Arg His Gln Val Gln Ile
Asp His Tyr Leu Gly Leu Ala 165 170 175 Asn Lys Ser Val Lys Asp Ala
Met Ala Lys Ile Gln Ala Lys Ile Pro 180 185 190 Gly Leu Lys Arg Lys
Ala Asp 195 22 3579 DNA Homo sapiens CDS (1)..(3579) 22 atg gaa gac
ctg gac cag tct cct ctg gtc tcg tcc tcg gac agc cca 48 Met Glu Asp
Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro 1 5 10 15 ccc
cgg ccg cag ccc gcg ttc aag tac cag ttc gtg agg gag ccc gag 96 Pro
Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu Pro Glu 20 25
30 gac gag gag gaa gaa gag gag gag gaa gag gag gac gag gac gaa gac
144 Asp Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Asp
35 40 45 ctg gag gag ctg gag gtg ctg gag agg aag ccc gcc gcc ggg
ctg tcc 192 Leu Glu Glu Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly
Leu Ser 50 55 60 gcg gcc cca gtg ccc acc gcc cct gcc gcc ggc gcg
ccc ctg atg gac 240 Ala Ala Pro Val Pro Thr Ala Pro Ala Ala Gly Ala
Pro Leu Met Asp 65 70 75 80 ttc gga aat gac ttc gtg ccg ccg gcg ccc
cgg gga ccc ctg ccg gcc 288 Phe Gly Asn Asp Phe Val Pro Pro Ala Pro
Arg Gly Pro Leu Pro Ala 85 90 95 gct ccc ccc gtc gcc ccg gag cgg
cag ccg tct tgg gac ccg agc ccg 336 Ala Pro Pro Val Ala Pro Glu Arg
Gln Pro Ser Trp Asp Pro Ser Pro
100 105 110 gtg tcg tcg acc gtg ccc gcg cca tcc ccg ctg tct gct gcc
gca gtc 384 Val Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala
Ala Val 115 120 125 tcg ccc tcc aag ctc cct gag gac gac gag cct ccg
gcc cgg cct ccc 432 Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro
Ala Arg Pro Pro 130 135 140 cct cct ccc ccg gcc agc gtg agc ccc cag
gca gag ccc gtg tgg acc 480 Pro Pro Pro Pro Ala Ser Val Ser Pro Gln
Ala Glu Pro Val Trp Thr 145 150 155 160 ccg cca gcc ccg gct ccc gcc
gcg ccc ccc tcc acc ccg gcc gcg ccc 528 Pro Pro Ala Pro Ala Pro Ala
Ala Pro Pro Ser Thr Pro Ala Ala Pro 165 170 175 aag cgc agg ggc tcc
tcg ggc tca gtg gat gag acc ctt ttt gct ctt 576 Lys Arg Arg Gly Ser
Ser Gly Ser Val Asp Glu Thr Leu Phe Ala Leu 180 185 190 cct gct gca
tct gag cct gtg ata cgc tcc tct gca gaa aat atg gac 624 Pro Ala Ala
Ser Glu Pro Val Ile Arg Ser Ser Ala Glu Asn Met Asp 195 200 205 ttg
aag gag cag cca ggt aac act att tcg gct ggt caa gag gat ttc 672 Leu
Lys Glu Gln Pro Gly Asn Thr Ile Ser Ala Gly Gln Glu Asp Phe 210 215
220 cca tct gtc ctg ctt gaa act gct gct tct ctt cct tct ctg tct cct
720 Pro Ser Val Leu Leu Glu Thr Ala Ala Ser Leu Pro Ser Leu Ser Pro
225 230 235 240 ctc tca gcc gct tct ttc aaa gaa cat gaa tac ctt ggt
aat ttg tca 768 Leu Ser Ala Ala Ser Phe Lys Glu His Glu Tyr Leu Gly
Asn Leu Ser 245 250 255 aca gta tta ccc act gaa gga aca ctt caa gaa
aat gtc agt gaa gct 816 Thr Val Leu Pro Thr Glu Gly Thr Leu Gln Glu
Asn Val Ser Glu Ala 260 265 270 tct aaa gag gtc tca gag aag gca aaa
act cta ctc ata gat aga gat 864 Ser Lys Glu Val Ser Glu Lys Ala Lys
Thr Leu Leu Ile Asp Arg Asp 275 280 285 tta aca gag ttt tca gaa tta
gaa tac tca gaa atg gga tca tcg ttc 912 Leu Thr Glu Phe Ser Glu Leu
Glu Tyr Ser Glu Met Gly Ser Ser Phe 290 295 300 agt gtc tct cca aaa
gca gaa tct gcc gta ata gta gca aat cct agg 960 Ser Val Ser Pro Lys
Ala Glu Ser Ala Val Ile Val Ala Asn Pro Arg 305 310 315 320 gaa gaa
ata atc gtg aaa aat aaa gat gaa gaa gag aag tta gtt agt 1008 Glu
Glu Ile Ile Val Lys Asn Lys Asp Glu Glu Glu Lys Leu Val Ser 325 330
335 aat aac atc ctt cat aat caa caa gag tta cct aca gct ctt act aaa
1056 Asn Asn Ile Leu His Asn Gln Gln Glu Leu Pro Thr Ala Leu Thr
Lys 340 345 350 ttg gtt aaa gag gat gaa gtt gtg tct tca gaa aaa gca
aaa gac agt 1104 Leu Val Lys Glu Asp Glu Val Val Ser Ser Glu Lys
Ala Lys Asp Ser 355 360 365 ttt aat gaa aag aga gtt gca gtg gaa gct
cct atg agg gag gaa tat 1152 Phe Asn Glu Lys Arg Val Ala Val Glu
Ala Pro Met Arg Glu Glu Tyr 370 375 380 gca gac ttc aaa cca ttt gag
cga gta tgg gaa gtg aaa gat agt aag 1200 Ala Asp Phe Lys Pro Phe
Glu Arg Val Trp Glu Val Lys Asp Ser Lys 385 390 395 400 gaa gat agt
gat atg ttg gct gct gga ggt aaa atc gag agc aac ttg 1248 Glu Asp
Ser Asp Met Leu Ala Ala Gly Gly Lys Ile Glu Ser Asn Leu 405 410 415
gaa agt aaa gtg gat aaa aaa tgt ttt gca gat agc ctt gag caa act
1296 Glu Ser Lys Val Asp Lys Lys Cys Phe Ala Asp Ser Leu Glu Gln
Thr 420 425 430 aat cac gaa aaa gat agt gag agt agt aat gat gat act
tct ttc ccc 1344 Asn His Glu Lys Asp Ser Glu Ser Ser Asn Asp Asp
Thr Ser Phe Pro 435 440 445 agt acg cca gaa ggt ata aag gat cgt cca
gga gca tat atc aca tgt 1392 Ser Thr Pro Glu Gly Ile Lys Asp Arg
Pro Gly Ala Tyr Ile Thr Cys 450 455 460 gct ccc ttt aac cca gca gca
act gag agc att gca aca aac att ttt 1440 Ala Pro Phe Asn Pro Ala
Ala Thr Glu Ser Ile Ala Thr Asn Ile Phe 465 470 475 480 cct ttg tta
gga gat cct act tca gaa aat aag acc gat gaa aaa aaa 1488 Pro Leu
Leu Gly Asp Pro Thr Ser Glu Asn Lys Thr Asp Glu Lys Lys 485 490 495
ata gaa gaa aag aag gcc caa ata gta aca gag aag aat act agc acc
1536 Ile Glu Glu Lys Lys Ala Gln Ile Val Thr Glu Lys Asn Thr Ser
Thr 500 505 510 aaa aca tca aac cct ttt ctt gta gca gca cag gat tct
gag aca gat 1584 Lys Thr Ser Asn Pro Phe Leu Val Ala Ala Gln Asp
Ser Glu Thr Asp 515 520 525 tat gtc aca aca gat aat tta aca aag gtg
act gag gaa gtc gtg gca 1632 Tyr Val Thr Thr Asp Asn Leu Thr Lys
Val Thr Glu Glu Val Val Ala 530 535 540 aac atg cct gaa ggc ctg act
cca gat tta gta cag gaa gca tgt gaa 1680 Asn Met Pro Glu Gly Leu
Thr Pro Asp Leu Val Gln Glu Ala Cys Glu 545 550 555 560 agt gaa ttg
aat gaa gtt act ggt aca aag att gct tat gaa aca aaa 1728 Ser Glu
Leu Asn Glu Val Thr Gly Thr Lys Ile Ala Tyr Glu Thr Lys 565 570 575
atg gac ttg gtt caa aca tca gaa gtt atg caa gag tca ctc tat cct
1776 Met Asp Leu Val Gln Thr Ser Glu Val Met Gln Glu Ser Leu Tyr
Pro 580 585 590 gca gca cag ctt tgc cca tca ttt gaa gag tca gaa gct
act cct tca 1824 Ala Ala Gln Leu Cys Pro Ser Phe Glu Glu Ser Glu
Ala Thr Pro Ser 595 600 605 cca gtt ttg cct gac att gtt atg gaa gca
cca ttg aat tct gca gtt 1872 Pro Val Leu Pro Asp Ile Val Met Glu
Ala Pro Leu Asn Ser Ala Val 610 615 620 cct agt gct ggt gct tcc gtg
ata cag ccc agc tca tca cca tta gaa 1920 Pro Ser Ala Gly Ala Ser
Val Ile Gln Pro Ser Ser Ser Pro Leu Glu 625 630 635 640 gct tct tca
gtt aat tat gaa agc ata aaa cat gag cct gaa aac ccc 1968 Ala Ser
Ser Val Asn Tyr Glu Ser Ile Lys His Glu Pro Glu Asn Pro 645 650 655
cca cca tat gaa gag gcc atg agt gta tca cta aaa aaa gta tca gga
2016 Pro Pro Tyr Glu Glu Ala Met Ser Val Ser Leu Lys Lys Val Ser
Gly 660 665 670 ata aag gaa gaa att aaa gag cct gaa aat att aat gca
gct ctt caa 2064 Ile Lys Glu Glu Ile Lys Glu Pro Glu Asn Ile Asn
Ala Ala Leu Gln 675 680 685 gaa aca gaa gct cct tat ata tct att gca
tgt gat tta att aaa gaa 2112 Glu Thr Glu Ala Pro Tyr Ile Ser Ile
Ala Cys Asp Leu Ile Lys Glu 690 695 700 aca aag ctt tct gct gaa cca
gct ccg gat ttc tct gat tat tca gaa 2160 Thr Lys Leu Ser Ala Glu
Pro Ala Pro Asp Phe Ser Asp Tyr Ser Glu 705 710 715 720 atg gca aaa
gtt gaa cag cca gtg cct gat cat tct gag cta gtt gaa 2208 Met Ala
Lys Val Glu Gln Pro Val Pro Asp His Ser Glu Leu Val Glu 725 730 735
gat tcc tca cct gat tct gaa cca gtt gac tta ttt agt gat gat tca
2256 Asp Ser Ser Pro Asp Ser Glu Pro Val Asp Leu Phe Ser Asp Asp
Ser 740 745 750 ata cct gac gtt cca caa aaa caa gat gaa act gtg atg
ctt gtg aaa 2304 Ile Pro Asp Val Pro Gln Lys Gln Asp Glu Thr Val
Met Leu Val Lys 755 760 765 gaa agt ctc act gag act tca ttt gag tca
atg ata gaa tat gaa aat 2352 Glu Ser Leu Thr Glu Thr Ser Phe Glu
Ser Met Ile Glu Tyr Glu Asn 770 775 780 aag gaa aaa ctc agt gct ttg
cca cct gag gga gga aag cca tat ttg 2400 Lys Glu Lys Leu Ser Ala
Leu Pro Pro Glu Gly Gly Lys Pro Tyr Leu 785 790 795 800 gaa tct ttt
aag ctc agt tta gat aac aca aaa gat acc ctg tta cct 2448 Glu Ser
Phe Lys Leu Ser Leu Asp Asn Thr Lys Asp Thr Leu Leu Pro 805 810 815
gat gaa gtt tca aca ttg agc aaa aag gag aaa att cct ttg cag atg
2496 Asp Glu Val Ser Thr Leu Ser Lys Lys Glu Lys Ile Pro Leu Gln
Met 820 825 830 gag gag ctc agt act gca gtt tat tca aat gat gac tta
ttt att tct 2544 Glu Glu Leu Ser Thr Ala Val Tyr Ser Asn Asp Asp
Leu Phe Ile Ser 835 840 845 aag gaa gca cag ata aga gaa act gaa acg
ttt tca gat tca tct cca 2592 Lys Glu Ala Gln Ile Arg Glu Thr Glu
Thr Phe Ser Asp Ser Ser Pro 850 855 860 att gaa att ata gat gag ttc
cct aca ttg atc agt tct aaa act gat 2640 Ile Glu Ile Ile Asp Glu
Phe Pro Thr Leu Ile Ser Ser Lys Thr Asp 865 870 875 880 tca ttt tct
aaa tta gcc agg gaa tat act gac cta gaa gta tcc cac 2688 Ser Phe
Ser Lys Leu Ala Arg Glu Tyr Thr Asp Leu Glu Val Ser His 885 890 895
aaa agt gaa att gct aat gcc ccg gat gga gct ggg tca ttg cct tgc
2736 Lys Ser Glu Ile Ala Asn Ala Pro Asp Gly Ala Gly Ser Leu Pro
Cys 900 905 910 aca gaa ttg ccc cat gac ctt tct ttg aag aac ata caa
ccc aaa gtt 2784 Thr Glu Leu Pro His Asp Leu Ser Leu Lys Asn Ile
Gln Pro Lys Val 915 920 925 gaa gag aaa atc agt ttc tca gat gac ttt
tct aaa aat ggg tct gct 2832 Glu Glu Lys Ile Ser Phe Ser Asp Asp
Phe Ser Lys Asn Gly Ser Ala 930 935 940 aca tca aag gtg ctc tta ttg
cct cca gat gtt tct gct ttg gcc act 2880 Thr Ser Lys Val Leu Leu
Leu Pro Pro Asp Val Ser Ala Leu Ala Thr 945 950 955 960 caa gca gag
ata gag agc ata gtt aaa ccc aaa gtt ctt gtg aaa gaa 2928 Gln Ala
Glu Ile Glu Ser Ile Val Lys Pro Lys Val Leu Val Lys Glu 965 970 975
gct gag aaa aaa ctt cct tcc gat aca gaa aaa gag gac aga tca cca
2976 Ala Glu Lys Lys Leu Pro Ser Asp Thr Glu Lys Glu Asp Arg Ser
Pro 980 985 990 tct gct ata ttt tca gca gag ctg agt aaa act tca gtt
gtt gac ctc 3024 Ser Ala Ile Phe Ser Ala Glu Leu Ser Lys Thr Ser
Val Val Asp Leu 995 1000 1005 ctg tac tgg aga gac att aag aag act
gga gtg gtg ttt ggt gcc 3069 Leu Tyr Trp Arg Asp Ile Lys Lys Thr
Gly Val Val Phe Gly Ala 1010 1015 1020 agc cta ttc ctg ctg ctt tca
ttg aca gta ttc agc att gtg agc 3114 Ser Leu Phe Leu Leu Leu Ser
Leu Thr Val Phe Ser Ile Val Ser 1025 1030 1035 gta aca gcc tac att
gcc ttg gcc ctg ctc tct gtg acc atc agc 3159 Val Thr Ala Tyr Ile
Ala Leu Ala Leu Leu Ser Val Thr Ile Ser 1040 1045 1050 ttt agg ata
tac aag ggt gtg atc caa gct atc cag aaa tca gat 3204 Phe Arg Ile
Tyr Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp 1055 1060 1065 gaa
ggc cac cca ttc agg gca tat ctg gaa tct gaa gtt gct ata 3249 Glu
Gly His Pro Phe Arg Ala Tyr Leu Glu Ser Glu Val Ala Ile 1070 1075
1080 tct gag gag ttg gtt cag aag tac agt aat tct gct ctt ggt cat
3294 Ser Glu Glu Leu Val Gln Lys Tyr Ser Asn Ser Ala Leu Gly His
1085 1090 1095 gtg aac tgc acg ata aag gaa ctc agg cgc ctc ttc tta
gtt gat 3339 Val Asn Cys Thr Ile Lys Glu Leu Arg Arg Leu Phe Leu
Val Asp 1100 1105 1110 gat tta gtt gat tct ctg aag ttt gca gtg ttg
atg tgg gta ttt 3384 Asp Leu Val Asp Ser Leu Lys Phe Ala Val Leu
Met Trp Val Phe 1115 1120 1125 acc tat gtt ggt gcc ttg ttt aat ggt
ctg aca cta ctg att ttg 3429 Thr Tyr Val Gly Ala Leu Phe Asn Gly
Leu Thr Leu Leu Ile Leu 1130 1135 1140 gct ctc att tca ctc ttc agt
gtt cct gtt att tat gaa cgg cat 3474 Ala Leu Ile Ser Leu Phe Ser
Val Pro Val Ile Tyr Glu Arg His 1145 1150 1155 cag gcg cag ata gat
cat tat cta gga ctt gca aat aag aat gtt 3519 Gln Ala Gln Ile Asp
His Tyr Leu Gly Leu Ala Asn Lys Asn Val 1160 1165 1170 aaa gat gct
atg gct aaa atc caa gca aaa atc cct gga ttg aag 3564 Lys Asp Ala
Met Ala Lys Ile Gln Ala Lys Ile Pro Gly Leu Lys 1175 1180 1185 cgc
aaa gct gaa tga 3579 Arg Lys Ala Glu 1190 23 1192 PRT Homo sapiens
23 Met Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro
1 5 10 15 Pro Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu
Pro Glu 20 25 30 Asp Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp
Glu Asp Glu Asp 35 40 45 Leu Glu Glu Leu Glu Val Leu Glu Arg Lys
Pro Ala Ala Gly Leu Ser 50 55 60 Ala Ala Pro Val Pro Thr Ala Pro
Ala Ala Gly Ala Pro Leu Met Asp 65 70 75 80 Phe Gly Asn Asp Phe Val
Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala 85 90 95 Ala Pro Pro Val
Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro 100 105 110 Val Ser
Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Ala Val 115 120 125
Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro 130
135 140 Pro Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro Val Trp
Thr 145 150 155 160 Pro Pro Ala Pro Ala Pro Ala Ala Pro Pro Ser Thr
Pro Ala Ala Pro 165 170 175 Lys Arg Arg Gly Ser Ser Gly Ser Val Asp
Glu Thr Leu Phe Ala Leu 180 185 190 Pro Ala Ala Ser Glu Pro Val Ile
Arg Ser Ser Ala Glu Asn Met Asp 195 200 205 Leu Lys Glu Gln Pro Gly
Asn Thr Ile Ser Ala Gly Gln Glu Asp Phe 210 215 220 Pro Ser Val Leu
Leu Glu Thr Ala Ala Ser Leu Pro Ser Leu Ser Pro 225 230 235 240 Leu
Ser Ala Ala Ser Phe Lys Glu His Glu Tyr Leu Gly Asn Leu Ser 245 250
255 Thr Val Leu Pro Thr Glu Gly Thr Leu Gln Glu Asn Val Ser Glu Ala
260 265 270 Ser Lys Glu Val Ser Glu Lys Ala Lys Thr Leu Leu Ile Asp
Arg Asp 275 280 285 Leu Thr Glu Phe Ser Glu Leu Glu Tyr Ser Glu Met
Gly Ser Ser Phe 290 295 300 Ser Val Ser Pro Lys Ala Glu Ser Ala Val
Ile Val Ala Asn Pro Arg 305 310 315 320 Glu Glu Ile Ile Val Lys Asn
Lys Asp Glu Glu Glu Lys Leu Val Ser 325 330 335 Asn Asn Ile Leu His
Asn Gln Gln Glu Leu Pro Thr Ala Leu Thr Lys 340 345 350 Leu Val Lys
Glu Asp Glu Val Val Ser Ser Glu Lys Ala Lys Asp Ser 355 360 365 Phe
Asn Glu Lys Arg Val Ala Val Glu Ala Pro Met Arg Glu Glu Tyr 370 375
380 Ala Asp Phe Lys Pro Phe Glu Arg Val Trp Glu Val Lys Asp Ser Lys
385 390 395 400 Glu Asp Ser Asp Met Leu Ala Ala Gly Gly Lys Ile Glu
Ser Asn Leu 405 410 415 Glu Ser Lys Val Asp Lys Lys Cys Phe Ala Asp
Ser Leu Glu Gln Thr 420 425 430 Asn His Glu Lys Asp Ser Glu Ser Ser
Asn Asp Asp Thr Ser Phe Pro 435 440 445 Ser Thr Pro Glu Gly Ile Lys
Asp Arg Pro Gly Ala Tyr Ile Thr Cys 450 455 460 Ala Pro Phe Asn Pro
Ala Ala Thr Glu Ser Ile Ala Thr Asn Ile Phe 465 470 475 480 Pro Leu
Leu Gly Asp Pro Thr Ser Glu Asn Lys Thr Asp Glu Lys Lys 485 490 495
Ile Glu Glu Lys Lys Ala Gln Ile Val Thr Glu Lys Asn Thr Ser Thr 500
505 510 Lys Thr Ser Asn Pro Phe Leu Val Ala Ala Gln Asp Ser Glu Thr
Asp 515 520 525 Tyr Val Thr Thr Asp Asn Leu Thr Lys Val Thr Glu Glu
Val Val Ala 530 535 540 Asn Met Pro Glu Gly Leu Thr Pro Asp Leu Val
Gln Glu Ala Cys Glu 545 550 555 560 Ser Glu Leu Asn Glu Val Thr Gly
Thr Lys Ile Ala Tyr Glu Thr Lys 565 570 575 Met Asp Leu Val Gln Thr
Ser Glu Val Met Gln Glu Ser Leu Tyr Pro 580 585 590 Ala Ala Gln Leu
Cys Pro Ser Phe Glu Glu Ser Glu Ala Thr Pro Ser 595 600 605 Pro Val
Leu Pro Asp Ile Val Met Glu Ala Pro Leu Asn Ser Ala Val 610 615 620
Pro Ser Ala Gly Ala Ser Val Ile Gln Pro Ser Ser Ser Pro Leu Glu 625
630 635 640 Ala Ser Ser Val Asn Tyr Glu Ser Ile Lys His Glu Pro Glu
Asn Pro 645 650 655 Pro Pro Tyr Glu Glu Ala Met Ser Val Ser Leu Lys
Lys Val Ser Gly 660 665 670 Ile Lys Glu Glu Ile Lys Glu Pro Glu Asn
Ile Asn Ala Ala
Leu Gln 675 680 685 Glu Thr Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp
Leu Ile Lys Glu 690 695 700 Thr Lys Leu Ser Ala Glu Pro Ala Pro Asp
Phe Ser Asp Tyr Ser Glu 705 710 715 720 Met Ala Lys Val Glu Gln Pro
Val Pro Asp His Ser Glu Leu Val Glu 725 730 735 Asp Ser Ser Pro Asp
Ser Glu Pro Val Asp Leu Phe Ser Asp Asp Ser 740 745 750 Ile Pro Asp
Val Pro Gln Lys Gln Asp Glu Thr Val Met Leu Val Lys 755 760 765 Glu
Ser Leu Thr Glu Thr Ser Phe Glu Ser Met Ile Glu Tyr Glu Asn 770 775
780 Lys Glu Lys Leu Ser Ala Leu Pro Pro Glu Gly Gly Lys Pro Tyr Leu
785 790 795 800 Glu Ser Phe Lys Leu Ser Leu Asp Asn Thr Lys Asp Thr
Leu Leu Pro 805 810 815 Asp Glu Val Ser Thr Leu Ser Lys Lys Glu Lys
Ile Pro Leu Gln Met 820 825 830 Glu Glu Leu Ser Thr Ala Val Tyr Ser
Asn Asp Asp Leu Phe Ile Ser 835 840 845 Lys Glu Ala Gln Ile Arg Glu
Thr Glu Thr Phe Ser Asp Ser Ser Pro 850 855 860 Ile Glu Ile Ile Asp
Glu Phe Pro Thr Leu Ile Ser Ser Lys Thr Asp 865 870 875 880 Ser Phe
Ser Lys Leu Ala Arg Glu Tyr Thr Asp Leu Glu Val Ser His 885 890 895
Lys Ser Glu Ile Ala Asn Ala Pro Asp Gly Ala Gly Ser Leu Pro Cys 900
905 910 Thr Glu Leu Pro His Asp Leu Ser Leu Lys Asn Ile Gln Pro Lys
Val 915 920 925 Glu Glu Lys Ile Ser Phe Ser Asp Asp Phe Ser Lys Asn
Gly Ser Ala 930 935 940 Thr Ser Lys Val Leu Leu Leu Pro Pro Asp Val
Ser Ala Leu Ala Thr 945 950 955 960 Gln Ala Glu Ile Glu Ser Ile Val
Lys Pro Lys Val Leu Val Lys Glu 965 970 975 Ala Glu Lys Lys Leu Pro
Ser Asp Thr Glu Lys Glu Asp Arg Ser Pro 980 985 990 Ser Ala Ile Phe
Ser Ala Glu Leu Ser Lys Thr Ser Val Val Asp Leu 995 1000 1005 Leu
Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val Val Phe Gly Ala 1010 1015
1020 Ser Leu Phe Leu Leu Leu Ser Leu Thr Val Phe Ser Ile Val Ser
1025 1030 1035 Val Thr Ala Tyr Ile Ala Leu Ala Leu Leu Ser Val Thr
Ile Ser 1040 1045 1050 Phe Arg Ile Tyr Lys Gly Val Ile Gln Ala Ile
Gln Lys Ser Asp 1055 1060 1065 Glu Gly His Pro Phe Arg Ala Tyr Leu
Glu Ser Glu Val Ala Ile 1070 1075 1080 Ser Glu Glu Leu Val Gln Lys
Tyr Ser Asn Ser Ala Leu Gly His 1085 1090 1095 Val Asn Cys Thr Ile
Lys Glu Leu Arg Arg Leu Phe Leu Val Asp 1100 1105 1110 Asp Leu Val
Asp Ser Leu Lys Phe Ala Val Leu Met Trp Val Phe 1115 1120 1125 Thr
Tyr Val Gly Ala Leu Phe Asn Gly Leu Thr Leu Leu Ile Leu 1130 1135
1140 Ala Leu Ile Ser Leu Phe Ser Val Pro Val Ile Tyr Glu Arg His
1145 1150 1155 Gln Ala Gln Ile Asp His Tyr Leu Gly Leu Ala Asn Lys
Asn Val 1160 1165 1170 Lys Asp Ala Met Ala Lys Ile Gln Ala Lys Ile
Pro Gly Leu Lys 1175 1180 1185 Arg Lys Ala Glu 1190 24 373 PRT Homo
sapiens 24 Met Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp
Ser Pro 1 5 10 15 Pro Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val
Arg Glu Pro Glu 20 25 30 Asp Glu Glu Glu Glu Glu Glu Glu Glu Glu
Glu Asp Glu Asp Glu Asp 35 40 45 Leu Glu Glu Leu Glu Val Leu Glu
Arg Lys Pro Ala Ala Gly Leu Ser 50 55 60 Ala Ala Pro Val Pro Thr
Ala Pro Ala Ala Gly Ala Pro Leu Met Asp 65 70 75 80 Phe Gly Asn Asp
Phe Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala 85 90 95 Ala Pro
Pro Val Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro 100 105 110
Val Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Ala Val 115
120 125 Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro
Pro 130 135 140 Pro Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro
Val Trp Thr 145 150 155 160 Pro Pro Ala Pro Ala Pro Ala Ala Pro Pro
Ser Thr Pro Ala Ala Pro 165 170 175 Lys Arg Arg Gly Ser Ser Gly Ser
Val Val Val Asp Leu Leu Tyr Trp 180 185 190 Arg Asp Ile Lys Lys Thr
Gly Val Val Phe Gly Ala Ser Leu Phe Leu 195 200 205 Leu Leu Ser Leu
Thr Val Phe Ser Ile Val Ser Val Thr Ala Tyr Ile 210 215 220 Ala Leu
Ala Leu Leu Ser Val Thr Ile Ser Phe Arg Ile Tyr Lys Gly 225 230 235
240 Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro Phe Arg Ala
245 250 255 Tyr Leu Glu Ser Glu Val Ala Ile Ser Glu Glu Leu Val Gln
Lys Tyr 260 265 270 Ser Asn Ser Ala Leu Gly His Val Asn Cys Thr Ile
Lys Glu Leu Arg 275 280 285 Arg Leu Phe Leu Val Asp Asp Leu Val Asp
Ser Leu Lys Phe Ala Val 290 295 300 Leu Met Trp Val Phe Thr Tyr Val
Gly Ala Leu Phe Asn Gly Leu Thr 305 310 315 320 Leu Leu Ile Leu Ala
Leu Ile Ser Leu Phe Ser Val Pro Val Ile Tyr 325 330 335 Glu Arg His
Gln Ala Gln Ile Asp His Tyr Leu Gly Leu Ala Asn Lys 340 345 350 Asn
Val Lys Asp Ala Met Ala Lys Ile Gln Ala Lys Ile Pro Gly Leu 355 360
365 Lys Arg Lys Ala Glu 370 25 199 PRT Homo sapiens 25 Met Asp Gly
Gln Lys Lys Asn Trp Lys Asp Lys Val Val Asp Leu Leu 1 5 10 15 Tyr
Trp Arg Asp Ile Lys Lys Thr Gly Val Val Phe Gly Ala Ser Leu 20 25
30 Phe Leu Leu Leu Ser Leu Thr Val Phe Ser Ile Val Ser Val Thr Ala
35 40 45 Tyr Ile Ala Leu Ala Leu Leu Ser Val Thr Ile Ser Phe Arg
Ile Tyr 50 55 60 Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp Glu
Gly His Pro Phe 65 70 75 80 Arg Ala Tyr Leu Glu Ser Glu Val Ala Ile
Ser Glu Glu Leu Val Gln 85 90 95 Lys Tyr Ser Asn Ser Ala Leu Gly
His Val Asn Cys Thr Ile Lys Glu 100 105 110 Leu Arg Arg Leu Phe Leu
Val Asp Asp Leu Val Asp Ser Leu Lys Phe 115 120 125 Ala Val Leu Met
Trp Val Phe Thr Tyr Val Gly Ala Leu Phe Asn Gly 130 135 140 Leu Thr
Leu Leu Ile Leu Ala Leu Ile Ser Leu Phe Ser Val Pro Val 145 150 155
160 Ile Tyr Glu Arg His Gln Ala Gln Ile Asp His Tyr Leu Gly Leu Ala
165 170 175 Asn Lys Asn Val Lys Asp Ala Met Ala Lys Ile Gln Ala Lys
Ile Pro 180 185 190 Gly Leu Lys Arg Lys Ala Glu 195 26 473 PRT Homo
sapiens 26 Met Lys Arg Ala Ser Ala Gly Gly Ser Arg Leu Leu Ala Trp
Val Leu 1 5 10 15 Trp Leu Gln Ala Trp Gln Val Ala Ala Pro Cys Pro
Gly Ala Cys Val 20 25 30 Cys Tyr Asn Glu Pro Lys Val Thr Thr Ser
Cys Pro Gln Gln Gly Leu 35 40 45 Gln Ala Val Pro Val Gly Ile Pro
Ala Ala Ser Gln Arg Ile Phe Leu 50 55 60 His Gly Asn Arg Ile Ser
His Val Pro Ala Ala Ser Phe Arg Ala Cys 65 70 75 80 Arg Asn Leu Thr
Ile Leu Trp Leu His Ser Asn Val Leu Ala Arg Ile 85 90 95 Asp Ala
Ala Ala Phe Thr Gly Leu Ala Leu Leu Glu Gln Leu Asp Leu 100 105 110
Ser Asp Asn Ala Gln Leu Arg Ser Val Asp Pro Ala Thr Phe His Gly 115
120 125 Leu Gly Arg Leu His Thr Leu His Leu Asp Arg Cys Gly Leu Gln
Glu 130 135 140 Leu Gly Pro Gly Leu Phe Arg Gly Leu Ala Ala Leu Gln
Tyr Leu Tyr 145 150 155 160 Leu Gln Asp Asn Ala Leu Gln Ala Leu Pro
Asp Asp Thr Phe Arg Asp 165 170 175 Leu Gly Asn Leu Thr His Leu Phe
Leu His Gly Asn Arg Ile Ser Ser 180 185 190 Val Pro Glu Arg Ala Phe
Arg Gly Leu His Ser Leu Asp Arg Leu Leu 195 200 205 Leu His Gln Asn
Arg Val Ala His Val His Pro His Ala Phe Arg Asp 210 215 220 Leu Gly
Arg Leu Met Thr Leu Tyr Leu Phe Ala Asn Asn Leu Ser Ala 225 230 235
240 Leu Pro Thr Glu Ala Leu Ala Pro Leu Arg Ala Leu Gln Tyr Leu Arg
245 250 255 Leu Asn Asp Asn Pro Trp Val Cys Asp Cys Arg Ala Arg Pro
Leu Trp 260 265 270 Ala Trp Leu Gln Lys Phe Arg Gly Ser Ser Ser Glu
Val Pro Cys Ser 275 280 285 Leu Pro Gln Arg Leu Ala Gly Arg Asp Leu
Lys Arg Leu Ala Ala Asn 290 295 300 Asp Leu Gln Gly Cys Ala Val Ala
Thr Gly Pro Tyr His Pro Ile Trp 305 310 315 320 Thr Gly Arg Ala Thr
Asp Glu Glu Pro Leu Gly Leu Pro Lys Cys Cys 325 330 335 Gln Pro Asp
Ala Ala Asp Lys Ala Ser Val Leu Glu Pro Gly Arg Pro 340 345 350 Ala
Ser Ala Gly Asn Ala Leu Lys Gly Arg Val Pro Pro Gly Asp Ser 355 360
365 Pro Pro Gly Asn Gly Ser Gly Pro Arg His Ile Asn Asp Ser Pro Phe
370 375 380 Gly Thr Leu Pro Gly Ser Ala Glu Pro Pro Leu Thr Ala Val
Arg Pro 385 390 395 400 Glu Gly Ser Glu Pro Pro Gly Phe Pro Thr Ser
Gly Pro Arg Arg Arg 405 410 415 Pro Gly Cys Ser Arg Lys Asn Arg Thr
Arg Ser His Cys Arg Leu Gly 420 425 430 Gln Ala Gly Ser Gly Gly Gly
Gly Thr Gly Asp Ser Glu Gly Ser Gly 435 440 445 Ala Leu Pro Ser Leu
Thr Cys Ser Leu Thr Pro Leu Gly Leu Ala Leu 450 455 460 Val Leu Trp
Thr Val Leu Gly Pro Cys 465 470 27 473 PRT Mus musculus 27 Met Lys
Arg Ala Ser Ser Gly Gly Ser Arg Leu Leu Ala Trp Val Leu 1 5 10 15
Trp Leu Gln Ala Trp Arg Val Ala Thr Pro Cys Pro Gly Ala Cys Val 20
25 30 Cys Tyr Asn Glu Pro Lys Val Thr Thr Ser Cys Pro Gln Gln Gly
Leu 35 40 45 Gln Ala Val Pro Thr Gly Ile Pro Ala Ser Ser Gln Arg
Ile Phe Leu 50 55 60 His Gly Asn Arg Ile Ser His Val Pro Ala Ala
Ser Phe Gln Ser Cys 65 70 75 80 Arg Asn Leu Thr Ile Leu Trp Leu His
Ser Asn Ala Leu Ala Arg Ile 85 90 95 Asp Ala Ala Ala Phe Thr Gly
Leu Thr Leu Leu Glu Gln Leu Asp Leu 100 105 110 Ser Asp Asn Ala Gln
Leu His Val Val Asp Pro Thr Thr Phe His Gly 115 120 125 Leu Gly His
Leu His Thr Leu His Leu Asp Arg Cys Gly Leu Arg Glu 130 135 140 Leu
Gly Pro Gly Leu Phe Arg Gly Leu Ala Ala Leu Gln Tyr Leu Tyr 145 150
155 160 Leu Gln Asp Asn Asn Leu Gln Ala Leu Pro Asp Asn Thr Phe Arg
Asp 165 170 175 Leu Gly Asn Leu Thr His Leu Phe Leu His Gly Asn Arg
Ile Pro Ser 180 185 190 Val Pro Glu His Ala Phe Arg Gly Leu His Ser
Leu Asp Arg Leu Leu 195 200 205 Leu His Gln Asn His Val Ala Arg Val
His Pro His Ala Phe Arg Asp 210 215 220 Leu Gly Arg Leu Met Thr Leu
Tyr Leu Phe Ala Asn Asn Leu Ser Met 225 230 235 240 Leu Pro Ala Glu
Val Leu Met Pro Leu Arg Ser Leu Gln Tyr Leu Arg 245 250 255 Leu Asn
Asp Asn Pro Trp Val Cys Asp Cys Arg Ala Arg Pro Leu Trp 260 265 270
Ala Trp Leu Gln Lys Phe Arg Gly Ser Ser Ser Glu Val Pro Cys Asn 275
280 285 Leu Pro Gln Arg Leu Ala Asp Arg Asp Leu Lys Arg Leu Ala Ala
Ser 290 295 300 Asp Leu Glu Gly Cys Ala Val Ala Ser Gly Pro Phe Arg
Pro Ile Gln 305 310 315 320 Thr Ser Gln Leu Thr Asp Glu Glu Leu Leu
Ser Leu Pro Lys Cys Cys 325 330 335 Gln Pro Asp Ala Ala Asp Lys Ala
Ser Val Leu Glu Pro Gly Arg Pro 340 345 350 Ala Ser Ala Gly Asn Ala
Leu Lys Gly Arg Val Pro Pro Gly Asp Thr 355 360 365 Pro Pro Gly Asn
Gly Ser Gly Pro Arg His Ile Asn Asp Ser Pro Phe 370 375 380 Gly Thr
Leu Pro Ser Ser Ala Glu Pro Pro Leu Thr Ala Leu Arg Pro 385 390 395
400 Gly Gly Ser Glu Pro Pro Gly Leu Pro Thr Thr Gly Pro Arg Arg Arg
405 410 415 Pro Gly Cys Ser Arg Lys Asn Arg Thr Arg Ser His Cys Arg
Leu Gly 420 425 430 Gln Ala Gly Ser Gly Ala Ser Gly Thr Gly Asp Ala
Glu Gly Ser Gly 435 440 445 Ala Leu Pro Ala Leu Ala Cys Ser Leu Ala
Pro Leu Gly Leu Ala Leu 450 455 460 Val Leu Trp Thr Val Leu Gly Pro
Cys 465 470 28 15 PRT Artificial Sequence synthetic 28 Ser Gly Val
Pro Ser Asn Leu Pro Gln Arg Leu Ala Gly Arg Asp 1 5 10 15 29 15 PRT
Artificial Sequence synthetic 29 Thr Arg Ser His Cys Arg Leu Gly
Gln Ala Gly Ser Gly Ser Ser 1 5 10 15
* * * * *